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Abstract 
Background and Aim: Studies of the epidemiology of respiratory syncytial virus (RSV) 
bronchiolitis to date have been small; focused only on the hospital setting and selective 
groups of high-risk infants such as those born preterm; lacked long-term follow-up and few 
have been based on data from the United Kingdom (UK).  Hence, the existing evidence base 
was likely to underestimate the scale and impact of RSV on health in UK infants.  The aim of 
this thesis was to provide better estimates of the wider clinical burden of RSV bronchiolitis 
among infants presenting across primary and secondary care settings in the UK.   
Methods: The clinical spectrum of bronchiolitis illness across different healthcare settings 
was examined using routine data from electronic health records to develop longitudinal, 
population-based cohorts with follow-up from birth through early childhood.  Databases 
examined in this thesis included Hospital Episodes Statistics (HES), the General Practice 
Research Database (GPRD) and the National Neonatal Research Database (NNRD).   
Results: The estimated bronchiolitis admission rate in NHS hospitals in England was 24.2 
admissions per 1000 infants aged less than 1 year (95% CI 23.7 to 24.8) with a median 
length of stay of 1 day (IQR 0 to 3 days) at a median age of 120 days (IQR 61 to 209 days). 
15% of infants admitted with bronchiolitis were born preterm (47.3 per 1000 infants) and 
24% had at least one known clinical risk factor for severe RSV infection.  Cystic fibrosis, 
cerebral palsy and Down‟s syndrome also increase an infant‟s risk of bronchiolitis admission.  
The bronchiolitis consultation rate in UK general practice was 58.1 per 1000 infants (95% CI 
56.5 to 59.8) at a mean age of 5.5 months (SD=3.2).  Using a broader bronchiolitis case 
definition the estimated consultation rate was 206.7 per 1000 infants (95% CI 204.0 to 
209.6).  36% of bronchiolitis consultations resulted in a prescription, of which 28% were for 
antibiotics and 27% for beta agonists, despite no evidence to support their use.  Bronchiolitis 
in infancy is a predictor of subsequent hospital admissions and general practice 
consultations for asthma and wheezing in early childhood.   
Conclusions: The clinical burden of RSV bronchiolitis across healthcare settings in the UK 
is greater than previously estimated.  Between 4% and 21% of infants have a bronchiolitis 
GP consultation in their first year.  2.4% of the national birth cohort are admitted to hospital 
with bronchiolitis in the first year of life, most of whom are born at term with no known clinical 
risk factors for severe RSV infection. This thesis has identified new groups of infants who 
may be at increased risk of severe RSV disease including those with cystic fibrosis, cerebral 
palsy and Down‟s syndrome. These findings highlight the need to prioritise development of 
new approaches for the prevention and treatment of RSV infection and have important 
implications for clinical training and management of bronchiolitis across healthcare settings.   
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1.0 Introduction 
 
Chapter overview 
This chapter explores the existing evidence base relating to respiratory syncytial virus (RSV) 
bronchiolitis among infants.  It begins by describing in general the significant burden of 
respiratory illness among children, followed by detailed information relating specifically to 
RSV infection in infancy.  The burden of RSV illness among infants in the wider global 
context is outlined before the incidence, diagnosis and management of bronchiolitis in the 
United Kingdom (UK) are described in detail.  This is followed by an exploration of existing 
preventative regimes and the possible future potential of an active vaccination against RSV 
infection.  The longer-term impact of RSV infection in infancy is then considered, examining 
the evidence for any association with subsequent respiratory morbidity in childhood and into 
early adulthood.  Finally a summary of what is known and the remaining gaps in our 
knowledge is presented, providing the rationale behind the central topic of this thesis.   
Literature review methodology 
A systematic approach to reviewing the existing evidence base was adopted.  The Cochrane 
Library, EMBASE, MEDLINE (OVID) and PUBMED databases were all searched for studies 
published in English, from January 1st 1990 to December 31st 2012.  Searches were carried 
out using varying combinations of the following search terms: ("Respiratory Syncytial Virus, 
Human"[Mesh]” OR "Respiratory Syncytial Virus Infections"[Mesh]), ("Bronchiolitis"[Mesh] 
OR "Bronchiolitis, Viral"[Mesh]), ("Risk" OR "Risk Factors"[Mesh]), ("Primary Health 
Care"[Mesh] OR "General Practice"[Mesh]), "Patient Admission"[Mesh]", “Community Health 
Services”[Mesh], Asthma"[Mesh], ”Wheez*”.   
Reference lists from selected papers and recent review articles were also examined along 
with published conference abstracts.  In addition to searching for published journal articles, 
grey literature was also searched to ensure a wider collection of relevant documents were 
identified, such as government reports, policy documents etc.   
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1.1 Childhood respiratory illness 
The fourth Millennium Development Goal aims to reduce mortality children under 5 years old by 
two-thirds by 2015.2  Despite advances in healthcare and availability of treatments, respiratory 
tract infections (RTIs) remain the leading cause of death in young children worldwide and present 
a major hindrance in achieving this target.3-5  Acute respiratory conditions including infectious 
illness are a major cause of childhood morbidity and remain important causes of health service 
use6;7 accounting for around 50% of consultations in primary care and an estimated 15% of 
hospital admissions in developed countries.8;9  Lower respiratory tract infections (LRTIs) are 
particularly common in infants worldwide,10 the most common cause of which is RSV, which is 
therefore considered the most important respiratory pathogen in childhood.11 
 
1.2 Respiratory syncytial virus (RSV) infection 
Clinical symptoms 
Most children will have been infected with RSV by 2 years of age.12  RSV infection will usually 
result in mild upper respiratory tract illness with nasal congestion, cough, rhinorrhoea and fever.13  
Around 40% of primary RSV infections will result in LRTI, principally bronchiolitis and also 
pneumonia.13;14   
RSV infection results in inflammation and oedema of the bronchiolar wall, mucus build up 
clogging the airways and necrosis of the respiratory epithelium.15;16  It is this damage which 
is thought may have longer-term effects on lung function in childhood and possibly into 
adulthood.13;17   
Virology 
RSV is a negative-strand, non-segmented RNA pneumovirus.16  There are two RSV 
subtypes which co-circulate, RSV A is more common than type B and is thought to cause 
more clinically significant illness.13;18  In temperate climates RSV tend to circulate during 
winter months, from October through to March,13;19;20 while in tropical climates outbreaks 
tend to occur during the rainy season.21;22   
Immunity 
Viral, host and environmental factors contribute to the pathogenesis of RSV, with the extent 
of their contributions varying considerably between infected individuals.16  Previous infection 
with RSV has been shown to only confer partial immunity to RSV, meaning individuals can 
be repeatedly infected with the same or different RSV strains throughout life.23  Reinfection 
tends to be less severe in childhood after a first illness13 and becomes progressively less 
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severe in early adult life but in later life, RSV infection presents a major cause of community-
acquired pneumonia among the elderly.24;25 
 
The underlying immune response to RSV infection remains a vast area for research since it 
is still poorly understood.  It was previously thought that an overly aggressive, hyper-
responsive immune response to RSV infection resulted in severe illness but more recent 
evidence suggests recovery is dependent on the innate immune response.25  It is unclear 
whether reinfection can occur because infants fail to generate sufficient antibody titres or if 
these wane too rapidly after infection.13  
 
Despite RSV long being a priority area for vaccine development and control,26 the difficulties 
in determining how RSV interacts with our immune system have resulted in it being the only 
organism of the three main pathogens that cause death from RTI, Haemophilus influenzae 
and Streptococcus pneumoniae being the other two, for which no vaccine is currently 
available.3;4   
Global burden 
RSV is the leading cause of acute LRTIs and admissions to hospital worldwide.3;21  A 
systematic review and meta-analysis published in the Lancet in 2010, estimated the global 
burden of acute LRTI due to RSV in young children, reporting an estimated 33.8 million new 
episodes of RSV LRTI worldwide, among children under 5 years in 2005.21  The study found 
that around 10%, or at least 3.4 million of these RSV episodes were severe enough to 
require hospital admission.21  RSV-associated mortality among infants in developed 
countries is relatively low, with studies in the United States of America (USA) for example, 
estimating that RSV was responsible for between 100 and 180 pneumonia related deaths 
among children between 1993 and 1995.14;27  Globally however, Nair et al report an 
estimated 66,000 to 199,000 children under 5 years die each year due to RSV LRTI, 99% of 
these occurring in developing countries.21   
UK burden 
RSV infection is the leading cause of hospitalisation in children under 1 year of age,28 with 
typical rates of 28 per 1000 children under 1 year admitted in England.29;30  The incidence 
decreases in older children as a study from the Health Protection Agency (HPA) found using 
data from the late 1990s, the mean annual incidence of hospital admissions attributable to 
RSV was 1.3 per 1000 children aged 1 to 4 years.30  A small, regional study carried out in a 
single strategic health authority in England also used data from this period and reported 
hospital admission rates for RSV illness were 24.4 per 1000 infants under 1 year and for 
bronchiolitis admissions the rate was 30.8 per 1000 infants under 1 year.31  The RSV-
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attributed death rate in infants aged one to 12 months has been estimated to be 8.4 per 
100,000 population in the UK.32   
 
1.3 Bronchiolitis 
Acute bronchiolitis is the most common LRTI in infants, estimated to affect around 10% of 
children under 1 year.21;31;33-35 It most commonly presents in infants aged 3 to 6 months.36  It is 
usually a mild, self-limiting illness usually lasting between 3 and 7 days, but in some infants may 
be more severe, requiring hospital admission.  Infants typically present with symptoms such as 
cough, breathing difficulties, poor feeding, irritability and apnoea.  The diagnosis is based on 
these clinical symptoms combined with wheeze and/or crepitations/crackles on auscultation.36  
Bronchiolitis is typically caused by RSV in around 75% of cases,37 with peak incidence during the 
winter months.38;39   
Other bronchiolitis cases can be caused by infection with a range of different viruses including 
parainfluenza virus, influenza virus, adenovirus, rhinovirus or human metapneumovirus (HMPV).  
The incidence of dual infection with more than one virus is between 5% and 10% among infants 
with severe bronchiolitis.40  Bacterial co-infections with community acquired organisms occurs in 
around 22% of infants hospitalised with bronchiolitis, who also required significantly more 
ventilator support than those without bacterial co-infection.40;41  There is also evidence the dual 
infection with RSV and HMPV may be associated with a more severe course of illness and the 
requirement for ventilation.40;42  There is also an increased risk of more severe bronchiolitis illness 
among infants with dual infection of RSV and human bocavirus.43  Rhinovirus infection is thought 
to cause a milder form of bronchiolitis than RSV.43 
Incidence 
An estimated 2 to 3% of all infants living in developed countries are admitted to hospital with 
bronchiolitis caused by RSV.21;31;34;44  In the UK, bronchiolitis admission rates in infants under 1 
year have previously been estimated from small regional studies to be 30.8 per 100031 and 31.2 
per 1000 in the USA.10  A more recent study in Texas reported higher bronchiolitis admission 
rates of 5.5% among children under 2 years,45 with the higher incidence estimate likely to be due 
to the wider inclusion of children aged 12 to 24 months in their study, coupled with variation in the 
clinical definition of bronchiolitis used in the USA compared with that used in the UK.13  To date, 
no national studies have reported the disease burden at a population level in the UK.   
Early findings from The Houston Family Study in the USA published in 1986, a birth cohort of 
125 infants with community follow-up for the first year of life, estimated the rate of RSV-
confirmed lower respiratory tract disease to be 21.6 per 100 infants under 1 year.46  Large 
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prospective birth cohorts are needed to determine the current clinical burden of bronchiolitis 
in the community, but these are expensive and not practical.  Previous studies have focused 
on identifying risk factors for hospitalisation with severe disease but there are no reliable 
community-based estimates of the incidence of bronchiolitis in the UK.  With widespread use 
of electronic patient records in general practices across the UK47, it could now be possible to 
estimate the frequency of acute bronchiolitis consultations in the community.   
 
1.4 Diagnosis and management of bronchiolitis in the UK 
The Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline on bronchiolitis in 
children, published in 2006, is the main source of information for bronchiolitis management 
in the UK.36  The guideline provides evidence based recommendations on prevention, 
diagnosis and treatment of bronchiolitis, grading each recommendation on the strength of 
the evidence on which it is based, ranging from 1 for high quality meta-analyses of 
randomised controlled trials (RCTs) to 4 where only anecdotal evidence from expert opinion 
is available.36 
Little is known about the presentation, natural history and management of bronchiolitis in the 
community and the SIGN guideline lacks sufficient evidence from and applicable to 
management of bronchiolitis in general practice.36  The guidelines recommends further 
research in needed to examine the prevalence of bronchiolitis in primary care and current 
treatment practice in the community and risk profiling to identify those who may have future 
respiratory symptoms.36   
Diagnosis 
RTI consultations are considered the „bread and butter‟ of daily practice in UK primary 
care.48  Despite this, it can be challenging for General Practitioners (GPs), presented with an 
infant with respiratory symptoms, to differentiate their diagnosis between bronchiolitis, 
bacterial respiratory tract infections and wheezy bronchitis/early asthma.  The diagnosis of 
bronchiolitis is clinical, based on history and physical examination, with symptoms including 
dry, wheezy cough, nasal discharge, fever and fine inspiratory crackles or high pitched 
expiratory wheeze.36;49-52   
Although virological testing for RSV is not routine practice and is not required for the clinical 
diagnosis of bronchiolitis to be made, it can be of benefit when admitting infants to hospital.  
For example a case-control study has shown this can reduce length of stay, antibiotic use 
and subsequent microbiological testing.53;54  Other studies have also reported that a 
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definitive viral diagnosis reduces unnecessary interventions.55-57 Rapid antigen testing has 
been shown to be a useful method for detecting RSV mediated disease in very young 
infants, with good specificity but decreasing diagnostic sensitivity in infants older than 3 
months.55;58;59 
Treatment 
Evidence from systematic reviews suggests no available treatments shorten the natural 
course or provide clinically relevant improvements in bronchiolitis symptoms.33;60-65  Since 
there is no universally effective drug treatment, the mainstay of management for infants with 
RSV bronchiolitis is supportive care and a small proportion of more severely affected infants 
are treated in intensive care.33;36;61;62   
A Cochrane systematic review into the use of antiviral ribavirin  for RSV infection, found that 
many of the studies reviewed, including RCTs, either had excluded children with significant 
comorbidities, had no placebo control group, included very small numbers, had too short 
follow-up or no blinding to treatment allocation, meaning the quality of evidence was quite 
poor, potentially biased and had questionable generalisability.36;60;63;66-68  Similarly, although 
many studies are underpowered, no current evidence supports the use of inhaled beta 2 
agonist bronchodilators or nebulised ipratropium for the treatment of infants with acute 
bronchiolitis.69;70  RCTs of anti-inflammatory treatments for RSV infection have also proved 
to be unsuccessful, as neither inhaled nor oral systemic corticosteroids have demonstrated 
any reductions in duration of symptoms of length of bronchiolitis hospital admission.62;71-73   
A multicentre, double-blind RCT of nebulised epinephrine was published in the New England 
Journal of Medicine (NEJM) in 2003, reporting that nebulized epinephrine did not 
significantly reduce the length of time until an infant admitted to hospital with bronchiolitis 
was ready for discharge.74  However, in more recent years, some evidence for the 
effectiveness and superiority of adrenaline for short-term outcomes among outpatients with 
bronchiolitis has emerged.75;76  This systematic review and meta-analysis published in the 
British Medical Journal (BMJ), also reports evidence from a single study suggesting benefits 
of combined epinephrine and dexamethasone steroid.  A Cochrane review published in 2008 
has also shown that nebulised 3% saline may be effective in reducing length of stay and 
clinical severity among infants hospitalised with bronchiolitis.77   
 
For infants hospitalised with bronchiolitis, nasal suction is recommended in those who exhibit 
respiratory distress due to nasal blockage and nasogastric feeding should be considered in 
those infants who cannot maintain oral intake or hydration.36  Although there is very little 
published evidence for its use, the expert clinical consensus is that supplemental oxygen 
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should be given to infants with severe respiratory distress, cyanosis or oxygen saturation 
level ≤92%.36  A Cochrane systematic review investigating the use of chest physiotherapy to 
treat bronchiolitis among infants without comorbidities, found no evidence that this improves 
clinical severity or reduces length of hospital stay.78-80   
 
1.5 Risk factors for bronchiolitis 
Children known to be at high risk of developing severe RSV infection include those with chronic 
lung disease,81-83 haemo-dynamically significant congenital heart disease,81;84-86 
immunodeficiency, low birth weight87 and those born preterm (approximately 8% of newborns in 
the UK).3;22;44;88-94  This is particularly concerning given the reported increases in preterm birth 
rates in developed countries over recent years, combined with improved survival of preterm 
infants, meaning that the population of at-risk infants is increasing.31;36;95  Evidence from the US, 
published in the NEJM in 2009, suggests most children (66%) admitted to hospital with RSV 
infection have no co-existing medical conditions or characteristics that significantly identify them 
as being at greater risk of severe disease.44   
Other factors may also be associated with RSV infection, for example deprivation,96 
residential crowding,97 tobacco smoke exposure,98-102 maternal smoking during 
pregnancy,103;104 air pollution and traffic exposure,105 lack of breast-feeding,106;107 multiple 
gestation,108 elective caesarean delivery,109 winter birth and discharge from NICU between 
September and December.110   
 
Although there is a wealth of evidence regarding the association between some known risk 
factors and severe bronchiolitis, the association between other potential risk factors and 
bronchiolitis remains unclear.  Furthermore, the effect of potential risk factors on disease 
severity needs to be determined.  There remains a poor evidence base of prognostic factors 
for hospital admission due to RSV infection.111  A 2008 Health Technology Assessment 
(HTA) identified further large observational studies are needed to estimate the mortality rate 
among children known to be at highest risk of RSV infection such as those with chronic lung 
disease, congenital heart disease and ex-premature infants.111  The specific effects of 
premature birth and low birth weight on risk of bronchiolitis hospitalisation have yet to be 
determined, as recommended by Wang et al, future research ought to, “address major 
uncertainties among patient subgroups, including preterm infants of different gestational 
ages”.111   
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A more recent update of the HTA examining Palivizumab use for  immunoprophylaxis of 
RSV bronchiolitis in high-risk infants and young infants, was published in 2011.112  This 
report explicitly recommended that larger, better powered studies are needed to derive 
better estimates of risk factor effect sizes.  In particular, improved estimates are needed to 
determine the effect size of parental education, multiple births, family history of atopy, lack of 
breastfeeding and gestational age.112  This information would help to improve Palivizumab 
cost-effectiveness estimates.   
A complex interplay between host and viral factors is thought to determine the severity of 
RSV infection.92  Despite the known clinical risk factors for RSV bronchiolitis hospital 
admission described above, the decision as to whether bronchiolitis should be treated in 
hospital or in the community is a difficult one.113  Whether an infant is hypoxic is commonly 
cited by clinicians as a factor noted when considering whether to admit an infant with 
bronchiolitis, yet the use of pulse oximetry for this purpose has questionable benefits.22;113;114  
Other studies have suggested that oxygen saturations below 92% are the strongest predictor 
of bronchiolitis hospital admission.113;115   
One UK study reported on the development and use of a simple clinical risk scoring system 
to aid decision making in busy Emergency Departments.113  The sensitivity and specificity of 
the tool varied according to risk factors included, but the study reported that the optimal 5 
risks to include in the scoring system were: symptom duration of less than 5 days, 
respiratory rate of ≥50 breaths per minute, heart rate of ≥155 beat per minute, oxygen 
saturation less than 97% and age at presentation of less than 18 weeks.  Further validation 
of the tool is required, among a much larger sample of infants, but this provides some 
positive development in the quest to improve the reliability of diagnosis and management of 
severe RSV bronchiolitis.   
 
1.6 Prevention 
1.6.1 Hygiene 
Interruption of RSV transmission can be achieved through conservative prevention 
strategies such as reducing exposure to potential environmental risk factors such as passive 
smoking and avoiding overcrowded areas during the peak winter transmission season.116  
The primary focus for reducing nosocomial RSV transmission, particularly in hospital 
settings, is encouraging good hand-washing techniques or glove and gown use among 
healthcare professionals and those in contact with infected individuals.53;116;117  This is 
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particularly important to prevent nosocomial RSV outbreaks among vulnerable, high-risk 
infants in neonatal units.118 
1.6.2 Passive immunotherapy  
Prophylactic passive immunotherapy with Palivizumab (Synagis®, MedImmune), a 
humanised mouse monoclonal antibody against RSV infection, is licensed for use in some 
countries for those most at high risk of RSV infection.13;119  Palivizumab only provides short-
term protection against RSV as it is a passive immunisation, not a vaccine.120;121  Two large 
randomised, double blind, placebo controlled trials have shown palivizumab to be both safe 
and effective in reducing RSV hospitalisation rates and serious complications among high-
risk infants.122;123  Infants aged less than or equal to 35 weeks gestational age or those with 
bronchopulmonary dysplasia (n=1502) were randomized to receive 5 injections of 
palivizumab (15 mg/kg) or equivalent volume of placebo every 30 days.  Overall, those 
receiving palivizumab (n=500) had a 55% reduction in RSV hospital admissions compared to 
the placebo group (n=1002).122   
Palivizumab is at present the only passive immunisation licensed in the UK for the 
prevention of serious LRTI requiring hospitalisation caused by RSV.  However, it is very 
expensive (the estimated cost for a single dose of palivizumab for an infant aged 6 months, 
weighing 7.5kg, is £1023.11112 so the total cost for 5 doses over the winter season is just 
over £5000 per patient).     
The Joint Committee for Vaccination and Immunisation (JCVI) RSV subgroup in the UK 
recently revised guidance for the use of palivizumab, though there was some debate over 
the limited evidence base on which these recommendations have been made.124  Currently 
the JCVI state that palivizumab is only cost-effective and recommended for use in the 
following sub-groups of infants at most risk of severe disease:111;112;124 
 Children < 2 years requiring treatment for chronic lung disease within the last 6 months 
 Children < 2 years with haemodynamically significant congenital heart disease 
 Children born at 35 weeks of gestation or less and less than 6 months of age at the 
onset of the RSV season.   
 Children who have severe combined immunodeficiency syndrome (SCID), until 
immune reconstituted.   
 All long term ventilated (LTV) children less than 12 months at the start of the RSV 
season and LTV children aged less than 24 months with additional co-pathology (heart 
disease/intrinsic lung disease as reflected by oxygen dependency).  
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Experts from the American Academy of Pediatrics have recently highlighted the insufficiency 
of current evidence for the benefits of prophylaxis particularly in immuno-compromised 
infants (such as solid organ or hematopoietic stem cell transplant recipients, HIV-infected 
infants and children with other primary and secondary immune deficiencies).125 Further 
experimental studies are currently evaluating the use of palivizumab in infants with cystic 
fibrosis and immunosuppressed bone marrow transplant recipients.13;116   
A HTA published in May 2011, considered population subgroups with different combinations 
of risk factors for whom the use of palivizumab may be cost-effective.  The study found that 
at a willingness-to-pay threshold of £30,000 per quality adjusted life year (QALY), 
prophylaxis with palivizumab is only cost-effective among the subgroups of children with no 
chronic lung disease or congenital heart disease if they have at least two other risk factors 
besides gestational age at birth (including siblings at school, being male, smoking exposure, 
household overcrowding or multiple births).126   
Adding to the continuing debate over precisely which infants are most at risk of severe RSV 
disease, a NEJM study published in 2009 reported that many children with RSV infection are 
previously healthy, so targeting only high risk infants with prophylaxis will be limited in its 
effects on the total RSV disease burden.44   
Another prophylactic drug was also under development, motavizumab, which is also a 
humanised monoclonal IgG antibody which attacks the RSV F protein and was developed to 
achieve greater binding affinity and virus neutralising activity than palivizumab127  A phase 
III, double-blinded, randomised, multinational trial was completed in 2006, comparing 
palivizumab and motavizumab, using the same inclusion and exclusion criteria as the 
original IMpact trial.127;128  The study found motavizumab was non-inferior to palivizumab, 
with a 26% reduction in RSV hospital admissions compared with palivizumab.  However, 
recipients of motavizumab were found to be at increased risk of skin reactions compared 
with those receiving palivizumab.  Consequently, the USA‟s Food and Drug Administration 
(FDA) did not license use of motavizumab, expressing concerns over its safety regarding the 
increased hypersensitivity reactions.129;130  MedImmune who developed motavizumab, have 
discontinued development of its use for prophylaxis against RSV but are maintaining 
research into its possible use for treatment of RSV infection.127;131 
 
1.6.3 Active vaccination 
Ideally either vaccination in early infancy or a maternal vaccine is needed to prevent the 
large burden of RSV-associated illness in early infancy.  However, RSV presents a 
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significant challenge because of the difficulty in eliciting immunity in such young infants, 
combined with the inadequate attenuation of live viral vaccine candidates.13;132;133  
Furthermore, in this age group waning maternal antibody levels are not sufficient enough to 
protect against disease and can decrease vaccine immunogenicity.134  There are also 
considerable safety concerns about inactivated vaccine candidates following the failure of a 
formalin-inactivated RSV vaccine which was trialled in the 1960s and resulted in two infant 
deaths and more severe RSV disease in those who had received the vaccine.13;135;136  The 
potential impact of an RSV vaccine in the Netherlands has been modelled with the results 
suggesting it would be a cost-effective intervention, but in the absence of clinical trial data 
many assumptions about the vaccine characteristics had to be made.137   
 
1.7 Impact on respiratory health in early childhood 
In addition to the acute effects of RSV bronchiolitis, evidence suggests RSV may be associated 
with short and longer-term respiratory complications in childhood, including breathing difficulties 
and cardiovascular abnormalities.138;139  Other studies have shown that RSV infection may have a 
long-term effect on the respiratory tract, causing recurrent wheezing, asthma and reactive 
airways disease in early childhood.14;40;140-152  A further study of a prospective cohort in Sweden, 
showed RSV bronchiolitis is associated with an increased prevalence of allergic asthma 
persisting at age 18 years, but this was a small study with follow-up of only 46 RSV cases and 92 
matched controls.141  There is a growing body of evidence suggesting severe RSV infection in 
infancy may predict asthma and exacerbations of allergic airway disease in adulthood.153;154  In 
addition, the long-term as well as acute effects of RSV have been shown to be associated with 
decreased quality of life and increased healthcare utilisation.103;155-157   
However, the 2008 HTA concluded that there are still major uncertainties about the effects of 
RSV infection on long term respiratory health and mortality among infants in the UK.111  For 
example, conflicting evidence has shown RSV infection in infancy to be a risk factor for 
reduced lung function in early adult life but not for atopy or asthma.158  Other research has 
examined the role of genetic versus functional predisposition to chronic respiratory morbidity 
following RSV infection.159  Recent studies have hypothesised that the disease phenotype 
may be more important than the causative agent, in predicting future asthma and wheeze.160  
This is supported by evidence from immunological studies which have shown the 
inflammatory response in acute bronchiolitis is quite different from that observed in 
asthma.161 
 24 
 
It is not possible to determine from observational studies alone, whether RSV infection 
causes recurrent wheeze or asthma or is an indicator of pre-existing pulmonary 
vulnerability.162  The double-blind, placebo controlled MAKI trial has provided new evidence 
of the association between RSV infection and wheezing in early childhood, as otherwise 
healthy preterm infants who received palivizumab prophylaxis were found to have a 61% 
relative reduction in risk of wheezing in the first year of life compared with those not 
receiving the passive immunisations.162;163  Another prospective multi-centre trial found that 
palivizumab decreases the relative risk of pre-school recurrent wheezing by 80% among 
non-atopic children but had no impact on children with history of atopy.164  This finding 
implies that in the absence of any genetic predisposition to atopy, RSV infection may have 
an important causative role in wheezing pathogenesis.164  However, the study focused on 
preterm born infants only, so may not be generalisable to all children.   
Emerging evidence has also shown that the inception of asthma may be associated with the 
persistence of latent RSV residing in bone marrow, where resident stromal cells which 
provide an immunologically privileged sanctuary, harbour the virus and allow persistence of 
infection.165   
 
1.8 Summary of chapter 
In this chapter current knowledge about the burden of RSV bronchiolitis has been 
summarised, from the wider global context to its current management and importance in the 
UK.  Known risk factors have been described and current gaps in our existing knowledge of 
RSV epidemiology have been identified.  Since there is no recommended treatment which 
shortens the natural course of infection and passive immunotherapy is only cost-effective in 
those at very severe risk, there is a real need to improve our understanding and the current 
evidence base for what constitutes optimal management of bronchiolitis in both primary and 
secondary care settings in the UK.  Large, population-based observational studies have 
been recommended to derive better estimates of risk factor effect sizes.  This is important 
information to inform future policy if an effective active vaccination candidate is found.   
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Key findings from literature review justifying this work 
 
1) RSV infection is the leading cause of childhood LRTI with an estimated 33.8 million new 
episodes of RSV LRTI worldwide each year, among children under 5 years.  It is 
therefore a priority area for development of novel prevention strategies and treatments.   
 
2) There is a paucity of evidence surrounding the burden of bronchiolitis illness in the 
community, with no UK studies reporting the incidence in primary care settings.   
 
3) In developed countries including the UK, small regional studies have estimated that 2 to 
3% of all infants are admitted to hospital with RSV bronchiolitis.  No recent, large, 
observational studies have estimated the clinical burden of RSV bronchiolitis at a 
population scale.   
 
4) There is no known treatment to shorten the natural course of RSV bronchiolitis hence 
the mainstay of intervention is passive immunotherapy.     
 
5) In the UK passive immunotherapy is only considered cost-effective and recommended 
for use in a small sub-group of high-risk infants.   
 
6) Preterm birth, immunodeficiency, chronic lung disease and congenital heart disease 
increase the risk of hospital admission with severe RSV infection.  However, evidence 
from the US suggests around two thirds of infants admitted to hospital are previously 
healthy with none of the known clinical risk factors.   
 
From the literature review I conclude that large observational studies are needed to improve 
risk factor effect estimates.  Policy makers need reliable estimates to model the risks and 
benefits and predict the impact of any emerging preventive interventions such as a novel 
passive or active immunisation against RSV infection. Since the wider impact of RSV 
disease in the community is not clear, larger studies with long-term follow-up are needed to 
clarify the impact of RSV bronchiolitis in infancy on subsequent respiratory health in the UK.   
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2.0 Aim and objectives 
 
Chapter Overview 
This chapter outlines the overall aims of this thesis.  It begins by summarising the gaps in 
our existing knowledge of the clinical burden of RSV bronchiolitis and the opportunities that 
the availability of routine electronic health records could present, in enabling the 
development of large, observational cohorts with long-term follow-up to facilitate child health 
research.  This forms the rationale for the methodology used and research topic that forms 
the focus of this thesis.  The hypothesis being tested and research questions are then 
presented, followed by the overall aim and specific objectives of this thesis.   
 
2.1 Summary of priorities identified for further research: 
 
 Identify the key clinical risk factors that predict hospital admission with severe RSV 
bronchiolitis in the UK.   
 Determine which of these pre-disposing factors are most important in relation to 
disease severity.   
 Determine what proportion of infants with RSV bronchiolitis is born at term and has no 
known clinical risk factors. 
 Address major uncertainties among patient subgroups – in particular, determine the 
specific impact of gestational age at birth on risk of RSV bronchiolitis hospitalisation. 
 Estimate the incidence of RSV bronchiolitis in the community.     
 Determine the impact of RSV bronchiolitis in infancy on longer-term respiratory health.   
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2.2 Rationale for thesis 
It is well established that RSV infection is the leading cause of childhood LRTI worldwide 
and is a significant cause of morbidity particularly in infancy.21  With birth rates in the UK 
rising and improved survival of infants born preterm, the population at risk of severe RSV 
disease is increasing.88;166  This in combination with the lack of effective treatment for RSV 
bronchiolitis and expensive passive immunotherapy only being considered cost-effective in a 
minority of extremely high risk infants, raises the importance of improving the existing 
evidence base from which we can determine how best to manage affected infants.   
Presently there are no national estimates of the incidence of bronchiolitis in the community 
and even less is known about how it is being managed in primary care and whether GPs are 
following existing guidance.  Existing research has focused on the more severe end of the 
disease spectrum, but even research examining the risk of hospital admission with RSV 
bronchiolitis has been limited to small, regional studies, many from individual hospitals and 
few based on UK data.  To date, no large, observational studies have estimated the clinical 
burden of RSV bronchiolitis at a population scale.  Such studies are needed to improve risk 
factor effect estimates.   
Longer-term follow-up of affected infants is required, to address current uncertainty 
surrounding the impact of RSV bronchiolitis in infancy on subsequent respiratory health.  
However, prospective follow-up and large cohort studies, particularly in child populations, are 
often precluded by cost and practicability.   
Databases of routinely-collected electronic health records, particularly here in the UK where 
everyone has universal access to healthcare, can provide a solution to some of these issues 
which have previously hindered progress in this field of research.  Observational studies 
designed using these data will provide representative, population-level data that are highly 
generalisable, relate directly to real clinical practice and are sufficiently powered to detect 
small effect sizes.  Hence this justifies the use of such databases as the approach I have 
chosen to explore the specific research questions in this thesis.   
The gaps in our current knowledge of the epidemiology of RSV bronchiolitis in the UK have 
not only been identified by my own review of the existing literature evidence, but these areas 
for further research have also been highlighted in current UK guidance for bronchiolitis 
management, as well as recommended in the National Institute for Health Research (NIHR) 
Health Technology Assessments on this topic.  This provides further justification that it is 
essential that we identify which infants are at high risk and quantify the wider, clinical burden 
of RSV bronchiolitis across healthcare settings in the UK, in order to ensure appropriate 
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distribution of resources and optimal management of affected infants.  This information could 
be useful for developing an electronic risk prediction tool to aid clinical decision making when 
managing infants with bronchiolitis.   
The findings of this thesis will be of vital importance in the event that a successful, safe and 
effective RSV vaccination candidate is identified.  Health policy makers in the UK will need 
this information to help them to determine the target population for an emerging vaccine and 
to model the potential risks and benefits to predict its impact.  This research will also provide 
more detailed clinical evidence from across healthcare settings in the UK, to ensure existing 
recommendations for the use of palivizumab passive immunotherapy are targeting infants at 
greatest risk of severe RSV infection.  In this thesis I seek to add to and improve the existing 
evidence base on which recommendations for the prevention and clinical management of 
RSV bronchiolitis can be made.  
 
2.3 Hypothesis 
Existing evidence underestimates the wider clinical burden of RSV bronchiolitis 
among infants presenting across healthcare settings in the UK. 
 
2.4 Research questions 
What is the clinical burden of RSV bronchiolitis among infants in the UK? 
 
To describe the total clinical burden of disease, it is necessary to examine the wider clinical 
spectrum of bronchiolitis illness across different healthcare domains (Figure 1).   
 
1) What are the risk factors for admission to hospital with RSV bronchiolitis and how do 
admission rates vary between infants with comorbidities, preterm and term born 
infants?  
 
2) What is the incidence of acute bronchiolitis among infants presenting to general 
practitioners and how is it being managed in the community? 
 
3) What is the long-term impact of RSV bronchiolitis on subsequent respiratory health in 
early childhood?  
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Figure 1: Pyramid of care for infants with RSV bronchiolitis. 
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2.5 Aim 
 
To improve estimates of the wider clinical burden of RSV bronchiolitis among infants in the 
UK. 
 
2.6 Objectives 
 
1. To describe the clinical burden of RSV bronchiolitis among infants admitted to 
National Health Service (NHS) hospitals in England, comparing admission rates 
between infants with and without clinical risk factors for the condition (Study 1 – 
Using linked HES hospital records to develop a nationally representative birth 
cohort). 
 
2. To estimate the incidence of RSV bronchiolitis among infants presenting in primary 
care and to describe how it is being managed by general practitioners, in relation to 
national guidance (Study 2 Using GPRD patient records longitudinally linked across 
time to develop a nationally representative cohort). 
 
3. To determine the longer-term effects of RSV bronchiolitis on subsequent respiratory 
health in early childhood (Study 3 - GPRD and HES long-term follow-up studies). 
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3.0 Use of routinely collected data for child health research 
 
Chapter overview 
In this chapter the practical issues and ethical challenges that arise when conducting child 
health research are described in detail.  The use of electronic patient records for 
observational research in children and linkage between such databases is discussed.  This 
chapter provides important background and rationale for the methodological approach 
applied in this thesis.   
 
3.1 Problems in conducting child health research 
Events in early childhood have a significant impact on health and development throughout 
life.167;168  Infant health is therefore a very important area of research, where the impact of science 
on clinical care has long-lasting effects into adult life.  Multidisciplinary research is required to 
improve the scientific basis of strategies to prevent, diagnose and treat diseases affecting the 
health and well-being of children.  Conducting clinical research in child populations can be 
logistically difficult, expensive, time consuming and ethically challenging.169  Large 
epidemiological studies are a crucial tool for enhancing the evidence base used to inform clinical 
practice.  Unfortunately, assessing health outcomes in large populations of children has been 
severely limited by costs and complexity of acquiring data.170  Alternative methods for 
investigating child health over longer periods of time are required.  Routinely collected electronic 
patient records could provide an invaluable data resource for clinical research among children.   
Undertaking clinical research studies in children presents distinct challenges to researchers, 
in what is a rapidly evolving, dynamic field.171;172  Yet it is widely recognised that research 
into the determinants, diagnosis, treatment and prevention of childhood disease is of vital 
importance,171 not least because clinical decisions need to be justified  with valid up-to-date 
evidence.173  In the field of paediatrics this can be challenging, given the dearth of clinical 
trials addressing issues relevant to child health.174;175 Closer integration and translation of 
child health research into core National Health Service (NHS) activities is required.176  Over 
recent years steps have been taken to address these issues in the UK and utilise the 
research opportunities presented by a NHS providing universal coverage.  We now have 
research support organisations such as Clinical Research Networks and the necessary 
infrastructure to facilitate improvements in paediatric research.174  The Medicines for 
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Children Research Network (MCRN) reported a total of 75 studies of medicines in children in 
the UK on their portfolio, in 2008,177 7 of which were registered studies open or in set-up with 
their clinical trials unit.  The production of the British National Formulary for Children (BNFC) 
was also a landmark event in improving medicines for children.  The Royal College of 
Paediatrics and Child Health (RCPCH) are implementing initiatives such as „Turning the 
Tide‟ to try to strengthen child health research by increasing exposure and involvement 
among undergraduate medical students through to paediatric trainees and consultants.178  
Despite these improvements, the difficulties of establishing clinical studies among child 
populations remain.  Here, in the context of paediatric research, I will evaluate alternative 
study designs and highlight how more efficient use of routine data might improve the quality 
and range of research produced in the UK.   
3.1.1 Experimental study design 
Clinical trials are the preferred study design for investigating the effects of a particular 
intervention and comparing with existing alternatives or placebo.  The obvious advantage of 
such experimental studies is that the assignment of an exposure or treatment to individuals 
is controlled by the investigator.  Even distribution of potential unknown confounders can be 
maintained through randomisation and participants can be blinded as to which intervention 
they receive to reduce bias.  Randomised controlled trials (RCTs) can therefore provide 
strong empirical evidence of the efficacy and safety of therapeutic interventions in a clinical 
setting.   
However, conducting clinical trials in child populations presents distinct ethical challenges.  
There have been several tragic examples where infant deaths or disease may have been 
prevented had more in-depth studies been conducted.  These include the effects of 
thalidomide on development of the fetus, the use of propofol as a sedative resulting in at 
least 15 deaths of critically ill children179-181 and the association between grey baby 
syndrome and use of the antibiotic chloramphenicol in neonates.181;182 
In addition to valid ethical anxieties, the logistical considerations, intensive resources and 
financial requirements of establishing trials in children are extensive and often prohibit long-
term follow-up of patients enrolled in trials.  Costs of conducting trials among children are 
greater than among healthy adults180 and consequently most medicines used in children, 
particularly among neonates, have not been subjected to the same level of clinical 
evaluation as in adults.183  Recruitment of children to RCTs can be difficult with complex 
issues in acquiring consent.  Consequently, where trials in child populations are established, 
sample sizes are frequently too small; one review reported that around 50% of published 
trials had sample sizes below 40.174;184  Limited sample sizes means trials are frequently 
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under powered for examining side effects and have limited generalisability.  Following the 
marketing of a drug, funding from pharmaceutical companies may be less forthcoming.  
Indeed, many phase IV trials cannot recruit large enough populations to sufficiently monitor 
side-effects associated with long-term use, especially as very large numbers of individuals 
need to be exposed to a drug in order to detect reactions that occur with a low probability.185  
So findings from artificial trial settings among highly selected individuals may not always 
translate into sustainable, safe interventions in routine clinical practice.   
3.1.2 Non-experimental study designs 
Whilst RCTs are considered the gold standard study design, it is also important to consider 
situations where alternative approaches to clinical research may be more appropriate.  Large 
observational studies such as case-control, case-series, ecological and cohort designs are a 
crucial tool in expanding the clinical evidence base, particularly for child health.   
Observational studies can provide more generalisable findings than experimental studies, as 
included individuals tend to be more representative of the general population since there are 
not the strict exclusion criteria required for clinical trials, eliminating the inherent healthy 
volunteer bias present in most RCTs.  Observational studies can also provide data on real-
life effectiveness and complications, which may differ from findings from artificial trial settings 
with strict participant selection criteria.  Sufficiently large sample sizes and long-term follow-
up are more easily achieved in observational studies such as EPICure (UK) and EPIPAGE 
(France); longitudinal population-based birth cohorts of extremely preterm babies born in the 
mid-1990s.186  Large prospective cohort studies such as these with long-term follow-up over 
many years are rare because they are so expensive and time consuming.  Even with large 
cohort studies, teasing out the burden of many conditions at a national population level, 
especially very rare disorders, is still a challenge.  Assignment of individuals is not easily 
controlled by researchers conducting observational studies, so the strength of evidence 
provided can be limited by the potential for biases due to unknown confounders.  Non-
experimental studies are usually less expensive than RCTs but can similarly be limited by 
attrition difficulties.187;188  Observational research can provide the firm hypothesis base and 
information for sample size calculations required for subsequent experimental studies and as 
such are an invaluable clinical research tool, providing scientific justification for clinical trials.   
 
3.2 Use of routinely collected electronic patient health records 
A new challenge in paediatric research is to better utilise evolving healthcare technologies to 
facilitate faster dissemination of population-level interventions into the public domain.170  This 
should certainly be possible in the UK which is considered to be at the forefront of research 
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involving secondary use of healthcare data, as the NHS provides a unique source of national 
data due to its universal coverage.189  In light of the current financial climate and widely 
anticipated cutbacks to funding for research, universities and the NHS, attention is turning 
towards the utilisation of existing data sources for health services and clinical research.  
Data from routinely collected electronic patient health records are increasingly being used to 
address the methodological difficulties of carrying out research in populations that are 
typically challenging to study, due to significant ethical concerns and vulnerability, such as 
patients with very rare diseases, pregnant women and children.  Already secondary use of 
routinely collected data from children has significantly contributed to improvements in child 
health research in the UK.6;190-194  
For example, real-time data has been used to alert trusts of safety issues such as higher 
than expected child mortality following cardiac surgery.195  The fundamental advantages of 
using such routine databases are the minimal costs involved and magnitude of information 
they can provide, often at a national level.  These are factors which have previously severely 
limited evaluation of health outcomes over long periods of time, in large geographically 
defined populations.170  Where survival is reported in neonatal studies for example, data are 
often from specialised units and are therefore subject to inherent selection bias resulting 
from different criteria for admissions, treatment or referrals.95  Routine data permit 
investigation of long-term outcomes which is so rarely feasible in RCTs, thereby providing 
invaluable information about real-world implementation in populations outside trial inclusion 
criteria.   
3.2.1 Ethical considerations and consent for long-term follow-up 
The inherent difficulties surrounding anonymity and obtaining consent when using secondary 
data are well established189;196  and it has been suggested that current UK research 
regulations can impede follow-up in multicentre studies.197-199  Difficulties in acquiring data on 
long-term outcomes were highlighted by the Bristol Royal Infirmary inquiry in 2001.197  The 
requirement for an individual's consent to confirm they are alive and monitor survival often 
precludes effective long-term follow-up for prospective studies due to the ethical and 
practical complications of tracing participants who change address or die.197  A series of BMJ 
editorials highlighted some important issues surrounding the use of identifiable personal data 
for medical research purposes.189;196;200  This series stressed the need for regulating bodies 
to accept that current UK laws permit the secondary use of data without consent or full 
anonymisation, provided the likely public benefit is demonstrably proportionate to the risks of 
identification and subsequent distress this may cause.189   
 35 
 
The National Information Governance Body (NIGB) Ethics and Confidentiality Committee 
determines when obtaining individual consent may not be practicable, for example when 
undertaking large population studies of survival, such as among children with chronic 
conditions.197  Hansson‟s BMJ article rightly argues the need for a wider view of autonomy in 
epidemiological research.201  Systematically obtaining individual signed consent for sharing 
patient identifiable information is difficult and can sometimes hamper research.201-204  though 
for particular research questions it may be wholly necessary to obtain individual/parental 
consent .198 
3.2.2 Potential uses of child health records for research 
Information on birth characteristics, such as gestational age and birth weight, is needed for 
many epidemiological and health services research studies examining short- and longer-
term clinical outcomes.205  Detailed information on early birth exposures is routinely captured 
in hospitals throughout England and can provide a rich electronic source of clinical 
information about the health status of individuals at birth, as well as for measuring the quality 
of maternity care.  Secondary use of such data involves comparatively minimal costs in 
comparison to bespoke prospective observational studies.  Large epidemiological datasets 
are particularly useful for infant health research where life-long assessment of outcomes is 
required, but all too often precluded by reason of cost, methodological difficulty and 
practicability.  Consequently, much infant research is selective, poorly generalisable and 
focused on short-term outcomes.  The secondary uses of data from electronic health records 
cannot replace nor precisely replicate the value of data collected for prospective studies, but 
the potential benefits for clinical and health services research and impact on patient care are 
well established.206-209  These data can facilitate benchmarking and comparison of outcomes 
between different hospital sites or geographical areas.  Cohorts based on these data, 
particularly when combined with novel techniques such as Mendelian randomisation, can 
provide representative population-level information that is highly generalisable, has power to 
detect small effect sizes and relates directly to real clinical practice.  Such cohorts have the 
potential to answer an extensive range of research questions that require longitudinal follow-
up, from examining long-term health outcomes and healthcare utilisation following preterm 
birth, to identifying risk factors for childhood hospital admission with influenza or respiratory 
syncytial virus infection.   
 
3.3 Linkage with other health records  
In health systems with universal coverage, the value of clinical databases for research can 
be significantly enhanced by linking different data sources, creating the potential to develop 
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cradle-to-grave datasets for the whole population.  Probabilistic or deterministic linkage 
methods can be used to match records for the same individual from different databases, 
using unique personal identifiers such as NHS number.  Algorithms can be developed to 
assign individual unique identifiers using variables such as NHS number, date of birth and 
postcode.  Linkage between datasets can provide validation of recording, coding and 
completeness of data, help to develop more robust clinical case definitions and provide 
information on events that happen outside healthcare settings.210  For example, linking to 
Office for National Statistics (ONS) mortality data in England yields information on cause of 
death and out-of-hospital deaths.   
Successful matching of records is dependent on the quality of unique identifier variables 
available,189 but linkage methods can correctly identify a high proportion of matched records 
even with limited availability of personal identifiers.211  Large scale population-based linkage 
presents its own complex ethical challenges of consent, confidentiality and secure data 
storage that are best addressed by robust information governance systems and engaging 
patients and the public about how their records are to be used.189;212   
 
3.3.1 Examples of linkage between birth and child health records to date  
 
Non-UK 
The effectiveness of routine health record linkage in adults has been demonstrated in 
Australia and Canada,210;212-214 where it has improved both data quality and utility.210  Birth 
records have been successfully linked to hospital discharge data in Australia, with matching 
rates of 99%.215  In several regions of the United States, data from birth certificates have 
been linked to hospital discharge records to examine maternal outcomes.216;217  In 
Scandinavian countries, the assignment of unique personal identification numbers permits 
linkage between civil registration systems, enabling the development of population-based 
cohorts.  These have facilitated a broad array of epidemiological studies, including research 
in Denmark investigating the impact of place of birth and familial risk factors on risk of 
autism218 and examining the association between prenatal exposure to high levels of coffee 
and attention-deficit hyperactivity disorder in childhood.219 
 
UK 
In Wales, the Secure Anonymised Information Linkage (SAIL) databank brings together 
anonymised person-based electronic health and social care data, which are now also being 
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combined to establish an anonymised Wales wide Electronic Cohort for Children 
(WECC).220;221  This databank has successfully been used to assist with identifying potential 
clinical trial participants from primary care data.220;222  The Scottish Health Informatics 
Programme (SHIP) is an example of a complex database of linked electronic patient records, 
providing health and social care information from birth through to death.223  To date, SHIP 
data have primarily been used to conduct pharmacovigilance and diabetes epidemiology 
research.223;224    Another well-established system in the UK is the Oxford Record Linkage 
Study covering over 10 million records for around 5 million people since 1963.225  This 
database has been used to carry out longitudinal research studies identifying maternal and 
perinatal risk factors for a range of conditions such as inflammatory bowel disease226, 
asthma 227 and coeliac disease.228 
 
Administrative birth data are captured in England in both hospital discharge records and also 
birth registration information collected by the ONS.  Use of information contained within the 
English HES delivery and birth records for research has been limited.  A previous feasibility 
study showed high rates of linkage between HES maternity and ONS birth records.229  In 
addition to these national sources of birth data, the NHS Numbers for Babies (NN4B) 
Service, introduced in 2002, collects a small dataset containing some key fields that are not 
recorded in birth registrations, such as gestational age.230  This NN4B service ensures every 
baby is allocated a unique NHS number shortly after they are born.  Linkage between NN4B 
and HES birth records has indicated that improvements in the quality and completeness of 
HES maternity data are needed.230;231  HES maternity data have also been used to validate 
birth information recorded in the Millennium Cohort Study, a longitudinal observational cohort 
of nearly 19,000 babies born across the UK.232   
 
3.4 Database linkage 
With uncertainty surrounding the future of the Connecting for Health summary care record, it 
is imperative that we maximise the research potential of routinely collected patient data.  
Indeed previous reports have highlighted the need for initiatives to support linkage between 
different databases, recommending a “federated structure of data sources” rather than 
individual databases.233  Although the quality of clinical databases can vary,234 the intrinsic 
value of their use for research purposes can be significantly enhanced by linking different 
sources.  Furthermore, comparison between datasets can provide validation of clinical 
recording, coding and completeness of data.  As well as the quality assurance benefits of 
linking datasets, additional information on events that happen outside the healthcare setting 
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of data capture can be provided;210  for example linking to Office of National Statistics (ONS) 
mortality data to obtain vital information on out-of-hospital deaths.   
Probabilistic matching techniques have been developed to link health service data since the 
1960s235 and have been considered an acceptable method for conducting population based 
health research for some time,212 made possible by significant advances in computer 
technologies.  Field and colleagues report that although issues surrounding data ownership 
require some consideration, the advantages of routine linkage of health record databases 
are readily apparent and their effectiveness has already been demonstrated in countries 
such as Australia and Canada.210;213  Their study demonstrates the benefits of linkage 
between oncology databases and suggests routine combining of data from such sources can 
improve both data quality and utility.210  The value of linking individual records from disease 
registries and other healthcare databases for epidemiological and health services research 
has also been demonstrated in the UK.  For example, the Scottish Medical Record Linkage 
System and the Oxford Record Linkage Studies described earlier.225;236   
3.4.1 Advantages and limitations of using linked health records for research 
Databases of linked medical records could be useful for many purposes: as public health 
tools for conducting epidemiological research, to provide long-term data on patient care 
pathways, to evaluate interventions and also for health services planning and management.  
In comparison to conducting large prospective studies with several years‟ follow-up, linking 
existing patient health records is considerably less expensive and time consuming and when 
using national data findings are highly generalisable.  In addition, the development of very 
large cohorts with high statistical power permits the detection of even small effect sizes and 
can overcome some of the limitations of cross-sectional data such as under ascertainment of 
cases.237  For widely used medications, large routine datasets can provide useful information 
on side effects and safety, which under-powered clinical trials fail to sufficiently measure.  
Specifically for epidemiological research among groups that are conventionally challenging 
to study, linkage between databases represents a potentially invaluable tool.  This is 
especially true in the field of neonatal medicine as with improved neonatal care, survival 
rates among preterm babies are increasing so longer-term follow-up following discharge 
from neonatal intensive care units (ICUs) is imperative.   
There are some inevitable limitations of linking electronic patient records for research 
purposes which must be considered.  Using secondary data sources is not always ideal as 
researchers have no control over the information available since the data are often collected 
for an unrelated purpose.  In many clinical trials and observational studies, losing patients 
during follow-up due to death or moving residence can be a problem.  Utilising linked patient 
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health records should make it easier to track individuals for example between different 
hospitals or trusts within the UK.  A considerable limitation of using electronic records for 
research purposes is variation in the accuracy of clinical coding.  However, in recent years 
the quality of coding in many national datasets has improved238-240 and they are increasingly 
being used for clinical research. 
Possible methodological limitations of linking healthcare records include the degree to which 
data can be anonymised without losing vital information and the successful matching of 
records is dependent on the quality of unique identifier variables.189  However, provided 
methods are tailored to the datasets being used and the context of how data were collected 
is considered, linkage methods can correctly identify a high proportion of matched records 
even with limited quality or availability of identifiers.211  Furthermore, efficient methods of 
validating probabilistic record linkage have been widely reported.241  Large-scale population-
based linkage presents its own complex ethical challenges as well as considerable 
difficulties with respect to consent.189;212  The key to making linked resources useful and 
accessible is ensuring confidentiality and secure data storage.189;212 
Record linkage is not a viable solution to answer all research questions.  It will be necessary 
in some studies to obtain individual/parental consent.198  Equally, observational study 
designs are not appropriate for all paediatric research and are no substitute for rigorous 
RCTs of interventions.  However, record linkage can supplement clinical trials by providing 
information on long-term outcomes.  This is especially important in paediatric research 
where longitudinal data are so infrequently available.  To facilitate linkage between existing 
databases of patient records, cooperation between data owners will be vital as is the 
requirement for rigorous, research governance.   Educating and engaging with the public is 
essential to provide reassurance about the confidentiality of personal medical data used for 
research purposes, especially in a society where personal data are commonly shared 
among commercial organisations.   
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3.5 Summary of chapter 
High quality paediatric research is essential to provide a firm evidence base for clinicians, to 
improve patient care and develop better diagnostic tools and treatments for children 
throughout the UK and worldwide.174  The UK is in a unique position with many healthcare 
settings routinely collecting and storing detailed information on child health.  Existing data 
sources can be used to improve clinical trial design as well as for monitoring safety following 
the marketing of new interventions.  If discernibly high standards of patient confidentiality 
and data security can be guaranteed and linkage methods validated, utilising existing 
resources for research purposes should be encouraged.  Among populations that can be so 
challenging to study, this represents a cost-effective alternative source of data for 
longitudinal observational research.  Linking routinely collected electronic health records 
from different databases could help to address the current paucity of information on long-
term health outcomes among children, which is essential to improve the translation of 
research into clinical practice.   
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4.0 Overview of health record databases in the UK 
 
Chapter overview 
Having discussed in the previous chapter the use of electronic health records for child health 
research, this chapter presents more detailed contextual information about some specific 
databases of routinely collected healthcare records in the UK.  The research governance 
procedures and ethical approvals required to use these data are explained and the access 
and approvals I have to permit use of these particular databases are outlined.  These data 
sources will be used to try to answer the research questions I have developed and to test the 
hypothesis on which this thesis is based (chapter 2.0).   
 
4.1 Introduction to child health records in the UK 
The UK is in a unique position among developed countries, because of the universal access 
to healthcare provided by the NHS, unlike more fragmented healthcare systems such as in 
the USA.  The NHS is also more technologically advanced than healthcare systems in other 
developed countries, with most areas of healthcare using electronic systems to store health 
records.  As a result, a wealth of patient information is stored across a range of healthcare 
databases, which can provide valuable data for health services and clinical research, 
particularly among populations which are typically difficult to study such as pregnant women 
and children.   
Patient information is recorded whenever and wherever an individual accesses healthcare, 
from primary care settings such as visiting a GP to secondary and tertiary care settings 
where inpatient and outpatient records are collected.  Administrative, clinical, diagnostic, 
therapeutic and microbiological information from patients are all collected in different ways 
and recorded in different systems across different healthcare settings within the NHS.  In the 
absence of a universal care record which could contain all this information in one system, to 
be shared and accessed by all health professionals, the current fragmented approach 
means there is much duplication of effort and data collection.  There are therefore many 
different regional and national databases where these health data are stored.   
The literature from observational studies described in chapter 1, were predominantly from 
small scale, regional studies.  National patient datasets provide a means of estimating the 
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burden of illness at a much larger, population scale.  Not only for studies of ecological 
design, but the methods chapter will also describe how I piloted the use of these data to 
develop cohorts of children, with longitudinal follow-up over time, from birth.   
In this thesis I describe studies developed using secondary and primary care data.  National 
hospital admission data for England are recorded in the Hospital Episode Statistics (HES) 
database and the General Practice Research Database (GPRD) contains data from a 
nationally representative sample of 600 general practices in the UK.  The National Neonatal 
Research Database (NNRD) contains neonatal records from almost all neonatal units across 
the UK.   
 
4.2 Hospital Episode Statistics (HES) 
4.2.1 Overview of dataset 
HES is a national administrative database, electronically recording all admissions to NHS 
hospitals in England since 1989.242;243  HES contains a wide range of data including coded 
clinical diagnoses,  procedures, geographical information on where patients are treated and 
demographic information such as patient age, sex, socio-economic status and ethnicity 
(www.hesonline.nhs.uk). In addition to inpatient records, outpatient attendance data are 
available since 2003, with more than 40 million new records added annually and more 
recently A&E data have also been collected since 2007.242  Information on deaths is also 
available in HES, as records are linked to mortality data collected by the Office for National 
Statistics.   
The basic unit recorded in HES is the finished consultant episode, which covers the period of 
time during which a patient is under the care of a given consultant.242  A „spell‟ or admission 
is defined as the continuous period of time spent as a patient within one hospital,243 from 
admission to discharge or transfer to another provider.  Spells may therefore include more 
than one consultant episode, for example if a patient is transferred from a general medical 
ward to a specialist or intensive care unit.243   
HES data are divided into financial years from April 1st in a given year to March 31st in the 
following year.  The International Classification of Diseases system version 10 (ICD-10) 
codes are used to record the main reason for admission or „primary diagnosis‟, with up to 13 
secondary diagnoses.244;245  procedures and interventions are coded using the 4th revision of 
the Office of Population, Censuses and Surveys: Classification of interventions and 
procedures (OPCS-4).242;245   The dataset has changed over time, with older versions of 
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these clinical classification systems being used in earlier years, for example ICD-9 codes 
were used until 1995 when use of the tenth version was introduced.   
4.2.2 Data collection and purpose 
The mechanisms used to collect HES data have changed over time, as changes to the 
structure and organisation of the NHS have occurred.  Currently, providers of healthcare 
such as NHS Trusts, submit data to the National Programme for IT‟s Secondary Uses 
Service (SUS) (previously to the NHS-Wide Clearing Service).242  To support patient care 
and inform commissioners of that care, healthcare providers collect clinical and 
administrative information locally.  These data are submitted to the SUS, which make this 
information available to commissioners and also copy it into a database.  At set times 
throughout the year, SUS send an extract of their database to HES.242  This national HES 
data warehouse for England is run by the NHS Information Centre for Health and Social 
Care.  Data within SUS can continue to be updated and changed, whereas data in HES is 
fixed as it was on the date that the extract was taken, so there can be discrepancies 
between them.  HES data are then cleaned, validated, new fields are derived and quality 
checks are carried out.242;245   
There have been some concerns regarding the accuracy of diagnostic coding in HES and 
variation between hospitals, but coding has been improving over time.240;246-248  HES is the 
data source for a wide range of healthcare analysis, for research organisations, the NHS and 
the government.242  HES data have been used extensively for research, measuring quality of 
healthcare delivery, examining disease time trends, variations in practice and to make 
international comparisons.6;249-255   
4.2.3 HES maternity records and baby tails 
Maternity data in HES consists of delivery records (for mothers) and birth records (for 
babies).  These contain additional data fields known as the “baby tail”, which include 
information such as birth weight and gestational age.245;256;257  As soon as a mother has 
given birth, her hospital admission record changes from a general inpatient admission record 
to a maternity record and is updated as such before it is submitted to HES.242  HES contains 
two types of maternity record, the delivery and the birth record, both of which contain a “baby 
tail” of an additional 19 fields.242  The delivery record is for the mother and contains the same 
information as a general record plus an additional baby tail with information about the 
delivery.242  The birth record is for the baby and also contains general record information 
plus the baby tail, which contains identical information to the corresponding baby tail in the 
mother‟s delivery record.242  Diagnoses and procedures recorded in the birth record refer to 
the baby and, conversely, diagnoses and procedures in the delivery record refer to the 
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mother.242  For multiple births, separate tails for each baby will appear in the mother‟s 
delivery record, but each birth record will contain only the individual baby‟s relevant tail.242  
HES data are collected from births in NHS and non-NHS hospitals and at home, although 
information from births outside NHS hospitals is often incomplete.242  A list of some of the 
maternity data collected within HES can be found in Box 1: Key information collected in HES 
maternity records. 
.   
 
 
 
 
 
Box 1: Key information collected in HES maternity records. 
 
 Method of onset of labour 
 Place and date  of delivery 
 Miscarriages and ectopic pregnancies 
 Live and still births 
 Deliveries and births with complications 
 Multiple deliveries 
 Length of gestation 
 Birth weight 
 Neonatal unit admissions and level of care 
 Antenatal and postnatal length of stay 
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4.3 The General Practice Research Database (GPRD) now part of 
the Clinical Practice Research Datalink (CPRD) 
 
4.3.1 Overview of dataset 
The General Practice Research Database (GPRD) database contains computerised clinical 
records from about 5 million active patients, 12 million patients overall, from 600 primary 
care practices across the UK and is a nationally representative sample of around 8% of the 
UK population.258  From 29th March 2012, GPRD is now part of the Clinical Practice 
Research Datalink (CPRD), the new observational data and interventional research service 
for the English NHS, funded by the Medicines and Healthcare Regulatory Agency (MHRA) 
and the NIHR.258;259  The CPRD aims to maximise the way anonymised clinical data from the 
NHS can be used for observational research, using linkage to integrate data from primary 
care, secondary care and disease registries, with the aim of facilitating research that is 
beneficial to improving public health.259 
It is estimated that over 98% of the UK population are registered with a GP, almost all of 
whom use computerised record systems.260  Databases such as the GPRD are therefore a 
rich source of longitudinal patient data.  Information collected from GP records includes 
demographics, diagnoses, symptoms, preventative care, prescriptions and referrals.260   In 
the UK, a standardised hierarchical classification system of READ codes is used to record 
medical information in patient records.261  The Oxford Medical Information System (OXMIS) 
is another clinical coding system that was previously used by GPs contributing to the GPRD.   
4.3.2 Dataset uses 
The C/GPRD is the largest and most comprehensive source of primary care data in the UK 
and has been widely used for research, from pharmacovigilance to risk score 
development.258;262  It has been particularly useful for child health research, for example for 
studies examining the association between antiepileptic drugs and child mortality,263 
antibiotic use and the risk of community-associated methicillin-resistant Staphylococcus 
aureus (MRSA)in children264 and quantifying the risk of convulsions in children who received 
the monovalent H1N1 and trivalent influenza vaccines.265  The GPRD was also used to 
examine any possible association between the mumps, measles and rubella (MMR) vaccine 
and autism, with the findings showing no association between use of the vaccine and 
autism.262;266;267 
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4.4 The National Neonatal Research Database (NNRD) 
 
4.4.1 Overview of dataset 
In 2003 a Department of Health review268 led to the reorganisation of neonatal services in 
the NHS into clinical networks with coordinated care services and shared management.170;269  
As a result, a new system of electronic neonatal records was developed and is now in use 
by the majority of neonatal intensive care units (NICUs) across the UK (approximately 165 
units).170;270;271  The Neonatal Data Analysis Unit (NDAU) is an independent academic unit at 
Imperial College London, established in 2007 to analyse data held on electronic neonatal 
records. The NDAU obtain a standard core clinical dataset from NICU admission to 
discharge, which was developed by the British Association of Perinatal Medicine (BAPM)272 
and is held on a common NHS platform, neonatal.net.  This database is now known as the 
NNRD and is held at the NDAU.  The NDAU undertake clinical audits, monitoring, service 
evaluations, administrative reports and health services research. The NDAU Steering Board 
currently includes representation from Imperial College London, the National Perinatal 
Epidemiology Unit, BAPM and the new-born charity BLISS.   
Included in the dataset are data from ten audit questions which form the National Neonatal Audit 
Programme (NNAP) which was set up by the RCPCH in January 2006, with the aim of informing 
good clinical practice in aspects of neonatal care by auditing national standards.273  The dataset 
also incorporates the mandatory National Critical Care minimum dataset.  In 2012, the UK 
National Neonatal Collaborative was established, comprising all NHS trusts that contribute data 
to the NNRD, to support UK neonatal units in utilising clinical data to improve patient care and 
outcomes and to support service delivery and evaluation and the NNAP.271;273   
4.4.2 Data collection and uses 
 
The data held in the NNRD are entered by neonatal clinical staff through a system of drop-
down boxes, incorporating entry-level logic and range checks, with minimal free text entry.271  
In general, data are of a high quality as they are used daily for clinical care, generating 
discharge summaries and to support commissioning and network management.  Babies are 
frequently transferred between neonatal units providing different levels of care, so these 
electronic records provide instant access to full clinical details by a receiving hospital when a 
baby is transferred.  Since 2011, these data have also provided the basis for Payment by 
Results (PbR) for newborn services.   
 47 
 
At present, records from around 60,000 babies admitted to NHS neonatal units across the 
UK are entered onto the electronic neonatal data system each year, which is managed by 
Clevermed, an authorised NHS hosting company.274   
The neonatal database is unique internationally as data are collected in a standardised 
format during the course of clinical care.  The database provides information from a large 
geographically defined population which can be used to facilitate applied neonatal 
research.271;275   
Data are entered onto the neonatal.net platform by clinical staff on neonatal wards, so these 
are actively recorded, integrated records of clinical care which are used to produce final 
discharge summaries.  A range of data fields are collected, including static, episodic and 
daily items.  Static items are recorded once, usually when a baby is initially admitted and 
include items such as NHS number, name, gestational age and birth weight.  Episodic items 
are recorded at each episode of care and include information such as diagnoses, infections 
and admission and discharge times.  Daily items are recorded on each day of care and 
include information on care received such as respiratory support or enteral feeding.   
These neonatal records are securely uploaded and stored on an NHS server by Clevermed 
Ltd.  For all UK units who have provided the required Caldicott Guardian permission, these 
records are then encrypted and securely transferred via NHS connection to the NDAU where 
they are stored on an NHS server.  The NDAU then examine the data, particularly 
completeness of recording and carry out logical checks for consistency and realistic ranges 
of values.276  Some data cleaning and processing is also carried out, such as converting 
date variables, removing duplicate records and assigning numeric equivalents to string items 
or to free text items that occur frequently.   
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4.5 Research governance and ethical approval 
Aggregated, anonymised data from some of these routine healthcare databases are freely 
available and accessible to all online.  Where use of individual and/or identifiable patient 
data for research is required, ethical approval is needed.  The National Information 
Governance Board for Health and Social Care (NIGB) is an independent statutory body 
responsible for the improvement, monitoring and promotion of information governance in 
health and social care in the UK.277  Their role is to advise and ensure the lawful and ethical 
use of patient information, both for individual patient benefit and for the greater public good.  
Section 251 of the NHS Act of 2006 (previously Section 60 of the Health & Social Care Act 
2001), allows identifiable patient information to be used without individual consent, in specific 
circumstances where anonymised information may not be sufficient and obtaining patient 
consent may not be practicable.278  Researchers must apply to the Ethics and Confidentiality 
Committee (ECC) which oversees this aspect of the NIGB‟s remit.   
Confidentiality 
Data are defined as confidential if they may be personally identifiable.  Confidential 
information is subject to the provisions of the Data Protection Act 1998.   
 
4.5.1 HES data access and approval 
The Dr Foster Unit (DFU) at Imperial College London is within the Department of Primary 
Care and Public Health and is principally funded by a research grant from Dr Foster 
Intelligence (DFI), an independent healthcare information company and joint venture with the 
NHS Information Centre.  The DFU holds HES data consisting of inpatient, outpatient and 
A&E data for England which is deemed confidential as individual level information such as 
postcode, NHS number and date of birth are held, from which it may be possible to identify 
individuals.  The unit has permission from the NIGB under Section 251 of the NHS Act 2006 
(formerly Section 60 approval from the Patient Information Advisory Group) to hold such 
confidential data and has ethical approval to use them for research and measuring quality of 
delivery of healthcare, from the South East Ethics Research Committee.   
Through the DFU I have been granted access to HES data, in accordance with their non-
disclosure and confidentiality agreements and standard terms of data protection.   
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4.5.2 GPRD data access and approval 
I submitted a protocol outlining the study proposal described in the next chapter, which was 
approved by the Independent Scientific Advisory Committee for the MHRA who review all 
research proposals for the use of the GPRD.  Access to the data was granted free of charge 
under the previous Medical Research Council (MRC) license scheme with the GPRD.   
 
4.5.3 NNRD data access and approval 
In 2010 the NDAU was granted National Research Ethics approval to establish the NNRD.279  
As part of the Medicines for Neonates programme of work (of which this PhD research forms 
one component) we applied to the NIGB for approval to link the NNRD managed by the 
NDAU to national HES data at an individual level.   
Provisional approval was received in December 2010, subject to clarification and 
amendments to some aspects of the application, such as providing further information to 
parents about the potential uses of their baby‟s data and to facilitate a mechanism to permit 
dissent to be included.  Final NIGB approval was granted in January 2012.  Following this, 
an application to receive HES data on site at the NDAU, with personal identifiers to permit 
linkage to the NNRD, was submitted to the NHS Information Centre in February 2012.  This 
application was approved and a HES data extract provided to the NDAU at the end of 
August 2012.   
 
4.6 Summary of chapter 
This chapter has provided an overview of the electronic health record databases that I have 
access to and will be used to answer the research questions in this thesis, outlined earlier in 
chapter 2.0.  Specifically, HES, G/CPRD and the NNRD databases have been described, in 
terms of the history and purpose of each dataset, the types of information they contain and 
what these data are used for.  This chapter also presents important research governance 
information regarding the access and approvals I have for using these data for research.   
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5.0 Methods: Creating birth cohorts using child health records 
 
Chapter overview 
In this chapter the processes used to create birth cohorts using routine healthcare records 
are described.  First, I explain how RSV-associated admission rates were examined.  Then I 
describe in detail the novel application I developed of using HES data to create a cohort, by 
linking individual birth records to subsequent hospital admission records and the feasibility of 
doing this.  The coverage and completeness of recording in HES birth records is discussed 
and their validity tested by comparing to birth registration data collected by the ONS.  An 
approach for minimising the effect of variable data completion between hospitals is then 
presented, with sensitivity analyses to determine whether this is a valid solution.  I then 
describe how GP records were obtained and can also be linked over time to develop a 
cohort. Finally I describe how cohorts of children born in 2003 were developed using both 
the GPRD and HES datasets, to examine the impact of an episode of bronchiolitis on 
subsequent consultations and admissions for further respiratory diagnoses.   
 
5.1 RSV-associated admission rates 
In addition to developing a birth cohort of infants born in English hospitals and examining 
which factors increase their risk of bronchiolitis admission, I decided it would be useful to 
obtain some background information about underlying admission rates for RSV-associated 
illness among infants, over time.  This provides important contextual information as secular 
trends in RTI admissions and changing thresholds for childhood admissions may impact on 
RSV admission rates.  Examining trends over time will provide useful data to determine the 
robustness of the bronchiolitis admission rates I calculated. 
All emergency admissions to hospital among infants under 1 year, from 1997/98 to 2010/11, 
with a primary diagnosis of RSV-associated illness were identified using the HES database.  
This time period was chosen since these were the earliest and latest years for which these 
admissions data were available.  Following consultation with general practitioners, a 
paediatric infectious disease consultant and clinicians at the Health Protection Agency, a list 
of ICD-10 codes for RSV-associated illnesses was identified and these were categorised into 
the following groups:  
 Specific RSV diagnosis 
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J205 Acute bronchitis due to RSV 
J210 Acute bronchiolitis due to RSV 
J121 Respiratory Syncytial Virus pneumonia 
  
Unspecified bronchiolitis diagnosis 
J209 Acute bronchitis unspecified 
J219 Acute bronchiolitis unspecified 
 
Unspecified viral pneumonia diagnosis 
J128 Viral pneumonia unspecified 
J129 Bronchopneumonia unspecified 
J180 Lobar pneumonia unspecified 
J189 Pneumonia unspecified 
J22 Unspecified acute lower respiratory infection 
 
Annual admission rates were then calculated by dividing the total the number of admissions 
in each of the three groups in a given year, by the estimated number of live births in that 
year, using mid-year population estimates obtained from the ONS.   
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5.2 Creating a birth cohort using HES records 
A birth cohort is a longitudinal study design where individuals who are born within a defined 
period of time and location are followed up over time.  Among the group the incidence of one 
or more outcome is measured and information on exposures to different factors is recorded 
across the time period.  In this thesis I will be using routine data to carry out epidemiological 
research by developing birth cohorts of individual patient records linked across time.   
5.2.1 Linkage across time to produce a HES cohort 
The processing of HES birth records described for the first time here can be used to develop 
cohorts of children with the potential for long-term follow-up.  Using a unique personal 
identifier, individual birth records can be linked across time to subsequent admission 
records, so that longitudinal information on severe episodes of illness requiring 
hospitalisation can be provided.  The unique identifier used in HES (“HESID”) is derived by 
matching records for the same patient using a combination of NHS number and local patient 
identifier, plus the patient‟s date of birth, sex and postcode.242   
 
As well as the completeness of recording and quality of coding, it is important when linking 
records across time to consider the issue of cohort attrition, because although an individual 
may be born in an NHS hospital in England and therefore included in a HES birth cohort, 
migration, deaths and admissions outside of NHS hospitals in England are difficult to identify 
without individual patient consent and follow-up.  I will now outline the key data processing 
and methodological issues required to use HES birth records to develop a birth cohort.  
 
5.2.2 Processing and methodological issues using HES maternity data  
Identifying birth episodes 
The first step in developing a birth cohort study using HES was identifying all individual birth 
episodes within a given year.  To identify birth episodes, I used the “admimeth” variable 
which contains a code recording how the patient was admitted to hospital.245  This field was 
used to select all records with an admission method coded as 82 (other: babies born in 
health care provider), or 83 (other: babies born outside the health care provider, except 
when born at home as intended).   
Removing duplicate birth episodes 
The next step was identifying any duplicate birth episodes (a typical but limited problem with 
administrative data) using the unique personal identifier (“HESID”).  I looked specifically at 
the first episode within the given spell (i.e. the initial birth episode itself) using the “epiorder” 
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field which contains the number of the episode within the current spell.245  In the dataset 
from financial year 2007/08, 5600 individuals were identified with more than one birth 
episode recorded, of which 5545 had two and 55 had more than two birth episodes 
recorded.  Individuals with >2 birth episodes were excluded from the cohort because it would 
be almost impossible to decipher which birth record ought to be retained when comparing 
more than two duplicates.  Many records from individuals with two birth episodes were 
identical matches (2750 individuals), having two exact duplicate birth episodes with identical 
information recorded in all fields.  Where this was the case, one of the identical records was 
deleted.   
Among the remaining individuals with two birth episodes, the records did not contain 
matching information.  It is very difficult to determine which of two birth records with the 
same unique identifier is likely to be the true record of that individual‟s birth.  In previous 
studies using HES and similar databases, the common approach has been to retain only the 
first observation recorded.  Upon observation, it became clear that the basic demographic 
information for each pair of birth episodes tended to be common to both and for most it was 
only the diagnostic fields that differed.  Consequently, records for individuals with duplicate 
birth episodes were compared using recording of diagnostic information and only the birth 
episode with the most diagnostic information recorded (number of non-empty diagnosis 
fields) was retained in the cohort.  It was not possible to determine whether this approach is 
better than randomly retaining one birth episode.  However the record with the most 
diagnostic information might be the more accurate of the two because it is common for 
hospitals to resubmit data after they have carried out all their diagnosis coding more 
thoroughly (their first submissions may contain only very basic diagnostic information).  
Therefore, records can appear as duplicates if hospitals fail to report them as re-submissions 
to the Secondary Uses Service (SUS, the NHS data repository).  Consequently, for an 
individual with two birth episodes, the one with more diagnostic information may be the more 
accurate record.  Handling duplicate records is a common, challenging problem when using 
routine data such as HES and requires careful consideration of the study context.   
Summarising information from additional episodes in a birth spell  
Babies can have more than one episode of care within their birth admission, for example if a 
baby receives specialist care from a different consultant, is transferred between hospitals or 
is admitted to a neonatal unit.  These additional episodes occur within the same birth spell 
but, where the initial birth event would have an “epiorder” value of 1, subsequent episodes in 
the birth spell have an “epiorder” value >1.  To facilitate one-to-many linkage to subsequent 
hospital admission records, it is easiest to develop a dataset consisting of one observation 
(or row) per individual.  7410 individuals in our 2007/08 birth cohort had >1 episode in their 
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birth spell.  To simplify the dataset to consist of only one birth record per patient, key 
information such as any premature or congenital anomaly diagnoses was summarised using 
flags.  These were then linked back into the original birth episode and subsequent episodes 
in the birth spell were dropped.   
Cleaning variables 
A range of exclusion criteria were developed to clean key variable fields and examine the 
quality of coding.  The Care Quality Commission (CQC) conducted a review exploring quality 
indicator specifications, used to assess the quality of HES maternity data from 2009/10.280;281  
The criteria identified within the CQC review280 and HES inpatient cleaning rules282 were 
combined and applied to the HES birth fields to ensure suspicious data and invalid records 
were removed.  In addition, any stillbirths that were recorded were identified (using the birth 
status and discharge method fields) and removed from the final cohort of live births.   
Identical baby tail information recorded for each baby can be found in their mother‟s delivery 
record.  Maternity systems can record up to 9 birth tails for each delivery, allowing 
information from multiple births to appear in the mother‟s delivery record.  In some instances, 
I found baby‟s information was not recorded in the first field of a given variable. For example, 
if a baby was the second twin, their gestational age at birth (“gestat”) may have appeared in 
the second field (“gestat_2”) with the first field blank (“gestat_1”) because in the mother‟s 
delivery record this would contain the first twin‟s gestation.  To simplify analyses, I 
condensed individual birth records so that only one field for each variable existed.  So for the 
above example, I transferred the relevant information for the gestation variable from 
“gestat_2” into “gestat_1” and then removed all additional fields for that variable (i.e. 
“gestat_2” to “gestat_9”).  
5.2.3 Coverage and completeness of recording 
Each year, the NHS Information Centre publish quality reports examining coverage of the 
data submitted by NHS hospitals to HES.256;283  These reports have repeatedly found that for 
many hospitals completeness of mandatory fields relating to births is often inadequate.256;283  
I examined the completeness of recording for each baby tail field over five recent years and 
also compared the numbers with ONS birth registrations (see 5.2.4).  Recording of most 
fields was fairly consistent between years until 2008/09 when overall completeness of 
recording slightly improved (Table 1).  The values presented differ from those published by 
HES online because of the extensive data cleaning processes I applied, which resulted in 
removal of some invalid birth records (such as those with an invalid date of birth).  Among 
the 2008/09 dataset, birth weight and gestational age were recorded for 69% and 65% of 
births respectively.     
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The completeness of recording of information in hospital birth records is highly variable 
between hospitals but is generally improving.  The proportion of missing or unknown data in 
key birth record fields has been decreasing annually, such as gestational age (from 46.2% in 
2005/06 to 34.6% in 2008/09) and birth weight (from 43.9% in 2005/06 to 31.3% in 2008/09).   
 
Table 1: Completeness of recording of baby tail fields in HES birth records (2005/06 to 
2009/010). 
*Total number of births in cohort after removal of duplicate episodes and completion of data 
cleaning processes as described earlier.   
 
 
Baby tail fields in HES birth records (field name) % 
missing 
or 
unknown 
2005/06 
% 
missing 
or 
unknown 
2006/07 
% 
missing 
or 
unknown 
2007/08 
% 
missing 
or 
unknown 
2008/09 
% 
missing 
or 
unknown 
2009/10 
P 
value 
Anaesthetic given during labour/delivery (delpren) 41.9 41.8 44.8 29.6 16.5 <0.001 
Anaesthetic given post-labour/delivery (delposn) 48.1 46.0 49.6 34.8 21.6 <0.001 
Antenatal days of stay (antedur) (derived field) 0.2 0.2 0.2 0.1 0.1 <0.001 
Baby‟s age in days (neodur) (derived field) 0.1 0.0 0.0 0.0 0.0 <0.001 
Birth order (birorder) 33.9 36.9 39.4 24.9 13.7 <0.001 
Birth weight (birweit) 43.9 47.1 50.1 31.3 16.9 <0.001 
Delivery place change reason (delchang) 45.2 45.8 47.4 34.6 21.7 <0.001 
Delivery method (delmeth) 35.1 35.8 44.3 30.6 14.9 <0.001 
Delivery place (actual) (delplace) 44.0 46.8 57.0 41.3 17.9 <0.001 
Delivery place (intended) (delinten) 41.3 42.7 43.6 30.2 14.9 <0.001 
First antenatal assessment date (anasdate) 41.7 44.3 44.6 34.7 20.4 <0.001 
Gestation (weeks) at first antenatal assessment (anagest) 54.5 63.9 55.2 45.6 28.3 <0.001 
Length of gestation (gestat) 46.2 54.2 48.0 34.6 18.1 <0.001 
Birth status (birstat) 43.9 47.0 48.0 32.9 16.2 <0.001 
Labour / delivery onset method (delonset) 36.2 37.7 41.1 25.5 11.5 <0.001 
Mother‟s age at delivery (matage)  42.4 43.3 43.0 34.5 30.5 <0.001 
Neonatal level of care (neocare)  16.1 16.0 17.1 18.4 12.4 <0.001 
Number of babies (numbaby) 31.8 33.3 36.1 23.6 11.9 <0.001 
Resuscitation method (biresus)  44.2 45.3 48.0 34.2 21.1 <0.001 
Status of person conducting delivery (delstat)  38.9 42.6 48.4 33.9 19.1 <0.001 
Total number of births* 554521 566749 575493 589684 603786 - 
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5.2.4 Comparison with data from ONS birth registrations 
Overall, the HES cohort captured 87% of all live births recorded by the ONS in England 
during the time period (Table 2).  There are various explanations for this difference.  An 
estimated 97% of all live births in England occur in NHS hospitals.  Less than 1% of births 
annually occur in non-NHS establishments and between 2-3% occur at home, according to 
ONS birth registration data.  Those occurring in private hospitals or at home may not be 
recorded in HES.  In addition, because HES contains discharge records, some births which 
occurred within the cohort year but were discharged from hospital after this period would not 
be captured in our dataset.  Most of the births that are not captured within this HES cohort 
may have been excluded as a result of the quality criteria I applied to remove records with 
invalid information reported in key fields, or due to the incomplete coverage issues described 
earlier.     
 
Table 2: Comparison of live birth recording in HES with Office for National Statistics 
reporting (2007/08). 
Month & 
year 
 
Number of live 
births reported 
in ONS data 
Number of live 
births in created  
HES cohort data 
Percentage of births 
reported by ONS that 
were recorded in the 
HES cohort 
Apr-07 51456 44841 87.1 
May-07 55863 49011 87.7 
Jun-07 53664 46971 87.5 
Jul-07 57158 49614 86.8 
Aug-07 57874 50048 86.5 
Sep-07 57189 49575 86.7 
Oct-07 57092 49843 87.3 
Nov-07 54195 46666 86.1 
Dec-07 54993 47712 86.8 
Jan-08 56621 49364 87.2 
Feb-08 52414 45963 87.7 
Mar-08 55919 45885 82.1 
Total for year 664438 575493 86.6 
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5.2.5 Approach for minimising the effect of variable data completion between 
hospitals 
Using a cut-off of 90% completeness of recording for key birth fields, hospitals with highly 
complete data were compared with the others in terms of hospital characteristics from 
available data, to assess how representative of all of England a birth cohort formed from 
babies at high-coding hospitals would be. 
In the 2007/08 dataset, 55% of records had no birth weight recorded, 48% were missing 
gestational age, 43% had no maternal age recorded and 17% had no indication of whether 
the baby received any specialist neonatal care, with considerable variation in the 
completeness of information recorded in birth records between NHS providers.  Some 
hospitals with many births had recorded gestational age and birth weight in less than 10% of 
birth records, whilst other similarly large hospitals recorded this information for >90% of 
births.  There appears to be no correlation between the number of births occurring in a 
hospital and the completeness of recording of these prematurity indicators.  Therefore, 
depending on study purpose and the exposure and outcome measures of interest, I suggest 
selecting birth records only from hospitals with the highest completeness of recording.  This 
was tested by creating a 2007/08 birth cohort where I selected only birth records from 
hospitals where ≥ 90% of their birth records contained complete recording of key variables, 
birth weight and gestational age.  The resulting cohort included 296,618 babies born at 71 
hospitals across England.   
Table 3 shows a comparison of characteristics of included (n=71) and excluded (n=85) 
hospitals (hospitals in the same NHS trust have been grouped together, as requested by 
journal peer reviewers).  The mean number of births, maternity beds and access to neonatal 
intensive care were similar among hospitals with high and low completeness of recording of 
birth record information.  There were no statistically significant differences between the two 
groups for any of the characteristics compared.  This suggests that a birth cohort derived 
from these 71 hospitals with high levels of completeness of recording would be 
representative of the whole country. 
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Table 3: Comparison of maternity characteristics between hospitals with high and low 
completeness of recording in their HES birth admission records†, from financial year 
2007/08. 
Hospital maternity factors Hospitals 
with high 
completeness 
(n=71) 
Hospitals 
with low 
completeness 
(n=85) 
P 
value 
Mean number of births in year (SD) 
 
3957 (2011) 
  
3465 (1997) 
 
0.1287 
Mean number of maternity beds available (SD) 
 
55.1 (30.3) 
 
55.3 (26.4) 
 
0.9649 
Mean number of maternity beds reported to be occupied 
(SD) 
 
35.4 (21.4) 
 
35.2 (18.0) 
 
0.9495 
Number with access to on site neonatal intensive care 
(%) 
 
52 (73) 
 
68 (80) 
 
0.3022 
Mean number of available beds in neonatal intensive 
care unit (SD) 
 
10.6 (11.7) 
 
11.4 (10.9) 
 
0.6595 
Mean maternal age (% birth records missing this data) 
 
Proportion of births per hospital in most deprived 
Carstairs Deprivation Score quintile (% birth records 
missing this data) 
 
Proportion of births per hospital of non white British 
ethnicity  
(% birth records missing this data) 
28.9 (18.4) 
 
0.472 (69.4) 
 
 
0.527 (7.1) 
29.0 (70.1) 
 
0.435 (56.2) 
 
 
 0.564 (5.1) 
0.3964 
 
0.6406 
 
 
0.6438 
 
 
† Low completeness of recording was defined as hospitals where <90% of their birth 
admission records contained complete recording of birth weight and gestational age.   
* SD = standard deviation  
 
 59 
 
5.2.6 Explaining these findings 
The Healthcare Commission‟s review of maternity services found that even among larger, 
well-respected maternity units, information technology was poor and data collection systems 
inadequate.280  One of the key recommendations from this review was that, “[hospitals] must 
ensure that maternity units are equipped with appropriate IT systems that comply with 
Connecting for Health, enabling completion of mandated national data sets and the provision 
of accurate and systematic data on outcomes and management information on which to 
plan, commission and manage the resources required for maternity care”.280  Coverage of 
hospital deliveries was estimated to be around 73% between 2001/02 and 2005/06, but for 
home deliveries the figure was just 14%.242  As a result of these quality concerns, additional 
rigorous validation was carried out by the NHS Information Centre on HES maternity data, 
including intensive cleaning of systematic coding errors.242  Some of the quality and 
coverage issues specifically affecting HES maternity data include:  
 
 Stand-alone maternity systems in around 20 hospitals are not linked to their patient 
administration system (PAS), from which HES data are obtained (via the Secondary 
Uses Service). 
 Some hospitals submit a significantly higher number of delivery episodes than birth 
episodes. 
 Some hospitals return data on the number of birth episodes or delivery episodes but not 
both. 
 Transfer of maternity information between systems leaves scope for data errors and 
shortfalls. 
 Stillbirths are not reliably recorded in every hospital and are not allocated an NHS 
number.229;232;256 
 Lack of a priori definitions for data variables resulting in inconsistencies in data entry. 
 Use of aggregate or categorised fields rather than raw data. 
 
5.2.7 Limitations of this work 
It was not possible to determine how accurately the identifier used to deterministically link 
records across time is allocated to unique individuals, although it is known that the NHS 
Information Centre now use an improved, complex algorithm to derive “HESID”, based on a 
combination of other identifiers as described earlier.  The comparison of maternity 
characteristics between hospitals with high and low completeness of recording, was limited 
to specific fields for which we had access to information from all hospitals, such as their 
mean number of births, maternity beds and specialist neonatal care facilities.  However, I am 
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confident that the comparison of these key hospital factors between hospitals with high and 
low completeness of recording of birth information, provides sufficient evidence that these do 
not significantly differ.   
 
5.2.8 Summary 
Detailed clinical information is routinely captured in hospital records in the HES database.  
Despite some complex data processing requirements, HES records provide a powerful 
source of national baseline data on birth episodes that can be used for population scale 
epidemiological research.  These records contain valuable clinical information on 
prematurity, birth weight, treatments, complications and comorbidities.  However, the 
completeness of birth information recorded in English hospitals is variable.  Where key birth 
information such as gestational age and birth weight are missing, it may be preferable to 
select data only from hospitals with high levels of completeness of recording; the analysis 
here suggests that the results may be generalisable to all hospitals.  Careful consideration of 
the context in which information in these records is collected and how this will be used is 
required.  HES data can be used to develop longitudinal cohorts by linking individual birth 
records to subsequent hospital admission records, providing information on longer-term 
health outcomes among infants.   
 
5.2.9 Birth cohort study 
This 2007/08 cohort was designed to examine research question 1 and objective 1 of this 
thesis.  As has been described in detail earlier, a birth cohort for all infants born in English 
NHS hospitals and discharged during a twelve month period (from 1st April 2007 to 31st 
March 2008) was created, using HES ID to link birth and subsequent admission records up 
to an infant‟s first birthday.  Births from 2007/08 were selected since this was the most 
recent and complete year of HES data available to me that would permit one year of follow-
up from birth, in which to examine hospital admissions in each individual‟s first year of life.  
This cohort included only records from live births and excluded infants born in hospitals 
(85/156) with poor recording (<90% complete) of key indicators (birth weight and gestational 
age), to enable us to group infants into term and preterm categories.257  Sensitivity analyses 
described earlier showed no statistically significant differences between included and 
excluded hospitals, so a study using only those with high completeness of recording of 
gestational age and birth weight should be generalisable.257  Pre-existing linkage of these 
records to ONS mortality records allowed us to identify any deaths among the birth cohort 
during their first year of life, including out-of-hospital deaths.   
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Outcome and exposure measures 
Information from the detailed review of current literature (described in chapter 1) was used to 
decide which prior exposures were clinically relevant to examine their association with a 
bronchiolitis hospital admission.  Diagnostic information recorded in individual birth records 
and any subsequent hospital admission records in the first year of life, were used to flag 
whether infants had any of these exposures/potential risk factors for severe RSV infection 
(Box 2), using specific ICD-10 codes or larger subgroups of codes based on the Agency for 
Healthcare Quality and Research‟s Clinical Classification System (CCS).284  CCS is a 
categorisation scheme which aggregates individual ICD-10 codes into broader diagnosis 
groups to facilitate reporting and statistical analyses.284  Only risk factors that were clinically 
diagnosed were examined, since information on other environmental risk factors such as 
exposure to passive smoking, is not available in these medical records.   
Infants were considered preterm if their gestational age at birth was less than 37 weeks (Box 
2), in accordance with the WHO definition of premature birth.1  Infants missing gestational 
age were assumed to be born at full term.  The reasons justifying this decision were three-
fold.  Firstly because sensitivity analyses revealed this group of infants with unknown 
gestational age had a similar median length of stay at birth and similarly low neonatal unit 
admission rates to those with a gestational age of ≥37 weeks.  Secondly, since infants born 
preterm are typically less healthy and may require clinical interventions, their gestational age 
at birth is perhaps more likely to be recorded that those born at term, who may be 
discharged quickly.  It is plausible therefore that the majority of infants missing gestational 
age are more likely to have been born at term than preterm infants requiring further hospital 
care.  The final justification for considering infants with missing gestational age to be born at 
term, was that the proportion of preterm births identified in the cohort was 7.5%, which is 
very similar to what one would expect based on ONS birth registration data which reports 
that 1 in 13 babies in England and Wales are born preterm.90;91;285 
Infants admitted as an emergency with a primary diagnosis of acute bronchiolitis were 
identified using the „J21‟ ICD-10 codes („J210‟ - acute bronchiolitis due to respiratory 
syncytial virus, „J218‟ - acute bronchiolitis due to other specified organisms and „J219‟ - 
acute bronchiolitis, unspecified).  Most bronchiolitis admissions were coded with unspecific 
aetiology and approximately a third were coded as being due to RSV.  All bronchiolitis codes 
were therefore subsequently grouped into a single “RSV bronchiolitis” category, since RSV 
is the commonest cause of bronchiolitis, but specific microbiological diagnoses are poorly 
coded in HES and testing for RSV is not standard clinical practice for bronchiolitis 
management.  Bronchiolitis admissions in children over 1 year were excluded because of the 
uncertain nature of this clinical diagnosis in older infants.  Infants were defined as all 
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individuals under 1 year of age.  Age at bronchiolitis admission was examined and the 
median length of stay (LOS) for bronchiolitis admissions was calculated to provide a proxy 
measure of severity of illness. 
Box 2: ICD-10 codes and CCS groupings used to identify at-risk groups. 
 
 
 
Prematurity  
Babies were categorised as born prematurely if their gestational age at birth was <37 
weeks.1   
If a birth record had no gestational age recorded, i.e. premature status was unknown, 
then they were assumed to be not premature (justified on the basis that infants in the 
unknown group had similarly low ICU admission rates and short length of stay at birth, to 
infants in the group known to be born at term.) 
Immunodeficiency:  CCS group 57 – Immunity disorders (This includes ICD-10 codes 
D80, D81, D82, D83, D84 and D89 which includes diagnoses such as 
hypogammaglobulinemia and severe combined immunodeficiency.) 
Cystic fibrosis:  CCS group 56 – Cystic fibrosis (This includes ICD-10 codes under 
E84.) 
Chronic lung disease:  ICD-10 codes P27 – Chronic respiratory disease originating in 
the perinatal period and P28 – Other chronic respiratory diseases originating in the 
perinatal period. 
Congenital heart diseases:  CCS group 213 (This includes ICD-10 codes Q20, Q21, 
Q22, Q23, Q24, Q25, Q26, Q27, Q28.)   
Nervous system congenital anomalies:  CCS group 216 (This includes ICD-10 codes 
Q00 to Q07 which incorporates conditions such as spina bifida, anencephaly and other 
congenital malformations of the nervous system.)  
Other congenital anomalies & perinatal conditions:  CCS groups 224 and 217 (This 
includes a broad range of congenital anomalies and perinatal conditions with ICD-10 P- 
and Q- codes, excluding those included within other definitions listed above, such as 
codes for chronic lung disease.) 
Down’s syndrome:  ICD-10 code Q90 
Cerebral palsy:  ICD-10 code G80 
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5.2.10 Statistical analyses 
The absolute risk of a bronchiolitis admission was calculated among infants with and without 
risk factors for severe RSV infection, including preterm infants and infants with a clinical 
diagnosis of cystic fibrosis, congenital heart disease, nervous system congenital anomalies, 
other congenital anomalies, immunodeficiency, cerebral palsy or Down‟s syndrome (case 
definitions and codes in Box 2).  Infants without a particular risk factor condition were 
considered “healthy”.  Associated 95% confidence intervals (CI) were calculated using 
Poisson approximation.  The relative risk (RR) of a bronchiolitis admission was calculated, 
with associated 95% CI for infants in each individual risk group, by comparing with the 
baseline group of infants without the particular risk factor.  Infants could belong to more than 
1 of these risk groups, so this potential confounding was controlled for using Poisson 
multiple regression models to calculate the adjusted RR of bronchiolitis admission for infants 
in each risk group.  Confounders controlled for in these analyses were selected a priori, 
based on a detailed literature review of risk factors for hospital admission with bronchiolitis.  
In addition to each of the diagnostic categories described earlier (see box 2) candidate 
covariates in each model included sex, month of birth, deprivation (using Carstairs score 
quintile which is based on patient postcode), age at bronchiolitis admission and multiple 
birth.  Covariates were selected for inclusion in the multivariable model if the p value was 
below the 0.05 significance level.  All the covariates listed were found to be significant and 
retained in the final model.   
Two-way interactions of variables deemed to be of clinical interest were explored (following 
consultation with clinicians), including between sex and deprivation (measured in Carstairs 
quintiles).  No interactions were found to be statistically significant.  Diagnostic plots of 
residuals against fitted values were produced and Pearson goodness of fit tests carried out 
to assess the validity of the model.  These showed no evidence of outliers or overdispersion.   
Clustering of observations within hospitals can lead to confidence intervals that are too 
narrow and to coefficient bias.  Hierarchical modelling techniques were initially conducted to 
adjust for clustering by hospital, but this resulted in intra-class correlation coefficients (ICC) 
with values less than 5% (a standard threshold above which adjustment for clustering is 
recommended) and similar coefficients and standard errors to those obtained without this 
clustering adjustment.  Hence, it was decided that the modelling would not include 
adjustment for clustering by hospital.  Indeed, different methods of adjustment are based on 
different assumptions and there is often disagreement about which methods are most 
appropriate to use in different contexts.286  
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Further work could involve comparison of the baby tail fields from birth records, with the 
corresponding maternal delivery record and baby tail, to determine the extent to which the 
information recorded in these correlates.  Linkage to other sources of data on potential 
confounders (for example environmental risk factors such as exposure to passive smoking) 
would strengthen the analyses as these could then be controlled for in the modelling 
process.   
Chi Squared tests were used to test for significant differences between proportions and 
Mann-Whitney tests were used to compare median values for non-normal data. Data were 
analysed using the SAS 9.2 software package (SAS Institute, Cary, North Carolina, USA).   
 
5.3 Creating a birth cohort using records from the GPRD 
Data for this study were obtained from the General Practice Research Database (GPRD), a 
computerised database of anonymised longitudinal medical records from primary care in the 
UK (described in more detail earlier in chapter 4.3).  The approach described below for 
creating a birth cohort, was used to address the second and third research questions and 
corresponding second and third objectives of this thesis: 
Objective 2 – To estimate the incidence of RSV bronchiolitis among infants presenting in 
primary care and to describe how it is being managed by general practitioners, in relation to 
national guidance (Study 2 – Creating a nationally representative birth cohort using GPRD 
patient records). 
Objective 3 – To determine the longer-term effects of RSV bronchiolitis on subsequent 
respiratory health in early childhood (Study 3 - GPRD and HES long-term follow-up studies). 
Research question 2 – What is the incidence of acute bronchiolitis among infants 
presenting to general practitioners and how is it being managed in the community? 
Research question 3 – What is the long-term impact of RSV bronchiolitis on subsequent 
respiratory health in early childhood?    
 
Description of study cohort  
82861 infants born in 2003 were identified, registered across 600 GPRD general practices in 
the UK (these were all “Up To Standard” practices for which the data are deemed to be of 
suitable research quality).258  Complete electronic primary care records for the first year of 
life were obtained for each of these infants, to create a retrospective cohort from birth to age 
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1 year, using a scientific workflow infrastructure.287  These workflow infrastructures have 
been developed specifically to assist with the challenges of mining large databases of 
primary care records, particularly to ensure reproducibility of methods used.287  Scientific 
workflows are a method for representing data processing operations, recording all steps 
taken in the cleaning of data, coding definitions used and variables selected for inclusion in 
final datasets, thereby making analysis of large databases more manageable and 
scalable.287   Individuals who died or transferred to a different general practice before their 
first birthday were then excluded (n=1885), so the birth cohort with complete follow-up for 
their first year of life consisted of 80976 infants.   
 
Outcome and exposure measures 
Following consultation with GPs and a consultant paediatrician, a diagnosis code list was 
developed to identify consultations where a diagnosis of acute bronchiolitis was made (Table 
4).   
Table 4: GPRD codes for acute bronchiolitis. 
GPRD Medcode Description 
1019 Acute bronchiolitis 
18451 
Acute bronchiolitis due to respiratory syncytial 
virus 
17917 Acute bronchiolitis NOS 
66228 
Acute bronchiolitis due to other specified 
organisms 
 
This dataset did not contain the free text components of GP records, so the definition of a 
bronchiolitis consultation was based solely on the clinical diagnostic codes recorded in the 
infants‟ medical records.   
For comparison I also examined the impact of expanding our conservative definition of acute 
bronchiolitis, to include consultations in the first year of life where other diagnosis codes 
were recorded which are also likely to represent infants with bronchiolitis, who may have 
been given a less specific or symptomatic diagnosis code.  For this wider definition, 
consultations in the first year of life with the following diagnosis codes were identified, as 
deemed appropriate after detailed discussion with the GPs and paediatricians I consulted 
(Table 5): 
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Table 5: GPRD code list for wider bronchiolitis definition of consultations in first year 
of life.   
GPRD Medcode Description   
1019 Acute bronchiolitis     
18451 Acute bronchiolitis due to respiratory syncytial virus   
17917 Acute bronchiolitis NOS   
66228 Acute bronchiolitis due to other specified organisms   
92 Cough   
1273 C/O cough   
292 Chesty cough   
68 Chest infection   
2581 Chest infection NOS   
2891 Wheezing symptom   
173 Wheezing   
4836 Nocturnal cough/wheeze   
5861 O/E – expiratory wheeze   
2210 [D] Wheezing   
74908 Viral wheeze   
83478 Viral induced wheeze   
78 Asthma 
  
81 Asthma monitoring 
 
10043 Asthma annual review 
13176 Asthma follow-up 
 
7378 Asthma management plan given 
185 Acute exacerbation of asthma 
719 H/O: asthma 
 
5515 Seen in asthma clinic 
13064 Asthma severity 
 
19539 Asthma monitoring check done 
16070 Asthma NOS 
 
10274 Asthma medication review 
13173 Asthma not disturbing sleep 
232 Asthma attack 
 
1555 Bronchial asthma 
 
19520 Asthma treatment compliance satisfactory 
26501 Asthma never causes daytime symptoms 
38143 Asthma never disturbs sleep 
13174 Asthma not limiting activities 
4442 Asthma unspecified 
 
26504 Asthma never restricts exercise 
11022 Asthma trigger 
 
10318 Suspected asthma 
 
16785 Asthma control step 1 
16667 Asthma control step 2 
18224 Asthma control step 3 
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26861 Asthma sometimes restricts exercise 
233 Severe asthma attack 
26503 Asthma causes daytime symptoms most days 
7416 Asthma disturbing sleep 
24884 Asthma causes daytime symptoms 1 to 2 times per week 
7229 Asthma prophylactic medication used 
42824 Asthma daytime symptoms 
31225 Asthma causes daytime symptoms 1 to 2 times per month 
1208 Childhood asthma 
 
3018 Mild asthma 
 
13065 Moderate asthma 
25181 Asthma restricts exercise 
13175 Asthma disturbs sleep frequently 
18223 Step down change in asthma management plan 
5138 Patient in asthma study 
19167 Asthma monitoring by nurse 
25791 Asthma clinical management plan 
45073 Intrinsic asthma NOS 
98185 Asthma control test 
18323 Intrinsic asthma with asthma attack 
24506 Further asthma - drug prevent. 
30382 Asthma monitoring admin NOS 
19519 Asthma treatment compliance unsatisfactory 
10487 Asthma - currently active 
41554 Asthma monitor offer default 
31167 Asthma night-time symptoms 
3458 Occasional asthma 
30815 Asthma causing night waking 
5267 Intrinsic asthma 
38144 Asthma limits walking up hills or stairs 
11370 Asthma confirmed 
9552 Change in asthma management plan 
3665 Late onset asthma 
20886 Asthma control step 4 
38146 Asthma disturbs sleep weekly 
18763 Referral to asthma clinic 
20860 Asthma control step 5 
25796 Mixed asthma 
45782 Extrinsic asthma NOS 
23481 Asthma – cardiac 
27926 Extrinsic asthma with status asthmaticus 
29325 Intrinsic asthma without status asthmaticus 
30458 Asthma monitoring by doctor 
4892 Status asthmaticus NOS 
8355 Asthma monitored 
47337 Asthma accident and emergency attendance since last visit 
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6707 Extrinsic asthma with asthma attack 
39570 Asthma causes night symptoms 1 to 2 times per month 
3366 Severe asthma 
26506 Asthma severely restricts exercise 
41020 Absent from work or school due to asthma 
12987 Late-onset asthma 
8335 Asthma attack NOS 
24479 Emergency asthma admission since last appointment 
14777 Extrinsic asthma without status asthmaticus 
 
The age of an infant at the time of the bronchiolitis consultation was estimated by selecting 
the mid-point of the infant‟s month of birth as their date of birth (since only month and year of 
birth were available in the dataset).  The week of the year that a bronchiolitis consultation 
took place was identified using the consultation date, to examine the seasonality of 
bronchiolitis consultations and determine whether the burden of contacts followed the winter 
peak pattern typical of RSV infection.39  Any records of prescriptions associated with a 
bronchiolitis consultation were also identified (using the consultation date and consultation 
ID fields).  The therapeutic codes were looked up on the GPRD medical codes browser disc 
which was supplied with the dataset.   
Primary care consultation patterns during the first year of life among the whole birth cohort 
were examined, specifically comparing infants with no bronchiolitis consultations with those 
with a bronchiolitis consultation.  To examine the most common symptoms and diagnoses 
among infants presenting in primary care, consultations relating to immunisations, 
administrative tasks, routine health checks and health promotion activities were excluded.  
The remaining diagnostic and symptomatic medical codes were then grouped into similar 
diagnosis and symptom groups, to examine the most common diagnoses among infants 
presenting to their GP in the first year of life (Table 6).   
The relative risk (RR) and associated 95% confidence intervals of any respiratory 
consultation in the first year of life were calculated, among infants with a history of 
bronchiolitis compared with those without.  The most common diagnostic and symptomatic 
codes recorded during any GP consultations that occurred in the 2 weeks before and 2 
weeks after a bronchiolitis consultation were also identified to provide an insight into clinical 
events surrounding a bronchiolitis diagnosis.   
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Table 6: Coded diagnosis groups for consultations in the first year of life. 
Diagnosis groups of 
consultations in 1st year of 
life 
GPRD 
Medcode 
GPRD Medcode description 
Respiratory tract infections 
and cough or wheezing 
symptoms 
 
1019 
2637 
76 
92 
1273 
6294 
2581 
68 
267 
292 
1246 
2891 
173 
4836 
78 
7818 
1142 
Acute bronchiolitis 
Upper respiratory infection 
Upper respiratory infection NOS 
Cough 
C/O cough 
Acute upper respiratory tract infection 
Chest infection NOS 
Chest infection 
Otitis Media NOS 
Chesty cough 
Acute coryza 
Wheezing symptom 
Wheezing 
Nocturnal cough/wheeze 
Asthma 
Neonatal snuffles 
Croup 
Eczema, dermatitis, rashes 
and other skin conditions 
 
 
4703 
610 
1741 
230 
1685 
5041 
304 
C/O rash 
Infantile eczema 
Atopic dermatitis/eczema 
Eczema NOS 
Nappy rash 
Non-specific viral rash 
Thrush 
Diarrhoea, vomiting and other 
gastro-intestinal symptoms 
 
 
176 
5134 
192 
139 
8416 
2182 
2004 
Vomiting 
Diarrhoea symptoms 
Diarrhoea 
Gastroenteritis 
Constipation 
Diarrhoea & vomiting symptoms 
Constipation symptoms 
Other infections  
 
1864 
6017 
1041 
145 
36525 
196 
Acute conjunctivitis 
Sticky eye 
Viral infection NOS 
Chickenpox varicella 
Infectious disease: control 
Oral thrush 
 
Statistical analyses 
The bronchiolitis consultation rate and associated 95% confidence intervals (95% CI) were 
estimated for infants under the age of 1 year by dividing the total number of bronchiolitis 
consultations by the total cohort population.  The mean and standard deviation (SD) for the 
age in months at which infants were diagnosed with bronchiolitis was calculated.  Two-
sample z tests were used to compare the proportion of primary care consultations for 
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different diagnoses, among infants with and without a history of bronchiolitis in their first 
year.  All statistical analyses were carried out using STATA/MP version 10.0.   
 
5.4 Creating birth cohorts with follow-up into early childhood 
 
5.4.1 Developing a cohort with longer follow-up after admission to hospital with 
bronchiolitis, using HES 
To address the third research question and objective described in chapter 2, the approach 
described above for creating a birth cohort using HES records was applied to earlier data to 
provide a sufficient number of years of follow-up.  Data from all births in financial year 
2003/04 were obtained and then the same data cleaning and processing as for the 2007/08 
dataset was applied.  I will now describe this 2003 cohort in more detail.   
Study cohort 
All births in NHS hospitals in England that were born and discharged during a twelve month 
period (from 1st April 2003 to 31st March 2004) were identified.  Birth records from each 
individual born in this time period were then linked to any subsequent hospital admissions up 
to their 5st birthday in 2008/09.   
Infants were then grouped according to whether they were at “high” or “low” risk of 
bronchiolitis, based on clinical risk factors and diagnoses identified within their birth records 
or from diagnoses from any other admissions during the neonatal period.  Information from 
an in-depth review of the literature and consultation with paediatricians was used to 
determine which risk factors were used to classify infants as “high-risk” (see code list in Box 
2).   
Outcome and exposure measures 
For infants in both groups, all hospital admissions during their first year of life with a primary 
diagnosis of acute bronchiolitis were identified (using the J21 ICD-10 codes described in the 
earlier cohort study).  As described earlier, most bronchiolitis admissions were coded with 
unspecific aetiology and approximately a third were coded as being due to RSV.  All 
bronchiolitis codes were therefore grouped into a single “RSV bronchiolitis” category, again 
justified on the basis that RSV is the commonest cause of bronchiolitis, but specific 
microbiological diagnoses are poorly coded in HES and testing for RSV is not standard 
clinical practice for bronchiolitis management.  Bronchiolitis admissions in children over 1 
year were excluded because of the uncertain nature of this clinical diagnosis in older infants.   
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Following an index admission for bronchiolitis, any subsequent admissions up to the age of 5 
years, with a primary respiratory diagnosis, were then identified.  Specifically, subsequent 
respiratory admissions with the following diagnoses were flagged using these ICD-10 codes: 
Asthma:  
J45 – asthma 
J46 – status asthmaticus (acute severe asthma) 
Lower respiratory tract infections (LRTI): 
J12 – Viral pneumonia, not elsewhere classified  
J13 – Pneumonia due to Streptococcus pneumonia 
J14 – Pneumonia due to Haemophilus influenza 
 J15 – Bacterial pneumonia, not elsewhere classified 
J16 – Pneumonia due to other infectious organisms, not elsewhere classified 
J17 – Pneumonia in diseases classified elsewhere 
J18 – Pneumonia, organism unspecified 
J20 – acute bronchitis 
J22 – unspecified acute lower respiratory infection. 
Upper respiratory tract infections (URTI): 
J00 - Acute nasopharyngitis 
J01 – Acute sinusitis 
J02 – Acute pharyngitis 
J03 – Acute tonsillitis 
J04 – Acute laryngitis and tacheitis 
J05 – Acute obstructive laryngitis (croup) and epiglottitis 
J06 – Acute upper respiratory infections of multiple and unspecified sites 
J09 – Influenza due to identified avian influenza virus 
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J10 – Influenza due to other identified influenza virus 
J11 – Influenza, virus not identified 
Wheezing:  
R062 – wheezing 
 
For comparison, infants at both high and low risk of bronchiolitis who did not then have any 
record of a bronchiolitis admission, were also followed-up to age 5 years.  In these groups 
any admissions for the above respiratory diagnoses from age 6 months onwards were also 
identified.  As these infants have no bronchiolitis admission to use as an index date, 
subsequent respiratory admissions were identified from age 6 months onwards as this is the 
typical age at which the bronchiolitis admissions from the comparison group occurred.  
 
Statistical analyses 
The relative risk (RR) of a subsequent respiratory admission in the first 5 years of life was calculated, 
with associated 95% CI, for children with a history of prior bronchiolitis admission compared with 
those without.  These RRs were calculated separately for children at high- and low-risk of severe RSV 
infection.  Associated 95% CI were calculated using Poisson approximation.  The attributable risk 
(AR) and population AR in these groups were also calculated to examine the difference in subsequent 
respiratory admission rates between children with and without a history of bronchiolitis admission in 
infancy.   Data were analysed using the SAS 9.2 software package (SAS Institute, Cary, North 
Carolina, USA).  
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5.4.2 Developing a cohort with longer follow-up after a bronchiolitis consultation in 
infancy, using the GPRD 
As described earlier in this chapter (see 5.3), GP records from the GPRD from infants born 
in 2003 were selected to develop a cohort.  The year 2003 was chosen specifically to 
provide a cohort with a sufficient number of years of follow-up to address the third research 
question and objective of this thesis (outlined in chapter 2.0).  So selecting data from the 
year 2003 meant I was able to examine consultations for asthma and wheezing in the first 7 
years of life, comparing rates between infants with and without prior history of a bronchiolitis 
episode in the first year of life.  The findings from this study are presented in chapter 8.2.2.   
Outcome and exposure measures 
Following consultation with GPs and a consultant paediatrician, a diagnosis code list was 
developed to identify consultations where a diagnosis of asthma or wheezing was made.  
The GPRD medical codes used to identify subsequent consultations for asthma and 
wheezing are listed within Table 5.  Consultations were included if a child was aged between 
1 and 7 years when the diagnosis was made.  In the 2003/04 HES cohort with follow-up to 
age 5 years described earlier, subsequent admissions for LRTI and URTI were examined.  It 
was not deemed feasible to explore subsequent GP consultations for LRTI and URTI 
because of the difficulties associated with trying to define a consultation for RTI.  There are 
hundreds of possible READ codes that can be used to denote a RTI consultation, including 
many vague, symptomatic codes which are not specific enough to reliably attribute to being 
lower or upper RTIs.  Although both this GPRD cohort and the 2003/04 HES cohort relate to 
children born at a similar time, there was no way of idenitfying whether there was any 
overlap between the cohorts to determine if any children were included in both.   
Statistical analyses 
The relative risks (RR) of a subsequent asthma or wheezing consultations in the first 7 years 
of life were calculated, with associated 95% CI, for children with a history of prior 
bronchiolitis consultation compared with those without.  The attributable risk (AR) and 
population AR in these groups were also calculated to examine the difference in subsequent 
asthma and wheezing consultation rates between children with and without a history of 
bronchiolitis consultation in infancy and the reduction in subsequent respiratory consultations 
that would be expected in a population unexposed to bronchiolitis.  All statistical analyses 
were carried out using STATA/MP version 10.0.   
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5.5 Summary of chapter 
In this chapter the methods I have used to develop birth cohort studies using routine health 
records have been described in detail, using both hospital and GP records.  These contain 
valuable clinical information that can be utilised to create large, population-based studies for 
epidemiological research.  Longitudinal cohorts can be developed by linking records 
belonging to the same individual over time, providing information on longer-term health 
outcomes among children.   
I have tested the feasibility of linking HES birth records to subsequent admission records to 
develop a longitudinal cohort with long-term follow-up.  HES birth records contain valuable 
clinical information on prematurity, birth weight, complications and comorbidities, but the 
completeness of recording of this birth information is highly variable between different 
hospitals.  Where key birth information such as birth weight and gestational age are missing, 
it may be preferable to select data only from hospitals with high levels of completeness of 
recording.  The analysis presented here suggests that a cohort developed in this way is 
representative of births across England.  The later part of this chapter described how GP 
records were obtained and can also be linked over time to develop a cohort of individuals 
with detailed clinical information about the primary care they have received, including 
diagnoses, prescriptions and vaccinations.  Finally I have explained how two cohorts of 
infants born in 2003, one from the GPRD and one from HES, were developed to examine 
subsequent respiratory health in early childhood following an episode of bronchiolitis.   
In the following three chapters the results of three separate studies are described, relating to 
each of the three research questions and objectives presented in chapter 2.0.   
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6.0 Results – Study 1: Bronchiolitis hospital admissions 
 
Chapter Overview 
This chapter presents findings in relation to research question 1 and objective 1.   
Research Question 1 - What are the risk factors for admission to hospital with RSV 
bronchiolitis and how do admission rates vary between infants with comorbidities, preterm 
and term born infants?  
Objective 1 - To describe the clinical burden of RSV bronchiolitis among infants admitted to 
NHS hospitals in England, comparing admission rates between infants with and without 
clinical risk factors for the condition. 
Using HES data a birth cohort from the year 2007/08 with 1 year of follow-up admissions 
data was developed, as described in detail in the earlier methods chapter.  Within the cohort 
I examined risk factors for hospital admission with bronchiolitis in the first year of life.  These 
findings are presented here along with additional HES data showing trends in RSV-
associated hospital admissions in England, to provide contextual information on background 
trends.   
 
6.1 Introduction 
In the UK, bronchiolitis admission rates in infants under 1 year have previously only been 
estimated from small regional studies, with the most frequently cited estimate of 30.8 per 
1000 infants calculated from data from just one health authority region.31  The geographical 
area the study was carried out in (Shropshire) had lower than average population density 
and deprivation for England, limiting the generalisability of their findings.  Another study used 
data from the late 1990s to estimate the annual incidence of hospital admissions attributable 
to RSV, reporting 28.3 per 1000 infants under 1 year.30  The only recent national data 
reporting trends in RSV infection rates over time for England and Wales are the weekly 
laboratory reports published by the HPA.39  However, RSV reporting is not mandatory so it is 
fairly random as to whether or not a laboratory consistently submits their RSV reports and 
denominator data to indicate the number of infants tested is not readily available either.  So 
there are no recent studies reporting the RSV bronchiolitis disease burden at a population 
level in the UK.   
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Infants known to be at high risk of developing severe RSV infection include those born 
preterm, with chronic lung disease, congenital heart disease, low birth weight or 
immunodeficiency.3;22;44;88  Although there is a sizeable base of evidence supporting this, 
much of what is known to date has been concluded from studies with small sample sizes 
which may be underpowered to detect smaller effect sizes.  For certain rarer conditions such 
as Down‟s syndrome and cerebral palsy, there has generally been an insufficient amount of 
published data available from the UK, to determine their risk of RSV bronchiolitis.  
Furthermore, despite evidence from the USA reporting that the majority of infants with 
severe RSV infection are born at term,44 most UK studies have so far focused on the burden 
of RSV-associated illness among high-risk infants born preterm.11;103;155;156;288;289   
 
The aim of this study therefore, was to examine which infants are most at risk of an RSV 
bronchiolitis admission in England in term, preterm and other high-risk infants and to 
determine the age at and duration of an RSV bronchiolitis admission in England as a proxy 
indicator of severity of illness (using the methods described in detail in chapter 5.2).  In 
addition, trends in RSV-associated hospital admissions over time were examined to provide 
background context to this study (see methods chapter 5.1). 
 
6.2 Results 
 
6.2.1 Trends in RSV-associated admissions 
During the 14 year time period from 1997/98 to 2010/11, trends in admission rates (per 1000 
live births) for diagnoses specifying RSV as the causative agent, remained quite stable 
(Figure 2).  In 1997/98 there were 6996 RSV admissions (12 per 1000 live births), compared 
with 7651 admissions in 2010/11 (11 per 1000 live births).  From 1997/98 to 2004/05 
unspecified bronchiolitis remained relatively stable (Figure 2).  There were 22 unspecified 
bronchiolitis admissions per 1000 live births in 1997/98 and 23 per 1000 in 2004/05.  
Similarly, unspecified viral pneumonia rates remained stable during this period, with 45 
admissions per 1000 live births in 1997/98 and 44 per 1000 in 2004/05.   
Since 2004/05, trends in unspecified bronchiolitis and unspecified viral pneumonia have 
been steadily rising.  There was a 43.5% increase in unspecified bronchiolitis admissions 
from 23 per 1000 live births in 2004/05 to 33 per 1000 in 2010/11.  Unspecified viral 
pneumonia admission rates increased by 36.3% over the same time period, from 44 to 60 
per 1000 live births.   
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Figure 2: Trends in RSV-associated hospital admissions per 1000 live births, from 
1997/98 to 2010/11. 
 
6.2.2 Birth cohort study 
 
Cohort characteristics 
296618 infants were included in the birth cohort, from 71 NHS hospitals in England.  410 
infants in the cohort died during the study year.  51% (151897/296618) of the cohort were 
boys, 1% (2891) were multiple births and 7·5% (22215) were born preterm before 37 weeks 
gestation (Table 7).   
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Table 7: Characteristics of birth cohort and infants admitted with bronchiolitis. 
 
 
 
Birth 
cohort 
N % 
Infants admitted 
with any 
bronchiolitis 
n (% of birth 
cohort) 
Infants 
admitted with 
RSV 
bronchiolitis  
n (% of group) 
Infants admitted 
with unspecified 
bronchiolitis  
n (% of group) 
Number of births 296618 100.0 7189 (2.4) 2015 (100.0) 5174 (100.0) 
Sex      
Male 151897 51.2 4257 (2.8) 1156 (57.4) 3101 (59.9) 
Female 144659 48.8 2927 (2.0) 859 (42.6) 2068 (40.0) 
Unknown 62 0.0 5 (8.1) 0 (0.0) 5 (0.1) 
Place of birth      
NHS hospital 290057 97.8 6942 (2.4) 1968 (97.7) 4974 (96.1) 
Home 5728 1.9 212 (3.7) 35 (1.7) 177 (3.4) 
Unknown 833 0.3 35 (4.2) 12 (0.6) 23 (0.4) 
Birth weight (grams)      
< 1500 5442 1.8 262 (4.8) 60 (3.0) 202 (3.9) 
≥1500 < 2000 2357 0.8 159 (6.7) 57 (2.8) 102 (2.0) 
≥2000 < 2500 9748 3.3 407 (4.2) 118 (5.9) 289 (5.6) 
≥2500 < 3000 40632 13.7 1164 (2.9) 334 (16.6) 830 (16.0) 
≥3000 < 3500 86654 29.2 2003 (2.3) 542 (26.9) 1461 (28.2) 
3500+ 96090 32.4 2070 (2.2) 572 (28.4) 1498 (29.0) 
Unknown 55695 18.8 1124 (2.0) 332 (16.5) 792 (15.3) 
Gestational age (weeks)      
<37 22215 7.5 1050 (4.7) 328 (16.3) 722 (14.0) 
≥ 37 ≤ 41 212282 71.6 4637 (2.2) 1352 (67.1) 3285 (63.5) 
≥ 42 10587 3.6 189 (1.8) 56 (2.8) 133 (2.6) 
Unknown 51534 17.4 1313 (2.5) 279 (13.8) 1034 (20.0) 
Multiple births      
 2891 1.0 94 (3.3) 30 (1.5) 64 (1.2) 
Specialist neonatal care admission at birth recorded 
 18284 6.2 845 (4.6) 280 (13.9) 565 (10.9) 
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Bronchiolitis admissions 
Among our birth cohort there were 7189 admissions to hospital with a primary diagnosis of 
bronchiolitis during their first year of life, 24.2 admissions per 1000 infants (95% CI 23.7 to 
24.8).  Only 2015 (28.0%) of these were specifically coded as being due to RSV, the 
remainder were unspecified.  1529 (21.3%) infants admitted with bronchiolitis, had more 
than one bronchiolitis admission during their first year of life.  The modal age of bronchiolitis 
admission was 1 month (Figure 3) and the median age was 120 days (Inter-quartile range 
(IQR) = 61 to 209).  The median length of hospital stay was 1 day (IQR = 0 to 3 days).  
51.5% of the bronchiolitis admissions were reported to have been admitted via an 
Emergency Department and 36.4% via referral from a GP.   
 
 
Figure 3: Age of bronchiolitis admission in months, for admissions coded as RSV or 
unspecified bronchiolitis. 
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Risk factors for bronchiolitis admission 
15% (1050/7189) of infants who had a bronchiolitis admission were born preterm. Admission 
rates were higher among infants born preterm (47.3 per 1000 infants (95% CI 44.4-50.2)) 
compared with those born at term (22.4 per 1000 infants (95% CI 21.8-22.9)) (Table 8). The 
median length of stay for a bronchiolitis admission among infants born preterm was 1 day 
(IQR = 0 to 3) and among those born at term it was also 1 day (IQR = 0 to 3). The median 
age of the bronchiolitis admission among infants born preterm was 136 days (IQR = 71 to 
221) compared with 118 days (IQR = 59 to 207) among infants born at term (p<0.001).   
1722 (24.0%) of infants admitted with bronchiolitis had one or more known risk factors for 
severe RSV infection. The adjusted RR of a bronchiolitis admission was high among infants 
with known risk factors for severe RSV disease, including those born preterm (RR 1.9 (95% 
CI 1.8-2.0)) or with congenital heart conditions (RR 3.4 (95% CI 2.9-3.8)) or chronic lung 
disease (RR 1.6 (95% CI 1.4-1.8)), compared with healthy infants without the risk factor 
(Table 8). Other conditions also significantly increased an infant‟s risk of bronchiolitis 
admission, including cystic fibrosis (RR=2.5 (95% CI 1.4 to 4.4)), Down‟s syndrome (RR 2.5 
(95% CI 1.7-3.7)), cerebral palsy (RR 2.4 (95% CI 1.5-4.0)) and other nervous system 
congenital abnormalities (RR=1.7 (95% CI 1.3 to 2.4)).   
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Table 8: The relative risk of a bronchiolitis hospital admission among infants in 
different risk groups.   
 
†Relative risk compared with infants without risk factor of interest.   
  
Risk Group† Number of 
bronchiolitis 
admissions 
(% of infants 
in risk 
group) 
Total 
number of 
infants in 
risk group 
(% of 
whole birth 
cohort) 
Median 
length 
of stay 
in days 
(IQR) 
Risk of 
bronchiolitis 
admission 
per 1000 
infants under 
1 year (95% 
CIs) 
RR† 
(95% 
CIs) 
Adjusted 
RR 
(95% CI) 
Born at term 6139 (2.2) 274403 
(92.5) 
1 (0 to 
3) 
22.4  
(21.8 to 22.9) 
- - 
    
Premature birth 1050 (4.7) 22215 (7.5) 1 (0 to 
3) 
47.3  
(44.4 to 50.2) 
 
 
 
2.11  
(1.98 to 
2.26) 
1.89 
    (1.77 to 
2.02) 
Cystic fibrosis 11 (6.4) 171 (0.1) 2 (0 to 
14) 
64.3  
(32.1 to 115.1) 
 
2.66  
(1.33 to 
4.76) 
2.45 
    (1.36 to 
4.43) 
Congenital heart  
Disease 
272 (12.1) 2239 (0.8) 2 (0 to 
5) 
121.5  
(107.5 to 
136.8) 
5.17  
(4.56 to 
5.84) 
3.35 
   (2.92 to 
3.84) 
Chronic lung 
disease 
 
282 (5.6) 
 
5016 (1.7) 2 (0 to 
4) 
56.2  
(49.9 to 63.2) 
2.37  
(2.10 to 
2.67) 
1.61 
  (1.42 to 
1.82) 
Immunodeficiency 7 (11.7) 60 (0.0) 8 (1 to 
58) 
116.7 
(46.9 to 240.4) 
4.82  
(1.94 to 
9.93) 
1.69 
    (0.80 to 
3.58) 
Nervous system  
congenital 
anomalies 
42 (8.6) 489 (0.2) 2 (1 to 
4) 
85.9  
(61.9 to 116.1) 
3.56  
(2.56 to 
4.82) 
1.73 
   (1.26 to 
2.36) 
Down’s syndrome 28 (15.4) 182 (0.1) 3 (0 to 
9) 
153.9  
(102.2 to 
222.4) 
6.37  
(4.23 to 
9.21) 
2.53 
    (1.72 to 
3.72) 
Cerebral Palsy 16 (10.7) 149 (0.1) 3 (1 to 
5) 
107.4  
(61.4 to 174.4) 
4.44  
(2.54 to 
7.21) 
2.43  
(1.48 to 
3.99)     
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A higher proportion of infants born in September (3.9%) or October (3.8%) were admitted 
with bronchiolitis than among infants born in any other month (p<0.001). Bronchiolitis 
admission rates among infants born in the North East (3.3%) and Yorkshire and the Humber 
(3.3%) SHAs, were higher (p<0.001) compared with in infants born in London (1.6%) (Figure 
4). 
 
 
Figure 4: Incidence of bronchiolitis hospital admissions among birth cohort, by 
Strategic Health Authority (SHA) of admission. 
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6.3 Summary of chapter findings 
In this chapter trends in diagnoses specifying RSV as the causative organism, unspecified 
viral pneumonias and unspecified bronchiolitis admission rates were estimated, over a 14 
year period from 1997/98 to 2010/11.  A birth cohort from the year 2007/08 with follow-up to 
age 1 year was created by linking HES birth and admission records and used to investigate 
risk factors for hospital admission with bronchiolitis.  The findings from these analyses of 
admission data from NHS hospitals in England are summarised here: 
 Infant admissions for diagnoses specifying RSV infection remained stable over the 14 
year period from 1997/98 (12 per 1000 live births) to 2010/11 (11 per 1000 live births).   
 
 From 2004/05 to 2010/11, trends in unspecified bronchiolitis and unspecified viral 
pneumonia admissions have steadily risen by 43.5% and 36.3% respectively.   
 
 Among a birth cohort of 296618 infants born in 2007/08, the bronchiolitis admission rate 
was 24.2 admissions per 1000 infants under 1 year (95% CI 23.7 to 24.8).   
 
 The median age at bronchiolitis admission was 120 days (IQR 61 to 209 days) and the 
modal age group at bronchiolitis admission was infants aged 1 month.  The median 
length of stay for a bronchiolitis admission was 1 day (IQR 0 to 3 days).   
 
 51.5% of infants with bronchiolitis were admitted via the Emergency Department.   
 
 15% (1050/7189) of infants who had a bronchiolitis admission were born preterm, 47.3 
admissions per 1000 infants (95% CI 44.4 to 50.2).   The bronchiolitis admission rate 
among infants born at term was 22.4 per 1000 infants (95% CI 21.8 to 22.9).   
 
 24.0% of infants admitted with bronchiolitis had one or more known clinical risk factor.  
 
 The relative risk of a bronchiolitis admission was high among infants with known risk 
factors for severe RSV disease, including those born preterm (RR 1.9 95% CI 1.8 to 2.0) 
or with congenital heart conditions (RR 3.4 95% CI 2.9 to 3.8) or chronic lung disease 
(RR 1.6 95% CI 1.4 to 1.8), compared with healthy infants without the risk factor.  
 
 Other conditions also significantly increased an infant‟s risk of bronchiolitis admission, 
including cystic fibrosis (RR=2.5 (95% CI 1.4 to 4.4)), Down‟s syndrome (RR 2.5 (95% 
CI 1.7-3.7)) and cerebral palsy (RR 2.4 (95% CI 1.5-4.0)).   
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7.0 Results - Study 2: Bronchiolitis in the community setting 
 
Chapter Overview 
This chapter presents findings in relation to research question 2 and objective 2.   
Research question 2 - What is the incidence of acute bronchiolitis among infants 
presenting to general practitioners and how is it being managed in the community? 
Objective 2 - To estimate the incidence of RSV bronchiolitis among infants presenting in 
primary care and to describe how it is being managed by general practitioners. 
 
For the first time, this study provides an insight into the incidence and management of 
bronchiolitis illness in UK primary care.  Using GPRD data a birth cohort from 2003 with 1 
year of follow-up was created, from 600 representative general practices across the UK, as 
described in the earlier methods chapter.  Within this cohort, GP consultations during the 
first year of life were examined, focusing particularly on those where a diagnosis of 
bronchiolitis or related symptoms were recorded.  Prescriptions given in relation to a 
bronchiolitis consultation were identified, to determine how GPs have been managing the 
condition.  These findings are presented followed by a discussion of the implications of what 
this study tells us about the burden of bronchiolitis illness in UK primary care.   
 
7.1 Introduction 
Previous studies have focused on identifying risk factors for hospitalisation with severe 
disease but there are no reliable community-based estimates of the incidence of bronchiolitis 
and little is known about the presentation, natural history and management of the condition 
in the community. 
It can be challenging for GPs, presented with an infant with respiratory symptoms, to 
differentiate their diagnosis between bronchiolitis, bacterial respiratory tract infections and 
wheezy bronchitis/early asthma.  Evidence from systematic reviews suggests no available 
treatments shorten the natural course or provide clinically relevant improvements in 
bronchiolitis symptoms.33;61;62   
SIGN guidelines are the main source of information for bronchiolitis management in the UK 
but lack guidance applicable to general practice.36  The guidelines recommends further 
research is needed to examine the prevalence of bronchiolitis in primary care and current 
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treatment practice in the community and risk profiling to identify those who may have future 
respiratory symptoms.36  Assessing the burden of bronchiolitis in UK primary care could 
improve the evidence base for management of this condition by GPs and improve our 
understanding of the epidemiology of RSV disease which will be particularly important 
should an effective vaccine be developed.   
Early findings from The Houston Family Study published in 1986, a birth cohort of 125 
infants with community follow-up for the first year of life, estimated the rate of RSV-confirmed 
lower respiratory tract disease to be 21.6 per 100 infants under 1 year.46  Large prospective 
birth cohorts are needed to determine the current clinical burden of bronchiolitis in the 
community, but these are expensive and not practical.  With widespread use of electronic 
patient records in general practices across the UK47, it is now possible to estimate the 
frequency of acute bronchiolitis consultations in the community.   
The main aim of this study was to identify how frequently acute bronchiolitis is diagnosed by 
GPs.  The methods used are described in the earlier chapter 5.3.   
 
7.2 Results 
 
7.2.1 Cohort characteristics 
The birth cohort included 80,976 infants born in the year 2003, from 600 general practices 
across the UK.  51% (41457/80976) of the cohort were males (39519 were females).   
7.2.2 Bronchiolitis consultations   
Among the birth cohort, 3543 infants were diagnosed with bronchiolitis during a general 
practice consultation in their first year of life, with a total of 4707 bronchiolitis consultations 
among the cohort, 58.1 per 1000 infants under 1 year (95% CI 56.5-59.8).  The mean age of 
infants diagnosed with bronchiolitis in a GP consultation (Figure 5) was 5.5 months (SD = 
3.2).  There was a peak in bronchiolitis consultations during the winter months, particularly 
late December to early January (Figure 6), corresponding with the typical peak in laboratory 
reports of RSV infection sent to the HPA.   
Using the broader bronchiolitis definition 16744 “bronchiolitis” consultations were identified 
among the birth cohort, giving a consultation rate of 206.7 per 1000 infants under 1 year 
(95% CI 204.0 – 209.6).   
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Figure 5: Age in months at first diagnosis of bronchiolitis in a GP consultation. 
* Dataset contains only month and year of birth (no date) so age in months is approximate, 
based on the assumption that individuals are born in the middle of the month. 
 
Figure 6: Seasonality of acute bronchiolitis consultations in general practices across 
the UK. 
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7.2.3 Consultations in the first year of life 
Among infants with a bronchiolitis consultation, 176 (5.0%) had had no prior consultations 
with their general practitioner for any reason .The majority of those diagnosed with 
bronchiolitis, 2943/3543 (83.1%), had previously visited their GP for at least one 
immunisation.  Among infants with no history of bronchiolitis, the most common diagnoses 
and symptoms recorded during primary care consultations in their first year of life were 
respiratory conditions (47.6%).  In comparison, among infants who did consult with 
bronchiolitis during their first year, respiratory symptoms made up significantly more (60.1%) 
of all their primary care consultations (Table 9).  The relative risk of having a respiratory 
consultation in the first year of life was 1.26 (CI 1.23 to 1.29) among infants who consulted 
with bronchiolitis compared with those who did not.   
Table 9: The most common diagnoses recorded during consultations among infants 
in the cohort, comparing those with and without a bronchiolitis consultation during 
their first year of life. 
 
 
Diagnosis groups of 
consultations during the 
first year of life 
Infants with no 
bronchiolitis 
consultations (n=77433) 
Infants with a 
bronchiolitis 
consultation (n=3543) 
Comparison of 
proportions  
(z test) 
 Frequency (%) Frequency (%) 
 
P value 
Respiratory tract infections 
and cough or wheezing 
symptoms 
64791 (47.6) 6940 (60.1) 
 
<0.0001 
Eczema, dermatitis, rashes 
and other skin conditions 
 
27647 (20.3) 1577 (9.7) 
 
<0.0001 
Diarrhoea, vomiting and other 
gastro-intestinal symptoms 
 
21469 (15.8) 1333 (8.2) 
 
<0.0001 
Other infections  
22077 (16.2) 1689 (10.4) 
 
<0.0001 
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7.2.4 Consultations before and after bronchiolitis 
Infants who consulted with bronchiolitis had an average of 1.1 consultations during the 2 
weeks before their bronchiolitis diagnosis and an average of 1.0 consultation during the 
following 2 weeks.  During any GP consultation in the 2 weeks before a bronchiolitis 
consultation, the top 5 diagnostic or symptomatic codes recorded were upper respiratory 
tract infection (9.3%, n=329), cough (8.4%, n=297), chest infection (2.6%, n=93), acute 
conjunctivitis (1.3%, n=45) and wheezing symptoms (0.9%, n=33).  The most common 
diagnostic or symptomatic codes recorded during GP consultations in the 2 weeks following 
a bronchiolitis consultation were acute bronchiolitis (9.5%, n=336), cough (2.9%, n=102), 
upper respiratory tract infection (2.0%, n=71), acute conjunctivitis (0.8%, n=27) and chest 
infection (0.7%, n=26).   
 
7.2.5 Prescriptions    
In total, there were 1684 prescriptions associated with a bronchiolitis consultation (35.8% of 
all bronchiolitis consultations resulted in a prescription).  Among these, 464 were for 
antibiotics (27.6%), 452 for beta agonists (26.8%) and 140 for antipyretics or analgesics 
(8.3%) and 12 for inhaled corticosteroids (0.7%). The mean age of infants receiving any 
prescription associated with a bronchiolitis consultation was 6.6 months (SD=2.9).   
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7.3 Summary of chapter findings 
 
In this chapter, findings from the first study to estimate the incidence of acute bronchiolitis in 
UK primary care are presented.  A cohort was created using medical records from the GPRD 
database and used to examine the natural history and management of bronchiolitis in the 
community setting.  The findings reported in this study have important implications for GP 
training and potentially for passive and future active RSV immunisation policy in the UK 
(which will be discussed in chapter 10).  The main findings from there analyses are of 
primary care data are summarised here: 
 
 From a cohort of 80,976 infants born in the UK in 2003, 3543 were diagnosed with 
bronchiolitis during a general practice consultation in their first year of life. 
 
 In total there were 4707 bronchiolitis consultations among the cohort, 58.1 per 1000 
infants under 1 year (95% CI 56.5 to 59.8), with a peak during winter months.   
 
 The mean age at bronchiolitis consultation was 5.5 months (SD = 3.2).   
 
 A broader bronchiolitis definition which included non-specific symptomatic codes, 
identified 16744 potential bronchiolitis consultations, giving a rate of 206.7 per 1000 
infants under 1 year (95% CI 204.0 to 209.6).   
 
 The relative risk of having a respiratory consultation in the first year of life was 1.26 
(95% CI 1.23 to 1.29) among infants who consulted with bronchiolitis compared with 
those who did not.   
 
 Infants who consulted with bronchiolitis had an average of 1.1 consultations during the 2 
weeks before their bronchiolitis diagnosis and an average of 1.0 consultation during the 
following 2 weeks.   
 
 35.8% of bronchiolitis consultations resulted in a prescription, of which 464 (27.6%) 
were for antibiotics, 452 (26.8%) for beta agonists and 140 (8.3%) for antipyretics or 
analgesics.   
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8.0 Results – Study 3: Impact of bronchiolitis on respiratory 
health in early childhood 
 
Chapter Overview 
This chapter presents findings in relation to research question 3 and objective 3.   
Research Question 3 - What is the long-term impact of RSV bronchiolitis on subsequent 
respiratory health in early childhood?  
 
Objective 3 - To determine the longer-term effects of RSV bronchiolitis on subsequent 
respiratory health in early childhood. 
Using the methods described earlier (chapter 5), two cohort studies were developed, one 
from the primary care setting using GPRD data and one from the secondary care setting 
using HES data.  Both studies included individual medical records from birth to age 5 years 
(for HES) or 7 years (for GPRD), providing sufficient follow-up data to examine respiratory 
outcomes in early childhood, following an episode of bronchiolitis in infancy.   
8.1 Introduction 
Evidence suggests RSV infection in infancy may be associated with subsequent, longer-term 
respiratory morbidity in childhood and even into early adulthood.  In particular, research has 
shown a link between RSV infection in infancy and recurrent wheezing and asthma in 
childhood.14;138;140-146  However, there remains some uncertainty about the physiology and 
immunological processes that may drive this association, with some research suggesting it is the 
disease phenotype that is of more importance than the causative agent, in predicting future 
asthma and wheeze.160  It is important to improve our understanding of this association given the 
long-lasting impact that a chronic respiratory illness such as asthma can have, on the quality of 
life of that individual and their family, as well as the associated healthcare costs.  However, long-
term follow-up of infants following RSV bronchiolitis is often precluded by practical and financial 
issues and much of the existing evidence has come from studies with a small number of 
participants.  Longitudinal linkage of routinely collected healthcare records presents an 
opportunity to examine any link between RSV bronchiolitis and longer-term respiratory morbidity, 
among a large, nationally representative cohort of children.   
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The aim of this study was to determine the longer-term effects of severe RSV bronchiolitis on 
subsequent respiratory health, specifically on admissions and consultations for wheezing and 
asthma, in early childhood.  The methods used in this study are described in chapter 5.     
8.2 Results 
8.2.1 HES cohort study with follow-up to age 5 years 
Description of birth cohort 
211772 individuals born in financial year 2003/04 were identified for inclusion in the birth 
cohort.  Among whom, 7.6% (n = 16084) were born preterm.  13% (n = 28503) of infants in 
the cohort were identified as having one or more risk factor for severe RSV infection and 
were categorised as “high-risk”.  The remaining 87% of the cohort were categorised as being 
at “low-risk” of bronchiolitis admission as they were previously healthy.   
Bronchiolitis admissions 
In total there were 5947 admissions to hospital with a primary diagnosis of bronchiolitis 
among the cohort, 28.1 per 1000 infants under 1 year (95% CI 27.4 to 28.8).  5.1% 
(1451/28503) of the high-risk infants were admitted to hospital with a diagnosis of 
bronchiolitis, compared with 2.5% (4496/183269) among the group of infants at low-risk 
(p<0.05).  Bronchiolitis admissions among infants in the high-risk group had a median length 
of stay of 3 days (IQR = 0 to 6 days), compared with a median of just 1 day in the low-risk 
group (IQR = 0 to 3 days) (p<0.05).  Infants admitted with bronchiolitis in the high-risk group 
were more likely to be admitted to an ICU during their stay (32% compared with 4% in the 
low-risk group).  Among the high-risk infants with a bronchiolitis admission, 28% had at least 
1 further bronchiolitis admission, compared with 15% among the low-risk group (p<0.05).  
The median age group at bronchiolitis admission was infants aged 3 to 6 months, for both 
the high- and low-risk groups.   
Subsequent respiratory morbidity 
A higher proportion of children with a history of bronchiolitis admission in infancy had 
subsequent admissions for asthma in the first five years of life (12.0%), compared with 
children with no prior bronchiolitis admissions (1.7%).  Hospital admissions for wheezing in 
the first 5 years of life were also more common among those who had been admitted to 
hospital with bronchiolitis in infancy (8.5%) compared with those who had not (1.3%).  
Among infants with a history of bronchiolitis admission, 14.5% were admitted to hospital with 
LRTI and 23.0% with URTI before the age of 5 years.  A smaller proportion of those children 
with no prior bronchiolitis admission were admitted to hospital with LRTI (2.7%) or URTI 
(7.7%).   
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The relative, attributable and population attributable risks of hospital admission with asthma, 
wheezing, LRTI or URTI in the first five years of life, among infants who had a bronchiolitis 
admission in infancy compared with those who did not, are presented in Table 10.   
Table 10: Risk of subsequent respiratory hospital admissions in first five years of life, 
following a bronchiolitis admission in infancy. 
 Relative Risk (RR) 
(95% CI) 
Attributable Risk (AR) 
(95% CI) 
Population AR 
Asthma 6.96  
(6.45 – 7.51) 
0.10  
(0.09 – 0.11) 
0.14 
Wheezing 6.52  
(5.95 – 7.15) 
0.07  
(0.06 – 0.08) 
0.13 
URTI 3.00  
(2.85 – 3.15) 
0.15  
(0.14 – 0.16) 
0.05 
LRTI 5.43  
(5.07 – 5.80) 
0.12  
(0.11 – 0.13) 
0.11 
Subsequent respiratory morbidity in high- and low-risk groups 
Among the high-risk group who had been admitted with bronchiolitis, 15% were 
subsequently admitted with a primary diagnosis of asthma, before the age of 5 years, 
compared with 11% among the low-risk group with a history of bronchiolitis (Figure 7).   In 
comparison, among high- and low- risk infants who had no bronchiolitis admissions during 
infancy, only 2% were admitted between the age of 6 months and 5 years with a primary 
diagnosis of asthma.   Subsequent admissions for wheezing in the first 5 years of life 
occurred among 7% of the low-risk and 13% of the high-risk group, who had a history of 
bronchiolitis admission.  In comparison, only 1% of the low-risk and 2% of the high-risk 
infants who had no previous bronchiolitis admission were admitted with a diagnosis of 
wheezing before the age of 5 (Figure 7).  Following a bronchiolitis admission, subsequent 
admissions for LRTIs and URTIs were common among both groups but highest among the 
high-risk infants (Figure 7).   
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Figure 7: Subsequent respiratory admissions in early childhood (up to age 5 years) 
among infants in high- and low- risk groups, comparing those with and without a 
history of bronchiolitis admission during childhood. 
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8.2.2 GPRD cohort study with follow-up to age 7 years 
 
Study cohort 
The birth cohort consisted of 80,976 infants born in the year 2003 and registered across 600 
general practices in the UK.  51% (41457/80976) of the cohort were males (39519 were 
females).  Complete primary care records up to the age of 7 years were available for 54540 
children in the cohort (67.4%), as others transferred out of the cohort upon registering at a 
different GP practice.   
Bronchiolitis consultations   
As described in the earlier results section (7.2), 3543 infants had at least one consultation in 
the first year of life with a diagnosis of acute bronchiolitis.  There were a total of 4707 
bronchiolitis consultations among the cohort, 58.1 per 1000 infants under 1 year (95% CI 
56.5-59.8).   
Subsequent respiratory consultations up to age 7 years 
Among children with a history of bronchiolitis consultation in infancy, 25.4% had at least one 
consultation with a diagnosis of asthma by the age of 7 years.  In comparison, 11.8% of 
children with no prior bronchiolitis consultations had an asthma consultation by age 7 years.   
A higher proportion of children who consulted with bronchiolitis in infancy had at least one 
consultation with a diagnosis of wheezing by the age of 7 years (57.6%), compared with 
children with no history of bronchiolitis, among whom 13.9% had a wheezing consultation by 
age 7 years.   
The relative, attributable and population attributable risks of subsequent GP consultations for 
asthma or wheezing in the first 7 years of life, comparing infants with a history of bronchiolitis 
consultation in infancy to those without, are presented in table 11.  The findings show that 
children with a history of bronchiolitis are over twice as likely to consult their GP with asthma 
and 4 times more likely to consult with wheezing, compared with children with no prior 
bronchiolitis consultations.   
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Table 11: Risk of subsequent GP consultations for asthma or wheeze in the first 7 
years of life, comparing children with a history of bronchiolitis consultation to those 
without. 
 Relative Risk (RR) 
(95% CI) 
Attributable Risk (AR) 
(95% CI) 
Population AR 
Asthma 2.15 
(2.01 – 2.30) 
0.14 
(0.12 – 0.15) 
0.05 
Wheezing 4.14 
(3.95 – 4.35) 
0.44 
(0.41 – 0.46) 
0.12 
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8.3 Summary of chapter findings 
In this chapter the findings of two cohort studies are described, examining the longer-term 
effect of RSV bronchiolitis on subsequent respiratory admissions and GP consultations in 
early childhood.  The findings from these analyses are summarised here: 
 In a cohort of 211772 children born in English NHS hospitals in 2003/04, 13% had one 
or more risk factors for severe RSV infection and were categorised as “high-risk”.  The 
bronchiolitis admission rate among the cohort was 28.1 per 1000 infants under 1 year.  
5.1% of high-risk and 2.5% of low-risk infants had a bronchiolitis hospital admission.     
 
 The relative risk of subsequent admissions for asthma in the first five years of life was 
6.96 (95% CI 6.45 to 7.51) and for wheezing was 6.52 (95% CI 5.95 to 7.15), among 
children with a history of bronchiolitis admission compared with children without.   
 
 14.5% of children with a history of bronchiolitis admission were admitted to hospital with 
LRTI and 23.0% with URTI before the age of 5 years, compared with 2.7% and 7.7% 
respectively among children with no prior bronchiolitis admission.   
 
 15% of high-risk children with a history of bronchiolitis admission were subsequently 
admitted for asthma by age 5 years, compared with 11% in the low-risk group with a 
history of bronchiolitis.  Among high- and low- risk children with no prior bronchiolitis 
admissions, only 2% had an asthma admission between age 6 months and 5 years.   
 
 Subsequent admissions for wheezing in the first 5 years of life occurred among 7% of 
low-risk and 13% of high-risk children with a history of bronchiolitis admission and in 
only 1% of low-risk and 2% of high-risk infants with no prior bronchiolitis admissions.   
 
 From a cohort of 80,976 infants born in the UK in 2003, 3543 (4.4%) were diagnosed 
with bronchiolitis during a general practice consultation in their first year of life. 
 
 Among children with a history of bronchiolitis consultation in infancy, 25.4% had at least 
one consultation with a diagnosis of asthma by age 7 years, compared with 11.8% of 
children with no prior bronchiolitis consultations (RR = 2.15 95% CI 2.01 to 2.30). 
 
 57.6% of children who consulted with bronchiolitis in infancy had at least one 
consultation with a diagnosis of wheezing by the age of 7 years, compared with 13.9% 
among children with no history of bronchiolitis (RR = 4.14 95% CI 3.95 to 4.35).   
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9.0 Preliminary developments and progress in linking neonatal 
care and subsequent hospital admission records 
 
Chapter overview 
In this chapter, I describe the progress made in linking individual neonatal care records from 
the NNRD to subsequent hospital admissions records in the HES database.  This work 
forms one component of the “Medicines for Neonates” programme funded by the NIHR 
under its Programme Grants for Applied Research funding scheme.  Over the three year 
PhD period considerable headway has been made, despite the lengthy and bureaucratic 
processes that were required to ascertain all the necessary research governance and ethical 
approvals.  Here I outline the progress that has been made to date, describe linkage 
methodology and summarise some potential uses of this linked longitudinal dataset.   
 
9.1 Background 
The NNRD was created to enhance the evidence base for neonatal care, (as described in 
the earlier chapter 4.4), harnessing the unique position of the universal care provided by the 
NHS, to integrate clinical and research processes and reduce the complexity and costs of 
conducting research.  One of the objectives of developing the NNRD was to link neonatal 
care records to other NHS data such as hospital admission and general practice records, 
using unique personal identifiers, to provide long-term follow-up to study subsequent health 
outcomes beyond discharge.  This rich source of data can facilitate applied research in 
neonatal medicine, as well as audit, monitoring and evaluation of interventions and service 
delivery.  It would also be useful for clinical trials in newborns where long-term follow-up can 
be logistically difficult and costly.   
 
The development of neonatal networks with coordinated care services and shared 
management has facilitated data collection and establishment of the NNRD.290;291  Through 
engaging with and involvement of NHS staff within these networks, high completeness in 
data recording has been achieved and continual feedback to networks ensures the quality of 
inputted data has continued to rise.  Since data are entered and actively used by clinicians at 
the point of care, data capture is likely to be more complete and accurate.  These records 
contain clinically relevant information captured in real-time, from a large geographically 
defined population that is nationally generalisable.   Linked neonatal and subsequent 
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hospital admission records could be used to establish if the contribution of previously 
identified variables on neonatal outcomes can be replicated, as well as to assess other 
important but hitherto unaddressed factors such as deprivation and ethnicity that may be 
major confounders in assessing long-term outcomes.279   
9.2 Research governance and applying for ethical approval 
 
As described earlier (see section 4.5), as part of the overall Medicines for Neonates 
programme of work (which this PhD research is part of) we applied to the NIGB for approval 
to link the NNRD managed by the NDAU to HES data at an individual level, using identifiers 
including NHS number, date of birth, sex, postcode and hospital number.  National Research 
Ethics approval was also obtained in 2010 for the NDAU to form the NNRD, including the 
linkage to other NHS records.279   
Although provisional NIGB approval was received in December 2010, final approval was not 
granted until the third year of my PhD in January 2012.  This was due to the request for 
various clarifications and amendments to some aspects of the application, such as providing 
further information to parents about the potential uses of their baby‟s data and the inclusion 
of a mechanism to permit them to opt out of their baby‟s data being stored.  Upon receipt of 
this final approval I was able to submit an application to the NHS Information Centre in 
February 2012, to receive identifiable HES data at the NDAU for the purposes of linkage to 
the NNRD.  The HES data arrived at the end of August 2012 and I have subsequently spent 
considerable time uploading, cleaning and formatting these records in preparation for 
linkage.   
The delays in receiving these necessary approvals and obtaining the identifiable HES data 
have consequently limited the amount of progress that could be made with the linkage stage 
of this work, given the 3 year time constraints of this PhD (from January 2010 to December 
2012).  However, I will now describe the methodology that will be used going forward with 
this linkage.   
9.3 Proposed linkage methodology 
Record linkage is the process of bringing together records pertaining to the same individual 
from disparate data sources.225;241  This is becoming increasingly important in an era when 
clinical records are now routinely captured in electronic format and maintained in large 
databases, frequently on a national scale.  The techniques and methodology to link 
individual records across different datasets are now being developed and implemented, as 
this is a cost-effective and efficient way to increase the amount of information available for 
research.292   
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Records may be linked using either deterministic or probabilistic methods.  Deterministic 
or exact record linkage requires a unique variable (or combination of variables) to be 
available in both files being linked.  Probabilistic record linkage is suitable when no unique 
identifier is available, data are „noisy‟ (i.e. contain random errors), or key identifier variables 
have missing values.225;235  Probabilistic procedures calculate and assign weights or 
probability based criteria on the basis of the degree of matching of the identifier variables.292-
294  This allows for missing data or data entry errors by utilising the cumulative accuracy of a 
number of variables.295  The likelihood that two records match is then related to the sum of 
these two weights, so this method requires a subjective decision to be made to accept as 
true matches all comparisons of record pairs with combined weights above a chosen 
threshold and reject all those below.241;294  The threshold for these weights is chosen to 
satisfy criteria for specificity and sensitivity, which varies depending on whether the linkage 
is one-to-many or many-to-many.292  The weights are based on the probability that the 
linking variable agrees among matches (which reflects the reliability and therefore error rate) 
and the probability that the linking variable agrees among non-matches (which reflects its 
discriminatory power).296  A high error rate increases the number of false matches while low 
discriminatory power increases the number of false links.296   
Deterministic methods result in the low false positive links but at the expense of missing 
matches, depending on the error rate of the linking variables.293;294;297  A priori knowledge of 
the quality of linking variables is needed to help determine which level of disagreement 
between matching variables should be tolerated.294  Which approach to use depends on the 
purpose of the record linkage.  If the aim is be able to make inferences about specific 
individuals then a high positive predictive value is needed, so a deterministic approach may 
be favoured or a probabilistic method with careful clerical review of matches close to the 
selected threshold of acceptability.293   
The basic theoretical and practical steps involved in probabilistic record linkage are 
summarised in Box 3.  The first stage involves formatting and blocking of datasets.  Linking 
variables need to be formatted consistently and ordered.  The data then need to be broken 
down into manageable blocks for linking, for example blocking by NHS number.  The next 
stage is matching and weighting of records.  Records within each particular block in one 
dataset are matched to every record in the corresponding block in the other dataset.295  
More than one round of blocking may be used, for example using NHS number and date of 
birth.  Weights are then assigned to linking variables within a pair of linked records, based on 
the contribution of each identifier, so that agreement on NHS number for example would 
carry more weight than agreement on hospital number or sex.298  The threshold is then set, 
which typically has an upper and lower limit based on the maximum permissible number of 
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mismatching variables and the minimum number of matched variables required for a pair of 
records to be a possible match.295  Records with total weights above the upper threshold are 
then automatically accepted as matches and those below the lower threshold are rejected as 
non-matches.295  Record pairs falling between the thresholds in the so called “grey area” 
require manual checking to decide if they are matches or not.   
Furthermore, efficient methods of validating probabilistic record linkage have been widely 
reported.231  
 
Box 3: Probabilistic linkage process. 
 
Methodological considerations 
In Australia routine linkage of health record databases is particularly well established in 
some regions, including the Western Australian Data Linkage System.299;300  Reporting 
guidelines have been developed to evaluate the methodological quality of studies using 
linked data, ensuring that researchers can consistently report and accurately appraise and 
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interpret findings derived from such studies.301  This is important since incomplete data 
linkage can result in systematic bias in reported clinical outcomes.302 
As discussed earlier (see sections 3.3 & 3.4), possible methodological limitations of linking 
healthcare records include the degree to which data can be anonymised without losing vital 
information and the successful matching of records is dependent on the quality of unique 
identifier variables.189  With neonates for example, this can be particularly challenging as 
NHS number may not always be recorded or maternal details may be used instead.  
However, provided linkage methods are tailored to the datasets being used they can 
correctly identify a high proportion of matched records even with limited quality or availability 
of identifiers.211  Furthermore, efficient methods of validating probabilistic record linkage 
have been widely reported.241  The key to making linked resources useful and accessible is 
ensuring confidentiality and secure data storage.189;212   
Adjustment for patient case-mix will be essential to allow for variations in co-morbidity and 
patient profile when comparing resource utilisation, survival and other outcomes.  Other 
statistical issues also need to be carefully considered, such as dealing with multiple 
measures per patient, multiple levels of data clustering (by neonatal unit/network/hospital), 
transfers between neonatal unit, missing data and imputation, adjustment for confounding 
factors and minimising the time between data collection and its analysis to allow near real-
time monitoring of outcomes.   
 
9.4 Progress to date and on-going work 
 
Delays in receiving the necessary ethical approvals and obtaining the identifiable HES data 
have consequently limited the amount of progress that could be made with the linkage stage 
of this work, given the 3 year time constraints of this PhD (from January 2010 to December 
2012).  However, I will now describe the considerable progress that has been made.   
HES inpatient, outpatient and Accident and Emergency (A&E) data from financial years 2006 
to 2011 were obtained.  The HES data capture and transfer pathway is illustrated in Box 4 to 
show how these data arrive at the NDAU for linkage to the NNRD.  The data were uploaded, 
merged and saved onto the secure NHS server at the NDAU in the Chelsea & Westminster 
NHS hospital.  The HES data fields were then cleaned and formatted, for example numeric 
admission and discharge date fields were converted in dates.  These HES data include the 
following personal identifier variables which are also present in the NNRD database and will 
therefore be used to link records across the two databases: 
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 NHS number 
 Date of birth 
 Post code 
 Sex 
 Hospital number 
 
Neonatal records are typically available in the NNRD within 3 to 6 months of collection at the 
point of care.  There is typically a longer delay in the availability of national HES data but the 
NDAU will obtain annual updates of HES data when it becomes available at the NHS 
Information Centre.   
 
 
Box 4: HES data capture and transfer pathway. 
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Management and analysis of the data are being conducted using SAS software (SAS 
Institute, Cary, N.C., USA).  Initially development and testing of linkage methods will be 
piloted using a small subset of records from babies admitted to Chelsea and Westminster 
neonatal unit only, from the years 2007 to 2010 so that sufficient data from subsequent 
hospital admissions will be available in the HES database.   
The following steps will then be taken to develop a linked database: 
 Examine how many records in the two databases could be linked by straight forward 
deterministic methods using only patient NHS number. 
 
 Develop algorithms to assign weights to variables for probabilistic linkage. 
 
 Test the linkage of electronic neonatal records to HES hospital admission records 
using various thresholds depending on the desired specificity and sensitivity and 
decide on the optimum cut-off to use.   
 
 Compare agreement between HES and NNRD neonatal data using fields common 
to both databases such as gestational age and birth weight (using standard Bland & 
Altman methodology for continuous measures and Kappa coefficients for categorical 
variables).    
 
 Examine secondary care activity, post-discharge resource utilisation and case-mix 
adjusted clinical outcomes among the babies with linked records.   
 
 Logistic regression modelling will be used to examine mortality after discharge from 
a neonatal unit (using the HES linked ONS mortality data to identify deaths occurring 
both in and outside of hospitals).   
  
 Validation tested by comparing wherever possible to outcomes reported in other 
population-based datasets,303 such as data from ONS birth registrations or data from 
large birth cohort studies such as EPICure.   
 
 
Best practice will be followed, ensuring personal identifiers are removed from the dataset 
and a new unique child identifier key will be derived so that data that will be subsequently 
provided to researchers will not be identifiable.304   
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An example of a pilot study which could provide a useful demonstration of the utility of these 
linked records, could be examining the risk of subsequent hospital admission for RSV 
bronchiolitis in the first year of life after discharge from a neonatal unit.  Indeed the JCVI in 
the UK have recommended that more detailed information on the specific risk of RSV 
infection by gestational age is needed.  Neonatal records provide more detailed and 
complete information on gestational age (by weeks and days), so the NNRD data linked to 
HES would add the longitudinal admission records to make such a study feasible on a 
national scale.   
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9.5 Summary of chapter 
 
In this chapter I have described the substantial progress that has been made towards linking 
individual neonatal care records from the NNRD to subsequent HES hospital admission 
records, to provide longitudinal follow-up of neonates post discharge.  This project is part of 
a continuing body of research within the NIHR-funded “Medicines for Neonates” research 
programme.  Having attained ethical approval to carry out this linkage and obtained the 
required identifiable datasets, piloting of the probabilistic methodology to link individual 
records is now progressing.  Establishing the feasibility and methodology for linking neonatal 
records to extract clearly defined information post discharge, is essential to realising the 
potential of the NHS in research spanning the life course, providing the possibility of cradle 
to grave research studies.  Once linkage of the NNRD to HES is completed and validated 
the next aim for this on-going work will be to link neonatal care records to other NHS data 
such as general practice records.   
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10.0 Discussion 
 
Chapter overview 
This chapter brings together the findings from the three results chapters, relating to each of 
the three objectives of this thesis.  The chapter begins by restating the thesis aim and 
research questions with an overall summary of the main findings from this thesis.  This is 
followed by an individual discussion of each of the three studies.  I then describe the overall 
strengths and weaknesses of the methods used in this thesis.  There is then a discussion of 
how the thesis findings relate to what the existing literature tells us and what the implications 
of this research are, for clinicians and policy makers.   
 
10.1 Overall summary of thesis findings 
The overall aim of this PhD thesis was to improve estimates of the wider clinical burden 
of RSV bronchiolitis among infants in the UK, by examining the full clinical spectrum of 
bronchiolitis illness across different healthcare settings.  Three research questions were 
derived to tackle this and the key findings relating to each of these are summarised below 
and in Figure 8. 
Research question 1: What are the risk factors for admission to hospital with RSV 
bronchiolitis and how do admission rates vary between infants with comorbidities, preterm 
and term born infants?   
 Hospital admissions for unspecified bronchiolitis have been increasing since 2004/05.   
 The estimated bronchiolitis admission rate in English NHS hospitals is 24.2 admissions 
per 1000 infants under 1 year (95% CI 23.7 to 24.8) with a median length of stay of 1 
day (IQR 0 to 3 days) and at a median age of 120 days (IQR 61 to 209 days).   
 15% of infants admitted with bronchiolitis are born preterm (47.3 per 1000 infants) and 
24% have at least one known clinical risk factor for severe RSV infection.  
 Risk of bronchiolitis admission is significantly higher in infants with known clinical risk 
factors for RSV infection or with cystic fibrosis, Down‟s syndrome or cerebral palsy.   
Research question 2: What is the incidence of acute bronchiolitis among infants presenting 
to general practitioners and how is it being managed in the community? 
 The bronchiolitis consultation rate in UK general practice is estimated to be 58.1 per 
1000 infants under 1 year (95% CI 56.5 to 59.8) at a mean age of 5.5 months (SD=3.2).   
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 36% of bronchiolitis consultations result in a prescription, of which 28% are for 
antibiotics, 27% for beta agonists and 8% for antipyretics or analgesics. 
 Using a broader bronchiolitis case definition which includes less specific symptomatic 
codes, the estimated consultation rate may be as high as 206.7 per 1000 infants.    
Research question 3: What is the long-term impact of RSV bronchiolitis on subsequent 
respiratory health in early childhood?  
 An episode of bronchiolitis in infancy is a predictor of subsequent hospital admissions 
and general practice consultations for asthma and wheezing in early childhood.   
 Subsequent hospital admissions for asthma and wheeze are particularly likely following 
an episode of bronchiolitis among high-risk infants such as those born preterm.   
 
 
Figure 8: Pyramid summarising estimates of RSV bronchiolitis across healthcare 
settings, derived from findings in this thesis. 
 
 
 
Specialist  &  
Intensive Care 
 Infants with  
comorbidities at higher risk  
of bronchiolitis admission.   
Secondary Care 
2.4% of infants are admitted to hospital for 
bronchiolits, at a median age of 120 days, 
with a median length of stay of 1 day.    
24% of these infants have at least one known 
clinical risk factor for severe RSV infection 
and 85% of them are born at term.   
Primary Care 
Between 4% and 21% of infants have a bronchiolitis GP consultation 
in their first year of life at a mean age of 6 months. 
36% of bronchiolitis consultations result in a prescription, 28% of 
these for antibiotics and 27% for beta agonists. 
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10.2 Discussion of study 1: Bronchiolitis hospital admissions 
This section discusses the findings presented in chapter 6.0 which relate to the first research 
question and first objective of this thesis.   
10.2.1 Main findings 
Infant hospital admissions for diagnoses specifying RSV as the causative organism have 
remained stable during the 14 year period from 1997/98 to 2010/11.  Unspecified 
bronchiolitis and unspecified viral pneumonia admissions were relatively stable between 
1997/98 and 2004/05.  Unspecified bronchiolitis admissions have since increased 43.5% to 
33 per 1000 live births in 2010/11, with unspecified viral pneumonia admissions increasing 
36.3% over the same 6 year period, to 60 per 1000 live births.   
Most (85%) infants admitted to hospital with bronchiolitis in England are born at term, with no 
known predisposing risk factors for severe RSV infection.  Risk of admission is higher in 
known risk groups.  Babies born with Down‟s syndrome, cerebral palsy and cystic fibrosis 
are also at higher risk of hospital admission with RSV bronchiolitis.  The early age of 
bronchiolitis admissions has important implications for the potential impact and timing of 
future active and passive immunisations.   
10.2.2 Strengths and weaknesses 
This is among the first studies reporting the population burden of bronchiolitis across NHS 
hospitals in England and reporting trends in RSV-associated admissions over the last 
decade.  The main strength of the cohort is that use of HES birth records provides a large, 
nationally representative sample of births across England during this time, when compared 
with ONS live births data.166 It was assumed that infants with unknown gestational age and 
birth weight were not born preterm, as infants in this unknown group had similarly short 
length of stay at birth to infants born at term. Despite incomplete recording of gestational age 
in some birth records, 7.5% of the cohort were born at < 37 weeks gestation which is 
consistent with ONS data reporting that around 7.7% of live births annually are delivered 
preterm.305 This suggests under-reporting of gestational age in HES birth records appears to 
be mostly among term babies. Similarly, rates of congenital heart disease, chronic lung 
disease and other risk factors for severe RSV disease compare well with published UK 
population data.31;306-311   
There are a number of important limitations to this study. The case definitions for RSV-
associated illness, bronchiolitis and co-morbidities are dependent on the accuracy of clinical 
coding and recording in diagnosis fields in HES records, although improvements in the 
quality of HES coding have been demonstrated in recent years.240;312  I combined RSV and 
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unspecified bronchiolitis, presenting data on all bronchiolitis admissions. Only 28% of the 
bronchiolitis admissions were coded as being due to RSV (ICD-10 code J210), the 
remainder having unspecific bronchiolitis codes („ICD-10 codes J218 and J219). No linked 
microbiological data to confirm the presence of RSV were available. A previous study in the 
UK has estimated that around 75% of unspecified bronchiolitis admissions were RSV 
related, but this was estimated using a regression modelling approach so was also not 
based on microbiologically confirmed RSV cases.30 Globally it is estimated that only between 
4% and 28% of children admitted with LRTI are tested for RSV.21   
A limitation of the cohort study design is attrition, as it was not possible to identify 
bronchiolitis admissions occurring outside NHS hospitals in England, or to identify individuals 
who migrated elsewhere, though I estimate this number should be low with only one year of 
follow-up. Migration data from the ONS suggests the number of infants migrating out of 
England may be small, for example approximately 30,000 children under 15 years migrated 
out of England and Wales in 2008.313  Using linked ONS mortality data it was possible to 
identify the small number of individuals in the cohort who died during the study period. The 
number of infant deaths directly attributable to RSV infection is reported to be very low.191  
There is potentially some inherent selection bias in the study, through the inclusion of only 
hospitals with good completeness of recording of birth record fields, but sensitivity analyses 
showed few differences between included and excluded sites in terms of supply factors 
(such as number of maternity beds and number of deliveries).  No data on other possible 
confounders were available, particularly environmental exposures such as passive smoking, 
residential overcrowding, air pollution and nursery/day care attendance.  No data were 
available to identify any individuals who had received palivizumab prophylaxis against RSV 
infection. However, there are very strict criteria for its use in the UK due to its significant 
cost, which means that very few babies in the cohort are likely to have received it.   
10.2.3 Findings in relation to other studies 
No comparable national studies were found to compare to these estimates of bronchiolitis 
hospital admission rates in the UK but one previous study from Shropshire reported a 
bronchiolitis hospital admission rate of 30.8 per 1000 infants in this region of England,31  
compared with my estimate of 24.2 admissions per 1000 infants.  Another study estimated 
the annual incidence of hospital admissions attributable to RSV in the late 1990s reporting a 
rate of 28.3 per 1000 infants under 1 year, but the authors used linear regression modelling 
to predict the proportion of admissions with unspecified aetiology that were attributable to 
different organisms.30  My estimate may be slightly lower than both of these because I 
applied a narrow case definition including only infants admitted with a primary diagnosis of 
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bronchiolitis (ICD-10 „J21‟codes). This is likely to underestimate the total burden of RSV 
illness in infancy as I have excluded pneumonias due to RSV and non-specific, symptomatic 
clinical codes from the bronchiolitis case definition, though some of these admissions may in 
reality have been related to RSV infection.  Another population-based study in the UK 
reported that 1.1% of the Avon Longitudinal Study of Parents and Children (ALSPAC) birth 
cohort, were admitted to hospital with confirmed RSV bronchiolitis in their first year of life.147 
A study from the USA has reported a bronchiolitis admission rate of 31.2 per 1000 infants 
under 1 year,10  but a more recent study in Texas reported higher bronchiolitis admission 
rates of 5.5% among children under 2 years.45  These higher incidence estimates are likely 
to be due to the wider inclusion of children aged 12 to 24 months in their study, coupled with 
variation in the clinical definition of bronchiolitis used in the US compared with that used in 
the UK.13  Zhou et al examined hospital discharge data from 13 states representing 
approximately 40% of the US population and calculated an RSV hospitalisation rate in 
infants under 1 year of 2350 per 100,000 person-years (95% CI 2220 to 2520 per 100,000 
person-years).314  Similarly Holman and colleagues estimated a rate of 2700 RSV 
hospitalisations per 100,000 person-years among infants in the USA.315  Both of these rates 
are more comparable to my findings particularly since infants over 1 year of age were 
excluded in these studies.   
One previous study attempted to estimate the proportion of unspecified admissions that may 
be attributable to RSV,30 but this is the first recent study to my knowledge to examine trends 
in RSV-associated admissions over a 14 year period, giving an insight into how coding of 
these admissions may have changed over time too.  Admissions coded as specifically being 
due to RSV remained stable over the time period, but from 2004 the unspecified diagnoses 
increased substantially, the majority of which may well in reality be attributable to RSV.  This 
increase may be explained in part by the general trend in rising childhood admissions since 
2004, which coincides with the changes in provision of out-of-hours primary care services at 
this time.6  However, the rise in child admission rates is not on the same scale as that shown 
in Figure 2.  So although rising short stay admissions among children may in part have 
contributed to this increase it does not entirely explain the increases in unspecified viral 
pneumonias and bronchiolitis.   
Diagnostic trends over time may also have impacted on the observed admission rates, 
particularly in the earlier years studied when bronchiolitis may commonly have been 
recorded as wheezy bronchitis or asthma in older infants.  Further examination of trends in 
asthma and wheezing admissions, among both children under 1 year and those aged over 1 
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year is now warranted.  This would help to identify any diagnostic transfer from bronchiolitis 
to asthma admissions, particularly in older infants.   
Improvements in the completeness of diagnostic recording in hospital admission records 
may also explain the trend in increasing unspecified bronchiolitis admission rates.  It is likely 
therefore that the increase has been driven by a combination of factors which may include a 
real increase in RSV disease incidence; rises in the incidence of other viral LRTIs 
(particularly influenza); improvements in completeness of diagnostic recording, changes in 
healthcare-seeking behaviour and a lower threshold for admitting children to hospital.   
21% of infants admitted with bronchiolitis, had more than one bronchiolitis admission during 
their first year of life. Previous infection with RSV only confers partial immunity, so it is 
possible for individuals to be re-infected with the same or different RSV strains over the 
course of one season. Re-admissions for bronchiolitis among older infants may in reality be 
incorrectly diagnosed episodes of post-bronchiolitic wheezing. The modal age of bronchiolitis 
admission was 1 month and the median was 4 months, confirming findings reported 
elsewhere which show increased risk of RSV admission with younger age.36;98;316-319  In 
recent years a trend in decreasing age of patients with bronchiolitis has been emerging 
across Europe.14;320;321  It is unclear why RSV may be affecting babies at a younger age than 
has previously been reported. It could be associated with changes to the virus itself or 
maternal immunological priming, but further investigation into what may be driving this trend 
is needed. The median age of bronchiolitis admission was 4 months which is consistent with 
other studies where RSV hospital admissions are typically reported during the first 3 to 6 
months of life.22;322  Although, there is some debate regarding the most common age of RSV 
admissions.317 A population-based cohort in Denmark found the median age of admission for 
RSV infections was 6 months.323  Similarly, a recent prognostic birth cohort study reported 
that the median age at time of RSV LRTI was 6 months.324  Emergency short stay hospital 
admissions in this age group have been increasing.6  In 2006 the unplanned admission rate 
among children less than 1 year in England was 181 per 1000 child years.6  Our findings 
suggest that approximately 1 in 6 of these unplanned admissions was for bronchiolitis.   
In this study the majority of infants admitted with bronchiolitis were not in high-risk groups, 
with only 24% (1722/7189) having one or more recognised clinical risk factors for severe 
RSV infection.  In a smaller US study, 34% of RSV-infected patients (189/564) had at least 
one high-risk condition for RSV infection.44 It is difficult to determine the effect of reverse 
causality on bronchiolitis admissions among infants with conditions known to increase risk of 
RSV infection.  A clinician‟s knowledge of an underlying co-morbid condition such as Down‟s 
syndrome may increase the likelihood of a child being admitted to hospital.  Preterm infants 
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accounted for only 15% of bronchiolitis admissions in our study.  A small study of five 
paediatric intensive care units (PICUs) in London also found that the majority of infants 
admitted were born at term, so current preventive interventions such as palivizumab have 
minimal impact on PICU workload.325  Infants with chronic lung disease or congenital heart 
disease each accounted for around 4% of bronchiolitis admissions. This is consistent with 
findings reported elsewhere, suggesting that the majority of infants with severe RSV 
infection do not have any underlying risk factors.44  A cohort study in the Netherlands has 
also demonstrated that Down‟s syndrome is a novel independent risk factor for severe RSV 
LRTI.326  6.4% of infants in my study who had cystic fibrosis were admitted with bronchiolitis, 
slightly lower than the 8.8% reported in an Australian study.327  Low rates of bronchiolitis 
admissions in some high-risk groups may also be driven by palivizumab use. However, no 
national prescribing data for palivizumab is available for us to estimate the number of 
admissions its use may have prevented.  The median age of bronchiolitis admission was 
only 18 days later in preterm infants (136 days) compared with those born at term (118 
days), so onset of RSV disease appears to occur at a similar corrected age.  Median LOS for 
bronchiolitis admissions was calculated as a proxy marker of severity of illness and was 
found to be similarly short (1 day) among both term and preterm born infants.   
Geographical variation in bronchiolitis admission rates may be a proxy for other risk factors 
for hospital admission with severe RSV infection, such as maternal smoking or 
deprivation.99;328  Variation in diagnostic coding practices across England could also have 
contributed to these regional trends in bronchiolitis admissions, although audits of discharge 
coding have shown improvements in accuracy throughout the UK.329-331  I think this finding is 
most likely driven by variation in clinical practice, with different thresholds for admission in 
different regions as there are no national evidence based guidelines giving criteria for 
admission.  Indeed, widespread variation in hospital management of bronchiolitis has 
previously been reported elsewhere.13   
10.2.4 Implications and future research  
This study has highlighted that the burden of RSV bronchiolitis hospital admissions among 
infants in England predominantly affects those born at term, without any risk factors for 
severe RSV infection and the age at admission appears to be significantly lower now than 
previously reported.  Since the majority of infants hospitalised with bronchiolitis are below 6 
months of age, this will limit the impact of any future vaccine which is unlikely to be capable 
of eliciting immunity in such young infants.  This has important implications for future 
vaccination strategies, suggesting that the cost-benefit of both active and passive vaccines 
needs detailed evaluation.  I found that the median length of stay for bronchiolitis admissions 
was only 1 day.  Improved management of symptoms in the community, through both 
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primary care and A & E services may further reduce the need for admission.  Additional 
studies examining the clinical burden of bronchiolitis in the community are needed and could 
confirm the clinical and health service burden to be greater still.36;111;112  Improved 
management of RSV is achievable through the use of improved, evidence-based 
guidelines.1  The regional variation in bronchiolitis admission rates I have presented 
suggests admission criteria vary widely and there is a need for clearer guidance about which 
infants to admit to hospital in the UK.328   
The findings reported in this study suggest that in addition to the recognised risk factors for 
RSV bronchiolitis hospital admission, namely congenital heart disease, chronic lung disease 
and preterm birth, several other clinical conditions may also increase risk. The factors I have 
identified are cerebral palsy, cystic fibrosis and Down‟s syndrome.  I suggest further 
investigation is warranted, into whether infants with these conditions would also benefit from 
palivizumab immunoprophylaxis.332    
 
10.2.5 Conclusion 
Bronchiolitis is an important cause of hospital admissions among infants in the UK. Several 
clinical subgroups are at increased risk of hospital admission, but the majority of bronchiolitis 
admissions in England are among infants born at term, with no known clinical risk factors for 
severe RSV infection.  This confirms findings previously only reported in the USA showing 
that the majority of infants admitted to hospital with RSV infection are born at term.  The 
early age at which infants are typically admitted with bronchiolitis is an important finding 
since this will have implications for the timing and potential effectiveness of any future active 
vaccine which pharmaceutical companies are trying to develop.  This is the first study from a 
large, population-based cohort in England, which has provided evidence that babies born 
with Down‟s syndrome, cystic fibrosis and cerebral palsy are also at higher risk of hospital 
admission with RSV bronchiolitis.  More research is needed to understand why this is and 
whether these babies might also benefit from palivizumab prophylaxis.   
 
 114 
 
10.3 Discussion of study 2: Bronchiolitis in the community setting 
This section discusses the findings presented in chapter 7.0 which relate to the second 
research question and second objective of this thesis.   
10.3.1 Main findings 
The bronchiolitis GP consultation rate was 58.1 per 1000 infants under 1 year, among our 
large birth cohort, at a mean age of 5.5 months.  Using a broader bronchiolitis case definition 
the estimated bronchiolitis consultation rate could be as high as 206.7 per 1000 infants 
under 1 year.  There was a peak in bronchiolitis consultations during December and 
January, corresponding with the typical seasonal peak in RSV infections.  In the 2 weeks 
before a bronchiolitis consultation, infants commonly present to their GP with consultations 
for upper RTIs, coughs, chest infections and wheezing symptoms.  The relative risk of 
having a respiratory consultation in the first year of life was 1.26 (CI 1.23 to 1.29) among 
infants who consulted with bronchiolitis compared with those who did not.  9.5% of infants 
had a subsequent bronchiolitis consultation in the 2 weeks following an initial diagnosis.  
Antibiotics and beta agonists have been widely prescribed by GPs to infants presenting with 
bronchiolitis in primary care.   
10.3.2 Strengths and weaknesses 
The main strength of this study was the large number of infants (80,976) included in the birth 
cohort, with detailed information on their general practice consultations during their first year 
of life.  Use of records from 600 general practices in the GPRD ensures these findings 
reliably reflect the burden of bronchiolitis across primary care and are generalisable to the 
whole UK population, although I did not have access to data to determine whether GPRD 
practices differ in any respect from other general practices.  However, the general validity of 
using the GPRD for epidemiological research has been widely reported192;333 and coded 
diagnoses and prescriptions in the database should be highly reliable since the patient 
records are completed at the point of clinical contact.   
This is the first study that I am aware of to estimate the burden of bronchiolitis illness in 
primary care, facilitated by the use of anonymised patient records from the 
GPRD.  Bronchiolitis is a clinical diagnosis and although we did not have microbiological 
data to confirm the presence of RSV, the timing of bronchiolitis consultations corresponds 
very closely with the characteristic seasonal peak in laboratory reports of RSV infections 
collected by the HPA.36;39   
A possible limitation of this study was the completeness of coding of acute bronchiolitis 
consultations in the GPRD.  It is likely that I have underestimated the incidence of 
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bronchiolitis in general practices because GPs could also have recorded the diagnosis with a 
non-specific symptomatic code or in the free text sections which I did not have access 
to.  An earlier study examined use of the GPRD for respiratory epidemiology research and 
found it to be valid when comparing consultation rates to the Fourth National Morbidity 
Survey in General Practice (MSGP4).334  The authors suggest “acute bronchiolitis and 
bronchitis” rates in the GPRD were an order of magnitude lower than expected when 
compared with the MSGP4 estimates, unless combined with non-specific codes for “chest 
infections”.334  Thus it is likely the more conservative definition used in this study 
underestimates the clinical burden of bronchiolitis consultations in primary care since it 
identified only consultations with a specific clinical code indicating a bronchiolitis diagnosis.  I 
tested the impact of expanding the conservative definition of acute bronchiolitis to include 
consultations in the first year of life with other diagnosis codes which are also likely to 
represent infants with bronchiolitis, such as those with “chest infection”, “chesty cough”, 
“wheezing” and “asthma”.  Using this wider bronchiolitis definition I identified 16744 
“bronchiolitis” consultations among the birth cohort during the first year of life, giving a much 
higher estimated bronchiolitis consultation rate of 206.7 per 1000 infants under 1 year (95% 
CI 204.0 to 209.6), suggesting as many as 1 in 5 infants require primary care for an episode 
of bronchiolitis.   
I have previously examined hospital admission rates for RSV bronchiolitis among term and 
preterm infants in England (data reported in chapter 6.0).  Among this cohort of infants with 
severe bronchiolitis requiring hospital admission, 51.5% were reported to have been 
admitted via an Emergency Department and 36.4% via referral from a GP.  It is difficult to 
determine the typical care pathway for an infant with bronchiolitis as it is dependent on the 
individual course of illness.  The recording of referral information is variable between general 
practices and I was unable to determine the accuracy and completeness of this recording 
within the GPRD so could not include referrals in this analysis.  It may be that only the most 
severely ill infants are directly referred to hospital following a GP consultation, while others 
may consult their GP but are then only admitted following presentation at an Emergency 
Department when their condition has deteriorated.  It remains unknown whether parents take 
more severely unwell infants directly to an Emergency Department or whether infants with 
bronchiolitis that is similar in severity are treated differently in hospital settings.  More 
research is needed to clarify how many infants who are admitted to hospital via an 
Emergency Department have previously attended primary care and how many are taken 
directly to an Emergency Department as the first point of contact.    
Access to more detailed information about some other potentially confounding variables 
would have benefitted this study, such as prematurity which is known to be a significant risk 
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factor for RSV bronchiolitis89;289  and also deprivation, as more deprived children have higher 
GP consultation rates 335 and higher risk of RSV infection.99  I was unable to identify any 
infants in the cohort who had received palivizumab prophylaxis against RSV infection, since 
this is not typically prescribed in general practice and is only recommended for use in a few 
extremely high-risk infants.   
10.3.3 Findings in relation to other studies 
Existing knowledge of the burden of bronchiolitis has primarily come from hospital-based 
studies, as an estimated 3% of infants are hospitalised with bronchiolitis each year.31;34  Until 
now limited information regarding the more minor end of the RSV disease spectrum and 
acute bronchiolitis consultation patterns in the community has been available.  Some of the 
first serological RSV studies examined the clinical and patient characteristics of infants with 
RSV infection in hospital and outpatient settings336 and an early prospective birth cohort 
study with longitudinal follow-up reported an RSV infection rate of 68.8 per 100 infants aged 
under 1 year, among whom the rate of symptomatic lower respiratory tract disease was 22.4 
per 100 infants.46  To my knowledge, this is the first study to estimate the incidence of 
bronchiolitis in the primary care setting.  This was a key recommendation for future research 
outlined in the national guidance for management of bronchiolitis published in 2006.36   
Age is an important factor in determining the potential impact of any future active vaccination 
against RSV infection. Data from the US have shown the highest proportion of RSV related 
hospital admissions occurs among the 3 to 6 month age group.337  In the HES cohort 
described earlier (chapter 6.0) using data from hospitals in England, I found the median age 
of bronchiolitis admission to be at 120 days (inter-quartile range 61 to 209 days), with a 
positively skewed age distribution showing a peak in admissions at the age of 1 month.  In 
this primary care study there was an approximately normal age distribution, with a mean age 
of 5.5 months for infants with bronchiolitis presenting to GPs.  It is unclear why the age 
distribution of infants hospitalised with bronchiolitis appears to be skewed towards younger 
infants than those presenting in primary care.  This could be a reflection of disease severity, 
with younger infants who may be immunologically more susceptible to infection more likely 
to be admitted to hospital.  Publishing of the National Institute for Health and Clinical 
Excellence (NICE) clinical guideline for the management of children with febrile illness, may 
also have impacted on management of bronchiolitis in both primary and secondary care.5   
National guidance for management of bronchiolitis was published later than this 2003 cohort 
study.  No available treatments shorten the natural course or provide clinically relevant 
symptomatic improvements from this viral illness, 33;338 including inhaled and oral 
corticosteroids, beta agonists and antibiotics.61;62;64;76;339-342  This study shows that despite no 
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evidence for their use, GPs have prescribed antibiotics and beta agonists to infants 
diagnosed with bronchiolitis, risking adverse effects including disruption of gut flora and the 
development of antimicrobial resistance.343  Although not from primary care, studies from 
Canada and across Europe also provide evidence of variation in RSV bronchiolitis treatment 
between different hospitals.344;345  
Following the creation of new bronchiolitis guidelines in Switzerland, an intensive 
implementation programme tailored to the specific needs of hospital and primary care based 
paediatricians and generalists, was shown to be highly effective and resulted in significant 
reductions in the reported prescription of bronchodilators, inhaled steroids and antibiotics for 
the management of bronchiolitis.33  A particularly successful component of this quality 
improvement programme was an information leaflet for parents which highlighted the lack of 
evidence to support the use of any drugs for the management of viral, self-limiting illnesses 
such as bronchiolitis.33;346  Houben et al carried out a prospective birth cohort study in the 
Netherlands in which they showed that a simple clinical prediction rule can be used to 
identify healthy newborns at risk of RSV LRTI, allowing primary care paediatricians to target 
preventive and monitoring strategies towards high-risk infants, such as warning parents 
about the risks associated with passive smoking.99;324   
10.3.4 Implications and future research 
Studies from elsewhere in Europe have shown that improved management of RSV is 
achievable through the use of improved, evidence-based guidelines33 and simple clinical 
predictions rules can be an effective tool for identifying infants at high risk of RSV infection in 
primary care.324 Clearer guidance about which infants to admit to hospital are required and a 
firmer evidence base from the community setting is needed to develop up-to-date 
recommendations for bronchiolitis management in primary care.  Increasing emergency 
hospital admission rates among young children in England are mostly for short stay minor 
illness episodes such as bronchiolitis,6 which may be potentially avoidable if better managed 
by primary care in the community.   
A GP consultation rate of 58.1 per 1000 infants under 1 year would result in approximately 
46480 bronchiolitis GP consultations across the UK, given the current live birth rate of 
around 800,000 per year.  Although as previously discussed, the reliance on clinical coding 
means this is likely to be an underestimate of the total burden of illness in the community.  
Using the less conservative and perhaps more realistic bronchiolitis definition, I estimated a 
consultation rate of 206.7 per 1000 infants under 1 year, which would equate to 
approximately 165,360 GP consultations across the UK each year.  Analyses of data from 
Emergency Department services are needed, which could confirm the clinical and health 
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service burden of RSV bronchiolitis to be greater still.36;111;112  Diagnoses in A&E data are 
coded using their own specific system and not ICD-10 codes, so linkage of A&E data to HES 
inpatient records would be necessary to investigate this further.   
Further work is needed to determine the typical care pathway of infants admitted with 
bronchiolitis. This could be facilitated through the use of linked patient medical records from 
general practices, Emergency Departments, hospitals and laboratories.  Population-based 
linkage between hospital admission records and laboratory data in Australia has highlighted 
how linkage to laboratory records can improve the accuracy of estimating the burden of RSV 
disease compared with relying on clinical diagnosis coding alone.347    
These findings have important implications for future vaccination strategies and identifying a 
target population for emerging active immunisations against RSV.  Previous studies have 
attempted to determine the total cost of RSV associated illness, in order to estimate the 
potential impact and cost-effectiveness of passive and active immunisations against RSV 
infection.111;112  However, the total burden of disease can only be estimated by examining the 
full, wider spectrum of illness and not only costs of hospitalisation but also costs of caring for 
infants with milder RSV-associated illness provided in the community.  Prospective studies 
are also needed, to determine the long-term impact of RSV infection in infancy on 
subsequent respiratory health.   
10.3.5 Conclusion 
This is the first study to quantify the significant burden of acute bronchiolitis among infants 
presenting in general practices across the UK.  Over 4% of infants are diagnosed with 
bronchiolitis during a GP consultation in the first year of life, typically during the seasonal 
winter RSV peak and around 10% of these re-consult with bronchiolitis during the following 2 
weeks.  Using a broader case definition which includes symptomatic diagnosis codes, it is 
estimated that as many as 21% of infants may have an episode of bronchiolitis requiring a 
GP consultation.  The findings suggest antibiotics and beta agonists have been widely 
prescribed by GPs to infants presenting with bronchiolitis, despite no evidence base for their 
use.  Estimating this burden of illness in the community setting, at the population level, has 
important policy implications for GP training and potentially for future passive and active 
RSV immunisation policy.   
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10.4 Discussion of study 3: Impact of bronchiolitis on respiratory 
health in early childhood 
 
10.4.1 Main findings 
Two cohort studies, one using data from primary care and one from secondary care settings, 
were developed to examine longer-term associations between RSV bronchiolitis in infancy 
and subsequent respiratory morbidity in early childhood.   
HES cohort study with follow-up to age 5 years 
The HES cohort study of 211772 children with follow-up to age 5 years showed that the 
relative risk of hospital admission with asthma or wheezing was 6.96 and 6.52 times greater 
respectively, among children with a history of bronchiolitis admission compared with those 
without.  12.0% of children admitted with bronchiolitis were subsequently admitted with 
asthma by age 5 years and 8.5% for wheezing illness.  In comparison, among children with 
no prior bronchiolitis admissions 1.7% had subsequent asthma admissions and 1.3% had 
subsequent wheeze admissions by age 5 years.  Children who had been admitted with 
bronchiolitis during infancy were also more likely than those who had not, to be admitted to 
hospital for URTI or LRTI.  High-risk children with a history of bronchiolitis were most likely to 
have subsequent respiratory admissions, followed by low-risk children with a history of 
bronchiolitis, then high- and low-risk children with no previous bronchiolitis admissions.   
GPRD cohort study with follow-up to age 7 years 
Findings from the primary care cohort of 80,976 children showed a similar association 
between history of bronchiolitis and subsequent respiratory consultations in early childhood.  
25.4% of children who had a bronchiolitis consultation in infancy had at least one 
subsequent asthma consultation by the age of 7 years and 57.6% had at least 1 consultation 
for wheezing illness.  In comparison, among children with no prior bronchiolitis consultations 
11.8% had subsequent asthma consultations and 13.9% had subsequent consultations for 
wheeze by age 7 years.  So children with a history of bronchiolitis consultation in infancy 
were 2 times more likely than those with no prior bronchiolitis consultations to consult their 
GP for asthma (RR = 2.15) and 4 times more likely to consult for wheezing (RR = 4.14) by 
the age of 7 years.   
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10.4.2 Strengths and weaknesses 
Strengths 
These are the first large-scale, population-based cohort studies to report the longer-term 
impact of RSV bronchiolitis on subsequent respiratory consultations and hospital admissions 
in early childhood, using individual-level clinical data from children in the UK.   
The main strength of both cohorts was the large number of children they included, from 
across England (for the HES cohort) or the whole of the UK (for the GPRD cohort).   Existing 
evidence of the impact of RSV infection on subsequent risk of asthma and other respiratory 
morbidity has predominantly come from small, prospective cohort studies in the USA and 
Sweden.  The only UK data on school age respiratory outcomes following RSV bronchiolitis 
are from small regional studies following up high-risk infants born preterm.156;289  These are 
the first population scale studies from the UK to provide estimates of wheezing and asthma 
incidence following RSV infection. 
Deriving large nationally representative cohorts by using routine clinical records in this way 
ensures that the study findings are likely to be highly generalisable to the wider population of 
children in the UK.  As discussed in relation to the two earlier studies (see sections 10.2.2 
and 10.3.2), another key strength of using HES and GPRD data is that their general validity 
for use in health services and epidemiological research has already been widely 
reported.192;312;331;333  Coding of diagnoses in the GPRD should be highly reliable since the 
patient records are completed at the point of clinical contact and it has been shown that the 
accuracy of diagnoses recorded in HES has greatly improved.331   
Weaknesses 
The main weakness of this study was that neither of the databases used to derive these 
cohorts contained information on environmental risk factors for severe RSV infection, such 
as household smokers, nursery/day care attendance, number of siblings or breast feeding 
duration, which are all potential confounders that could not be controlled for.   
A possible weakness of these retrospective cohort studies is attrition.  It is not possible to 
determine exactly how many of the children in the HES or GPRD birth cohorts may have 
migrated away from the area in which they were born but as described earlier, outgoing 
migration rates are low among children in the UK.313  In the GPRD cohort it was possible to 
identify individuals who had transferred out of the cohort because they had left the GP 
practice and registered elsewhere, but there may also have been “ghost patients” who 
changed GP practice without de-registering.348  It was possible though in both the GPRD 
and HES cohorts, to identify children who died during the study period, reducing possible 
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biases from attrition.  There is potentially some inherent selection bias in the HES cohort, 
since only children born in hospitals with good completeness of recording of birth record 
fields were included.  However, the sensitivity analyses described earlier (see section 5.2) 
revealed this approach for creating a birth cohort should be generalisable.257   
As the GPRD cohort study described earlier showed (chapter 7.2), using diagnostic codes 
for bronchiolitis alone may underestimate the total incidence, since many GPs record non-
specific symptomatic codes or record diagnoses in the free text sections.  A limitation of 
using HES and GPRD data is that it is not possible to check the validity of diagnostic coding 
for this particular study, since it is not feasible to identify and contact the large number of 
children in the cohort to clarify the diagnoses they received.  A further limitation of the GPRD 
cohort was the lack of clinical information available about the children‟s birth status.  Since 
no information on gestational age at birth was recorded in their GP records it was not 
possible to identify children born prematurely, who would be at higher risk of RSV 
bronchiolitis.   
It was not possible in either the HES or GPRD cohorts to identify infants who had received 
palivizumab immunotherapy to prevent RSV infection, since HES contains no information on 
prescriptions and infants are unlikely to receive it in a primary care setting.  However, I 
obtained national aggregate data from the Prescribing Cost Analysis (PCA) database from 
the NHS Information Centre, which showed that only a very small number of infants receive 
palivizumab annually so this is unlikely to be a major confounder in our study (Appendix 1, 
Chapter 11).  The number of palivizumab prescriptions in this dataset is likely to be an 
underestimate because it does not include all in-hospital prescribing, but it is the only 
national estimate of palivizumab prescribing that the NHS Information Centre were able to    
provide.  Given the stringent JCVI criteria for palivizumab prescribing,349 the total number of 
infants receiving the immunotherapy is still likely to be very low and so should have minimal 
impact on these cohort studies.   
Another limitation of both cohort studies is the lack of microbiological data to determine what 
proportion of the bronchiolitis consultations and admissions were due to RSV infection.  
However, it remains a subject of debate as to whether the etiologic agent causing 
bronchiolitis is clinically relevant if the course of disease caused by RSV is similar to that of 
other viruses.14;320  Testing for RSV infection is not currently recommended as routine clinical 
practice in the UK, so both GPs and paediatricians are rarely aware of the organism causing 
bronchiolitis when caring for a symptomatic infant.  The findings presented from these 
cohorts show that history of a bronchiolitis episode in infancy, regardless of the etiologic 
agent causing it, predicts increased risk of asthma and wheezing in early childhood.  It was 
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not possible given the constraints of the clinical data available, to determine the impact of 
reverse causality on these findings, since it may be that those with pre-existing chest 
disease are more prone to RSV infection and to the development of asthma, rather than 
RSV infection itself causing the subsequent respiratory illness.   
10.4.3 Findings in relation to other studies 
Bronchiolitis incidence rates in this study were comparable with the HES cohort study 
described earlier (see section 6.2) as well as with existing estimates of RSV associated 
admissions from smaller regional studies in the UK and USA.20;30;31;44  Evidence of an 
association between RSV bronchiolitis and subsequent respiratory complications in 
childhood, including recurrent wheezing and asthma, has mostly come from small 
prospective studies in developed countries, since long-term follow-up of children is not often 
feasible and expensive to do on a large scale.10;14;140-145;164;350  A HTA study published in 
2008 highlighted the major uncertainties surrounding our understanding of the effects of 
RSV infection on long term respiratory health among children in the UK.111   
A study from the USA assessed respiratory outcomes and healthcare utilisation 12 months after 
RSV diagnosis, among commercially insured late-preterm infants.351  They reported infantile 
asthma rates were six to nine times higher among infants with a history of RSV/unspecified 
bronchiolitis compared with those without.  This is very similar to the rates reported in my cohort 
studies which had longer follow-up, with asthma hospital admissions seven times higher (up to 
age 5 years), whilst asthma GP consultations were just two times higher (up to age 7 years), 
among children with a history of bronchiolitis compared with those without.  Their study also 
showed significantly higher Emergency Department and outpatient visits in children with a history 
of RSV LRTI compared with those without.351  Findings from the GPRD cohort enhance this by 
going beyond existing evidence to show that as well as children with a history of bronchiolitis 
hospital admission, non-hospitalised children with bronchiolitis are also more likely to have 
adverse respiratory outcomes during early childhood.   
This study also confirms on a larger, population scale, the findings reported by Henderson et al 
who examined data from 150 infants admitted to hospital in the UK with RSV confirmed 
bronchiolitis, from the ALSPAC cohort.147  They reported the prevalence of wheezing was 28.1% 
in the RSV group compared with 13.1% in the control group, at age 30-42 months.  Interestingly 
their study also found RSV bronchiolitis was associated with prevalence of asthma but not with 
development of atopy, by age 7 years.147 
Subsequent respiratory illness following RSV bronchiolitis not only has an impact on an individual 
child in terms of their increased suffering, but also results in a significant economic burden due to 
the associated healthcare costs as well as wider costs from parents requiring time off work.  
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Palmer et al followed up a group of children in the USA for a year following RSV/unspecified 
bronchiolitis and found that they had higher healthcare costs associated with subsequent 
respiratory episodes, when compared with infants without a history of RSV/unspecified 
bronchiolitis.352  These healthcare costs were greatest among late-preterm infants compared with 
full term infants.  Findings from the HES cohort study confirm this, since low-risk infants had 
lower subsequent respiratory admission rates than high-risk infants which included those born 
preterm.   
The subsequent costs of health care utilisation following RSV hospitalisation have been 
estimated in studies from the USA, UK and Canada,103;289;353;354 but these studies have focused 
on following-up infants born preterm or with chronic lung disease, despite the majority of infants 
with bronchiolitis being born at term (see chapter 6.2).  Many previous studies on this topic have 
been limited by an inability to generalise their findings to term infants.127;355   
10.4.4 Implications and future research 
This is the first study to identify, using cohort data from large, nationally representative 
populations, that subsequent healthcare utilisation in early childhood is greater across both 
primary and secondary healthcare settings, among not only high risk infants with CLD or 
preterm birth, but generally among all children with a history of bronchiolitis.  Not only are 
infants with RSV bronchiolitis which required hospital admission at increased risk of adverse 
respiratory outcomes, but infants with perhaps milder bronchiolitis presenting to their GP are 
also at higher risk of further GP consultations for asthma and wheezing.  This information 
highlights the importance of developing new preventive and therapeutic agents to tackle both 
the acute and longer-term effects of RSV infection in childhood.  These findings also have 
huge implications for the NHS in terms of healthcare utilisation costs among children with a 
history of bronchiolitis, as this study provides the first estimate of the subsequent respiratory 
burden in primary as well as secondary care settings.   
This is a topic of growing importance for GPs and respiratory consultants across the UK, 
because the burden of illness from acute bronchiolitis and subsequent respiratory morbidity 
is likely to rise, as preterm birth rates have increased to around 8% of births in the UK and 
survival of these babies is also increasing.88;170;356;357  Early life factors are important to 
consider not only in childhood but throughout the life course as their impact on the 
respiratory system continues through adulthood.141;358;359 
I have only been able to demonstrate the epidemiological relationship between RSV 
bronchiolitis and asthma and wheeze in early childhood, what remains unclear is whether 
there is any causal pathway underlying this association.160  The precise role of genetic 
susceptibility to respiratory conditions versus interactions with the environment remains 
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unknown.  It may be that RSV LRTI disrupts bronchiolar smooth muscle in infancy and 
therefore has a direct causal association with subsequent asthma, or it may simply be that 
affected infants already have pre-existing genetic susceptibility to sensitised airways and 
RSV bronchiolitis is just indicative of these susceptible, higher-risk individuals.360-363  Recent 
studies from Denmark suggest severe RSV infection and asthma may share a common 
environmental exposure and/or genetic predisposition.361;362  The increasing prevalence of 
asthma makes it even more important that this association with RSV in infancy is better 
understood.364   
Rhinovirus is an important cause of wheeze in children aged 3 to 6 years.365  There is 
evidence to suggest that bronchiolitis due to rhinovirus may be more severe than that due to 
RSV.37;363  Indeed a study from a hospital in Finland found children with a history of 
bronchiolitis not caused by RSV were substantially more likely than those who had RSV 
bronchiolitis, to develop recurrent wheezing during a 3 year follow-up period.366  However, 
another study has shown that both RSV and rhinovirus interact with atopy in infancy to 
promote the development of asthma.359  Conversely, other recent evidence suggests the 
disease phenotype may be more important for future wheeze than the causative agent.160  
So further immunological research is needed to truly delineate the association between RSV 
infection and bronchiolitis illness in infancy and subsequent respiratory morbidity in 
childhood.   
10.4.5 Conclusion 
This is the first UK study to report on respiratory diagnoses in early childhood following an 
episode of bronchiolitis, among both high- and low-risk children, using data from nationally 
representative, population-based cohorts.  Evidence from these cohorts of children in both 
primary and secondary care show that children who have an episode of bronchiolitis in 
infancy are at higher risk of subsequent asthma and wheezing episodes in early childhood, 
compared with children with no recorded history of bronchiolitis.  Children who have 
previously been admitted to hospital with bronchiolitis are also at increased risk of 
subsequent hospital admissions for both upper and lower RTIs, in the first 5 years of life.  
Among children with a history of bronchiolitis admission, the increased risk of subsequent 
respiratory admissions was greatest in those classified as “high-risk” such as children born 
preterm.  These findings have important implications for clinicians as an increased 
awareness of this association among GPs, paediatricians and respiratory specialists is 
required, to identify high-risk individuals and optimise management of affected children.  
When determining the potential impact of emerging treatments and vaccines against RSV 
infection, it will be necessary to consider how these might impact on longer-term respiratory 
health.   
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10.5 Methodological strengths and weaknesses 
Earlier in this discussion chapter I have separately described the strengths and weaknesses 
of the methods used in each of the individual studies that constitute this thesis.  I will now 
consider and summarise the general methodological issues that relate to the whole body of 
work that is my thesis.   
Strengths 
The primary strength of this thesis was the novel methodology developed to utilise routinely 
collected electronic databases of clinical records, to develop large, population-based, 
representative cohort studies using individual level data from children in the UK.  Unlike 
previous epidemiological studies of RSV infection among high-risk infants, this research 
focused on the wider population burden of bronchiolitis illness and yielded useful, clinically 
relevant findings that are generalisable to infants across the UK and consistent with those 
reported outside of the UK.   
Linkage between routinely collected hospital birth and other records offers the potential to 
study health outcomes by developing population level cohorts from birth with longitudinal 
cradle-to-grave follow-up.  The strength of the retrospective cohort study design is that 
several different outcomes can be assessed and the sequence of events from exposure to 
outcome can be studied.  In the HES cohort detailed clinical information from birth records 
such as gestational age, birth weight and comorbidities, provides crucial data to examine 
how early life factors might predict future health outcomes.  The methods I have developed 
to construct cohorts using routine hospital data therefore have the potential to answer a 
plethora of different research questions that might otherwise not be feasible to study in child 
populations.   
Another strength of utilising clinical data from the HES and GPRD databases was that 
previous studies have already tested their robustness and validity for use in health services 
and epidemiological research.192;312;331;333  Unlike the artificial settings established in many 
experimental study designs, using routinely collected clinical data increases the likelihood of 
findings relating and being transferable to, real clinical practice.   
Weaknesses 
A limitation of HES data is that they pertain to NHS hospitals in England only.  The 
demography and health of populations living elsewhere in the UK does differ from England 
but the findings reported are likely to be broadly generalisable to the wider UK population.  
As previously discussed, another limitation of the databases used in this thesis was the lack 
of microbiological data available, to confirm whether RSV was the causative agent in 
bronchiolitis cases.  RSV bronchiolitis and unspecified bronchiolitis admissions were collated 
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into a single “RSV bronchiolitis” diagnosis group which was deemed justified since RSV is 
the commonest cause of bronchiolitis.  Specific microbiological diagnoses are poorly coded 
in HES and testing for RSV is not standard clinical practice for bronchiolitis management.  It 
was not possible in any of the studies described to identify individuals who had received 
passive immunotherapy against RSV infection, but I estimate that only a very small number 
of infants qualify for its use (as described earlier in section 10.4).   
A weakness of not using prospectively collected data is that it makes it difficult to discount 
alternative explanations for reported findings, since data on potentially confounding variables 
may not be available.  For this reason it was not possible in either of the cohorts examining 
the longer-term impact of RSV bronchiolitis, to conclusively determine from these findings 
alone, whether RSV infection in infancy has any concrete causal role in the onset of 
childhood asthma or wheeze.  Data on many other possible confounders of this association 
were not available in these databases, particularly environmental exposures such as passive 
smoking, air pollution and nursery/day care attendance.  This information would be 
necessary to narrow the field of doubt surrounding any proposed possible causal 
mechanism.   
Chance, bias and confounding 
When interpreting the results of any epidemiological study it is important to consider 
alternative explanations for any observed effect of an exposure on the outcome of interest.   
In particular, one must consider the role of chance (or random error), bias and confounding 
in generating the observed results.  These are major methodological problems that can 
affect our interpretation of observational research studies, leading to type l (rejecting a null 
hypothesis that is true) and type II (not rejecting a null hypothesis that is false) errors, which 
result in associations that do not truly exist being found or associations that are present 
being missed.   
When conducting a large number of statistical analyses, for example when investigating 
associations between exposures at birth and risk of bronchiolitis admission, around 1 in 20 
of these associations will have p values below the adopted standard threshold of statistical 
significance of 0.05, simply by chance.  It is therefore advisable to be cautious when 
interpreting findings from such large numbers of analyses.     
Biases are systematic errors in the collection or analysis of data, or the study design itself, 
which violate the internal validity of a study.367  The large cohorts studied in this thesis are 
more likely to capture the natural variation that exists in the populations from which they 
were taken and are therefore less likely than much smaller, regional studies to be biased by 
lack of comparability in their exposure and outcome information to the wider population.  
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There may be some inherent selection bias in the hospitals and GP practices which were 
selected for inclusion in the cohorts.  However, the sensitivity analyses described earlier 
showed no significant variation in terms of key hospital and maternity factors, between 
hospitals which were included and excluded from the HES study birth cohorts.  The 600 GP 
practices from which the GPRD cohort was derived, are selected as being up-to-standard for 
research and are geographically widespread, covering an estimated 8% of the UK 
population.258  The retrospectively derived cohort studies used in this thesis were affected by 
losses to follow-up but such attrition bias is difficult to minimise and also affects prospective 
cohort studies.   
In both the HES and GPRD cohort studies described, there was likely to be some 
missingness in the outcome measures (bronchiolitis consultations/admissions), due to the 
reliance on clinical diagnosis coding which may miss some cases coded with less specific 
symptomatic codes.  This is likely to have resulted in underestimates of the burden of 
bronchiolitis in primary and secondary care.  Missing data on exposures was also a problem 
in the studies I carried out but where possible I used alternative, national data sources to 
provide validation.  For example, despite missing gestational age information in the HES 
birth cohorts, the overall preterm birth rate was very similar to national birth registration 
records collected by the ONS, justifying the decision to consider babies with missing 
gestational age to have been born at term.  In addition, the approach described to minimise 
the impact of missing HES birth record information and the sensitivity analyses presented, 
provide sufficient justification that selecting a cohort of infants born in hospitals with higher 
completeness of recording of gestational age at birth is a valid and generalisable approach.   
I considered potentially confounding variables in each study and tried to take these into 
account either in the study design or by controlling for them at the analysis stage (wherever 
this was possible given the constraints of routinely collected data).  For example, when 
calculating the relative risk of bronchiolitis hospital admission for infants with different clinical 
risk factors, I adjusted for any other clinical risk factors which might be confounders.  
Residual confounding due to measurement error in confounders, or poorly controlled or 
unmeasured factors, may result in biased estimates of the effect of an exposure on the 
outcome of interest.368  It was not possible to adjust for all possible confounders, particularly 
in the GPRD cohort where information on gestational age at birth and other neonatal 
exposures were not available.  However, wherever data on a confounder was available, I 
attempted to adjust for it in my analyses to minimise the chances of identifying spurious 
associations between exposures and outcomes.   
 128 
 
10.6 Implications for policy and practice  
Implications for health care policy and the development of clinical guidance 
The improved estimates of the clinical burden of RSV bronchiolitis which this thesis has 
provided are essential, because such quantitative evidence is required to form the basis of 
health care policy, informs the development of clinical guidelines and is useful for predicting 
and planning health service use.  Both health professionals and policy-makers require up-to-
date information on the country-specific impact of RSV infection and the extent to which it is 
concentrated in particular groups, in order to improve care and calculate the costs to health 
care providers.325 
The importance of this burden of RSV illness is growing because the pool of susceptible 
individuals is increasing as the UK birth rate rises and particularly because preterm birth 
rates have increased to around 8% of births, plus survival of preterm babies is also 
increasing.88  Furthermore, the burden is not limited to the acute episode of illness itself but 
is also associated with an increased risk of subsequent primary and secondary care 
consultations/admissions for asthma and wheezing in early childhood.  So these findings 
have huge implications for the NHS in terms of healthcare utilisation costs among children 
with a history of bronchiolitis.   
Despite caveats relating to the database used and reliance on clinical coding, this thesis has 
provided for the first time to my knowledge, an estimate of the bronchiolitis GP consultation 
rate in the UK, which can be used to inform future guidance for the optimal management of 
bronchiolitis.  SIGN guidelines highlight this as a priority area for research since there were 
previously no estimates of bronchiolitis incidence in primary care, which I have now 
attempted to address.   
This is the first large, population-based study in the UK which has provided evidence that 
babies born with Down‟s syndrome, cystic fibrosis and cerebral palsy are at higher risk of 
hospital admission with RSV bronchiolitis.  More research is therefore needed to understand 
why this is and whether these babies might also benefit from palivizumab prophylaxis.  If 
palivizumab is found to be efficacious and cost-effective in these subgroups of high-risk 
infants, then JCVI recommendations for palivizumab use may need to be revised.  Indeed 
current recommendations for the use of palivizumab from the American Academy of 
Pediatrics (AAP) suggest it should be considered for use in infants with cystic fibrosis, since 
evidence suggests their course of illness may be prolonged with impaired lung function for 
several months following a LRTI.369;370  Neither the AAP in the USA nor the JCVI in the UK 
specifically recommend the use of palivizumab for infants with Down‟s syndrome, but the 
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AAP do suggest it should be used in infants with compromised ability to handle secretions 
due to neuromuscular conditions.127;349;369  A randomised trial of palivizumab would be 
required in order to evaluate whether it may reduce hospital admissions for RSV LRTI 
among infants with these specific conditions, but the cost implications of this are likely to be 
prohibitive.122;127   
This thesis has provided valuable information which can be used to estimate the potential 
risk-benefit ratio of any emerging  vaccines or other passive immunisations against RSV 
infection,  at both the individual and societal level, which could then determine the target 
recipients.371;372  The total burden of RSV bronchiolitis can only be estimated by examining 
the full, wider spectrum of illness across health care settings, hence this was previously 
underestimated by research focused solely on hospitalisation costs among only the highest 
risk groups.  This thesis has highlighted the need to consider that the majority of infants 
affected are not born preterm and there are significant costs associated with caring for 
infants with bronchiolitis in the community.  Furthermore, my findings have implications for 
the timing of any novel prophylaxis as the analyses confirmed that the majority of infants 
hospitalised with bronchiolitis are below 6 months of age, limiting the impact of any future 
vaccine since it would be very difficult to elicit immunity in such young infants.  Developing 
an effective vaccine is challenging because immunogenicity needs to be effective during the 
most vulnerable period in the first 6 months of life but also balanced with the need for 
adequate attenuation.127   
Implications for clinical management and service provision 
Although the findings related to GP prescribing for bronchiolitis occurred before the SIGN 
guidance was published in 2006, prior to this it was still widely known that no treatment 
shortens the duration of bronchiolitis illness and antibiotics have never been recommended 
for use with this typically self-limiting viral illness.  So it is still worrying that antibiotics and 
beta agonists have been prescribed by GPs to infants presenting with bronchiolitis.  I believe 
this warrants further investigation of GP prescribing in relation to bronchiolitis consultations, 
particularly since the SIGN guidelines were made available.  Not only would these 
prescriptions be ineffective in improving the infants condition, but the use of antibiotics 
carries the risk of adverse effects including disruption of gut flora, wastes healthcare 
resources, contributes to the development of antimicrobial resistance and may increase 
future demand from parents presenting children for similar illnesses.192;343;373-375  Evidence 
based guidelines for bronchiolitis should be revised to include evidence from more recent 
studies and awareness of the recommended best practice may need reinforcement through 
GP training.  The development of a simple clinical prediction rule would be a useful next 
step, as this could be an effective tool to help GPs identify infants at high-risk of RSV 
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infection and to help determine which of them require hospital admission.113  Admission 
criteria have not been well established to date.36;376   
The short length of stay for many bronchiolitis hospital admissions implies some of these 
may be potentially avoidable, through improved symptom management and parental 
reassurance from clinicians in primary care and EDs.  The annual number of bronchiolitis 
consultations in UK general practices was estimated to be between 46480 and 165,360, 
depending on the diagnosis codes included in the bronchiolitis case definition.  This has 
important implications for planning and commissioning health services, since no estimates of 
primary care utilisation relating to acute bronchiolitis and subsequent respiratory 
consultations have previously been published.  Likewise, the finding that most infants 
admitted to hospital with bronchiolitis are previously healthy and born at term, is useful for 
planning health service provision.  Bolton et al have recently highlighted how important it is 
for clinicians specialising in respiratory medicine to take into account early life factors.358  
They suggest that given the increasing evidence of the impact of early life factors on late 
respiratory health (as shown in this thesis too), awareness of this needs to be promoted 
among respiratory specialists and greater emphasis placed on this in their training.358 
 
10.7 Remaining research questions and future work 
The findings presented in each of the results chapters of this thesis provide improved 
estimates of the total clinical burden of RSV bronchiolitis and enhance our epidemiological 
understanding of this illness, among infants in the UK.  However, as outlined earlier in this 
chapter in the separate discussion sections for each of the studies making up this thesis 
(see sections 10.2, 10.3 and 10.4 ), this research has also identified key areas where 
insufficient evidence currently exists and further research is now required.  Here I summarise 
these emerging themes to guide the direction and prioritising of future studies in this field.   
 
10.7.1 Improving our understanding of the typical care pathway for infants with RSV 
bronchiolitis 
Further observational studies are needed to examine the clinical burden of bronchiolitis in 
the community.  Investigation of data from Emergency Departments is particularly warranted, 
to help elicit what the typical care pathway is for infants with bronchiolitis symptoms.  This 
could be facilitated by linking individual medical records from general practices, Emergency 
Departments, hospitals and laboratories, to provide a more comprehensive picture of the full 
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clinical spectrum of illness and evidence of the typical patterns of bronchiolitis presentation 
to healthcare services.   
Such a database of linked records could then be used to evaluate the impact of any new 
guidance for the management of infants with bronchiolitis or to monitor the effect of any 
interventions implemented to reduce potentially avoidable, short stay bronchiolitis 
admissions.  For example, simple clinical prediction rules have been shown to be a highly 
effective tool for identify infants at high-risk of RSV infection in primary care. 324  A similar 
risk calculator tool needs to be developed and piloted in the UK, which may be used to help 
clinicians identify individuals at risk of severe RSV infection.  An electronic risk prediction 
tool could be useful across healthcare settings, from helping neonatologists in NICUs to 
identify infants requiring passive immunotherapy, to guiding management and referrals of 
infants presenting with bronchiolitis in general practice.377;378  There has been some recent 
debate about the utility of testing the etiologic diagnosis of bronchiolitis, with evidence 
suggesting that it may help to predict prognosis and reduce further unnecessary diagnostic 
tests.320;379  Prospective studies in the UK are needed to determine the value of routine 
testing for RSV among infants with LRTI.   
Although it may not be feasible to conduct a prospective cohort study on such a large scale 
as the retrospective cohort I developed using the GPRD (consisting of over 80,000 infants 
from 600 GP practices across the UK), a prospective study on a smaller scale could be used 
to validate the findings presented in chapter 7.0.  Such a study could be used to deduce how 
GPs are typically recording cases of bronchiolitis and whether the inclusion of symptomatic 
codes to identify cases of bronchiolitis provides a truer reflection of the burden of 
bronchiolitis illness, than relying on specific bronchiolitis codes alone.  Access to the free text 
in patient records could provide further insight into whether reliance on clinical diagnosis 
coding significantly underestimates bronchiolitis incidence.   
Other sources of data from primary care settings could be used to validate the findings I 
have presented using the GPRD.  For example, The Health Improvement Network (THIN) is 
a database of electronic anonymised medical records from general practices in the UK using 
the Vision software system.380  THIN data could be used to carry out a similar study 
estimating the frequency of bronchiolitis consultations in primary care.   
Further investigation is needed to determine whether the significant geographical differences 
in bronchiolitis admission rates reflect true variation in bronchiolitis incidence or are related 
to specific health services factors such as hospital admission policies; differences in access 
to specialty services; or due to variations between tertiary centres versus district hospitals.  
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10.7.2 Prevention and treatment of RSV bronchiolitis 
The findings presented in this thesis have highlighted the urgent need to develop novel 
preventive and therapeutic agents to target both the acute and longer-term effects of RSV 
infection in childhood.  This ought to be a high priority for research since the burden of 
bronchiolitis illness is greater than previously estimated, has an impact across healthcare 
settings, effects a wide spectrum of infants and is associated with longer-term respiratory 
morbidity in childhood.   
Further research is also needed to determine whether palivizumab immunoprophylaxis might 
be clinically and cost-effective if given to other high-risk infants such as those with cerebral 
palsy, cystic fibrosis or Down‟s syndrome.  To test this robustly, a multicentre, randomised, 
double-blind placebo controlled trial would be required, but this is unlikely to be feasible 
because of the considerable costs of such a study.   
Up-to-date economic evaluations are also needed to estimate the total costs of NHS 
healthcare utilisation associated with RSV bronchiolitis, incorporating not only costs of 
hospitalisation but also costs of caring for infants in the community and subsequent costs 
related to longer-term respiratory problems.   
10.7.3 Improve understanding of the longer-term impact of RSV infection on airways 
Further studies are needed to determine the role of genetic versus environmental factors on 
susceptibility to RSV infection in infancy.  The immune response to RSV infection remains 
poorly understood, so further microbiological studies are needed if a successful vaccination 
candidate is to be identified.  We need to determine whether there is a definite causal 
association between RSV infection and subsequent asthma or wheeze, or whether the 
disease phenotype plays a larger role in this than the etiologic agent.   
10.7.4 The future of using routine data for child health research 
With limited funding, restricted resources and improved recognition of the necessity for life-
long follow-up for infant research, it is imperative that the research community, funders and 
the public maximise the value of information that can be gleaned from existing routine data 
sources and avoid duplication of effort.  This was highlighted by the public inquiry report into 
the Bristol Royal Infirmary paediatric cardiac unit, which recommended that HES should be 
supported as a national resource and used to monitor healthcare outcomes.381;382   
 
Previously HES had been commonly used to examine disease time trends and standards of 
care at an aggregate level.  For the first time, I have demonstrated how HES data can be 
used to develop birth cohorts for epidemiological research.  Recording of birth information 
needs to improve in some NHS hospitals to provide robust baseline population estimates of 
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birth outcomes.  Encouragingly, the data I have presented from recent years indicate 
completeness of recording of HES birth records are improving.  Individual follow-up from 
birth is feasible using HES but the limitations and processing issues I have described are 
important methodological considerations that need to be taken into account.   
 
Data capture is likely to be more complete and most accurate in records that are entered by 
clinicians at the point of care.  In the UK for example, Neonatal Networks submit neonatal 
specialist care records to the NNRD, managed by the NDAU (based at Imperial College 
London in collaboration with Chelsea & Westminster NHS Foundation Trust).271  These 
records capture real-time operational data which are actively used in the processes of 
clinical care.  Collaboration between NHS organisations, academic institutions, the 
commercial sector and parents has enabled the successful development of this NNRD.   
A White Paper from the UK coalition government published in 2010 called for an information 
revolution, using data to drive up the quality of healthcare, improve patient choice and 
provide public accountability.279;383  Specialist neonatal care has already been leading the 
way regarding this challenge, since the establishment of the NNRD which provides 
comprehensive data collection on a national scale.279  The NHS Newborn Infant Physical 
Examination Programme (NIPE) and the Newborn Hearing and Bloodspot Screening 
programmes provide additional sources of neonatal healthcare data in the UK.384-387  
However, there are huge inconsistencies between some of these datasets in the types of 
data captured and how they are defined.   
The NHS Information Centre has been commissioned to develop a maternity record.  If this 
is to be truly useful it is essential that current uncertainties regarding the retention of 
identifiers, access for secondary use, clarity regarding data definitions and validation are 
addressed.  An integrated approach will be required to ensure that such data are captured 
once, serve multiple needs and can be responsive to changing requirements.279   
A logical next step must also be to develop robust linkage between birth records and more 
detailed clinical datasets.  For example, linkage between hospital and general practice 
records (belonging to both the mother and baby) would add substantial utility to these data, 
providing insight into the effects of exposures during pregnancy on subsequent infant health 
outcomes.  Rather than existing ad hoc approaches to linkage, the aim should be routine 
database linkage on a national scale.   
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10.8 Overall thesis conclusion 
The clinical burden of RSV bronchiolitis across healthcare settings in the UK is greater than 
previously estimated.  This thesis examines the wider clinical spectrum of bronchiolitis illness 
across primary and secondary healthcare settings, using routine data from electronic health 
records to develop longitudinal cohorts with follow-up from birth through early childhood.   
This thesis provides, to my knowledge, the first estimate of bronchiolitis incidence in UK 
primary care.  Between 4% and 21% of infants have a bronchiolitis GP consultation in their 
first year.  National hospital admission data have been utilised to improve estimates of the 
population burden of severe bronchiolitis illness and examine trends in hospital admissions.  
2.4% of the national birth cohort are admitted to hospital with bronchiolitis in the first year of 
life, the majority of whom are born at term, with none of the known clinical risk factors for 
severe RSV infection.  An episode of bronchiolitis in infancy is a predictor of subsequent 
hospital admissions and general practice consultations for asthma and wheezing in early 
childhood.   
The findings presented in this thesis provide evidence for the need to investigate the cost 
effectiveness of passive immunotherapy in other high-risk groups, such as infants with 
cerebral palsy, cystic fibrosis and Down‟s syndrome.  Further research is also needed to 
quantify the clinical and healthcare burden of RSV bronchiolitis among infants presenting in 
Emergency Departments in the UK.  Linkage between healthcare databases such as the 
NNRD and HES, will provide a valuable source of data to quantify risk of RSV bronchiolitis 
admission in specific groups such as by gestational age, as recommended by the JCVI.   
The improved estimates of the clinical burden of RSV bronchiolitis among infants in the UK 
presented in this thesis have important policy implications for clinical training and potentially 
for passive and future active RSV immunisation policy.  This thesis highlights the need to 
prioritise the development of new approaches for the prevention and treatment of RSV 
infection, given that the clinical and healthcare burden of bronchiolitis in the UK is greater 
than previous studies have been powered to estimate.   
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11.0 Appendices 
Appendix 1: Palivizumab prescribing data from the Prescribing Cost Analysis (PCA) 
database from the NHS Information Centre 
 
Annual number of Palivizumab prescriptions dispensed across England, recorded in the 
PCA system. 
Year 
Items 
(000s) 
NIC £ 
(000s) 
2003 0.059 50.768 
2004 0.054 43.720 
2005 0.110 65.106 
2006 0.155 90.984 
2007 0.197 131.593 
2008 0.152 99.651 
2009 0.123 77.023 
PCA Data 
Prescription information is taken from the Prescribing Cost Analysis (PCA) system, supplied 
by the Prescription Services Division of the NHS Business Services Authority (BSA), and is 
based on a full analysis of all prescriptions dispensed in the community i.e. by community 
pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by 
prescribing doctors for items personally administered in England.  Also included are 
prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed 
in England.  The data do not cover drugs dispensed in hospitals, including mental health 
trusts, or private prescriptions.  Prescribers are GPs, hospital doctors, dentists and non-
medical prescribers such as nurses and pharmacists. 
Prescription Items 
Prescriptions are written on a prescription form.  Each single item written on the form is 
counted as a prescription item. 
Net Ingredient Cost (NIC) 
NIC is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees 
or prescription charges income. 
Quantity 
The quantity of a drug dispensed is measured in units depending on the formulation of the 
product.  Quantities are not added together across preparations because of different 
strengths and formulations. 
Units 
All the data are measured in units of a thousand, with the exception of net ingredient cost 
per quantity which is measured in pounds sterling (£).    
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Appendix 2: Published methodology paper 
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